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2ABSTRACT
An HPLC method has been established for the determination of ubiquinone (C0 Q9 
and C0 Q10) levels in biological samples. This necessitated the synthesis of a novel internal 
standard for C0 Q9 and C0 Q10 measurement in rodent tissue. Rat glial cell lines contained 
C0 Q9 as the predominant ubiquinone isoform; this was C0 Q10 in human tissue. 
Comparison with primary cultures of rat astrocytes showed that these human and rat glial 
cancer cell lines had relatively less C0 Q9+10 than primary glial cultures, possibly reflecting 
a lower dependence of transformed cells upon OXPHOS for ATP generation.
Lovastatin decreased C0 Q9 (but not C0 Q10) in primary astrocytes and glial cell 
lines. Moreover, glial cell lines displayed an approximately 10-fold higher sensitivity to 
lovastatin or its P-hydroxy acid isoform than primary rat astrocyte cultures.
Cellular C0 Q9 levels did not appear to be limiting for mitochondrial complex 11+111 
activity, thus it is possible that C0 Q 10 is more intimately involved in OXPHOS than C0 Q9.
Primary cultures of rat astrocytes and neurons contained approximately equal levels 
of C0 Q9. However C0 Q10 levels were significantly higher in neuronal cultures. In contrast 
to transformed cell lines, the neuron’s reliance on mitochondrial OXPHOS to synthesise 
ATP may manifest as higher cellular availability of C0 Q10
Activation of iNOS in rat primary astrocytes to generate nitric oxide (NO) for 24h 
did not alter C0 Q9 or C0 Q10 levels. Following 36h exposure, activation of iNOS 
significantly decreased C0 Q9 and C0 Q10. An NO-donor decreased astrocyte C0 Q9 and 
C0 Q10 after 24h exposure, while in neurons, both CoQ isoforms were maintained. 
Additionally 36h exposure of astrocytes to DETA-NO appeared to cause a recovery in the
amount of C0 Q9 and C0 Q10, possibly representing a protective effect in response to RNS 
exposure.
Additionally, preliminary data demonstrated that small interfering RNA (siRNA) 
may decrease C0 Q9 but not C0 Q10 in rat primary astrocytes although not HEK293T cells.
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1. INTRODUCTION 
1.1. An introduction to mitochondria
The mitochondrion is an essential organelle in the majority of mammalian 
cells. While a number of theories exist as to the co-evolution of eukaryotic cells and 
these intrinsically interesting organelles, the widely-held theory of “endosymbiotic 
evolution” states that today’s eukaryotic mitochondria evolved as a result of the 
engulfment of a free-living, aerobic prokaryotic organism by another anaerobic 
proto-eukaryotic cell (proposed in Margulis, 1981).
To summarise 2 billion years of evolution and the considerable theoretical 
debate which will not be considered here, mitochondria have become indispensable 
for higher life. Although far from being their sole function, these organelles are 
involved in the synthesis of adenosine triphosphate (ATP) from adenosine 
diphosphate (ADP), a process coupled to the reduction of molecular oxygen to 
water. In the region of 1 pm in length, these double-membraned, classically "rod- 
shaped” structures contain a matrix, enclosed within the highly convoluted inner 
membrane which forms finger-like projections or “cristae” (reviewed in Frey & 
Manella, 2000). In reality, the diversity of mitochondrial size, shape and motility 
mean that there is no such thing as a typical mitochondrion. However, general 
mitochondrial topology is described in Figure 1.1, showing the double-membraned 
structure, cristae, matrix and the “studding” of ATP synthase on the matrix side of 
the inner membrane.
The mitochondrial matrix, bounded by the inner membrane, contains a 
number of soluble (i.e. non-membrane bound) biosynthetic enzymes. Enzymatic
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Figure 1.1 Generalised mitochondrial topology
Mitochondria are double-membraned organelles of between lpm and 10pm in 
length. Across the inner membrane exists a proton gradient, maintained by the proton- 
pumping machinery of the electron transport chain. The inner membrane is highly 
convoluted, and encloses the matrix. The inner membrane also contains the respiratory 
complexes and the ATP synthase (visible as a stalked particle on the matrix-side of the 
inner membrane. The matrix consists of a number of proteins, (including the Krebs 
cycle and other enzymes) and mitochondrial DNA.
(Image reproduced with permission from BioMedia Associates, Beaufort, USA)
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substrates may already be present in the matrix (such as acetyl CoA formed by the 
pyruvate dehydrogenase complex; PDHC; EC. 1.2.4.1), while others such as fatty 
acids and pyruvate need a transport mechanism (the camatine-acylcamitine 
translocase and monocarboxylate translocator respectively; reviewed in Heales et 
al., 2002).
Between the matrix and the inter-membrane space exists a proton gradient of 
approximately -150 to -170 mV, which is maintained by the respiratory chain, more 
than 80 polypeptides grouped into protein complexes (termed I to IV) embedded in 
the inner membrane. Electrons are passed along the chain through the redox centres 
of the respiratory complexes, while mobile electron carriers traffic electrons between 
the complexes. Reducing eqivalents from NADH and succinate are passed down the 
chain before finally being used to reduce molecular oxygen (O2). This functional 
unit is termed the mitochondrial respiratory chain, or more accurately the electron 
transport chain (ETC; Fig. 1.2). The passage of electrons through complexes I, II, 
III, and IV is made possible by the mobile redox-active electron carriers ubiquinone 
(in the hydrophobic phase of the inner membrane) and cytochrome c (in the 
hydrophilic phase of the inner membrane).
The process of electron transport through the protein complexes is coupled to 
the pumping of protons from the matrix into the inter-membrane space. The proton 
gradient is then dissipated through the ATP synthase (complex V) back into the 
matrix. This catalyses the phosphorylation of ADP to ATP, which can then be 
shuttled out of the mitochondrion in exchange for ADP by the adenine nucleotide 
translocase (ANT).
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Figure 1.2. The mitochondrial electron transport chain.
The mitochondrial respiratory chain is an assembly of electron carriers grouped 
into four polypeptide complexes [I (NADH : ubiquinone reductase), II (succinate : 
ubiquinone reductase), III (ubiquinol : cytochrome c reductase), and IV (cytochrome c 
oxidase)]. Complexes I, III, and IV act as oxidation-reduction-driven proton pumps. The 
flow of electrons from NADH, along the respiratory chain to oxygen is coupled to the 
pumping of protons across the inner mitochondrial membrane, resulting in the 
formation of a proton gradient. The flow of protons back into the matrix through the 
membrane sector of the mitochondrial ATP synthase alters the active site of the enzyme, 
leading to the synthesis of ATP.
Q = ubiquinone, C = cytochrome c. Both act as mobile electron carriers.
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1,1.1, Complex I
Complex I (NADH : ubiquinone reductase; EC. 1.6.5.3) is the largest enzyme 
of the ETC. Bovine heart complex I is comprised of at least 43 subunits (of which 
seven are coded for by mitochondrial (mt) DNA), and has a molecular mass in the 
region of 900kDa (Grigorieff, 1998). The enzyme is comprised of essentially two 
domains. Simplistically relating to enzyme function, an NADH oxidase projects out 
of the membrane on the matrix side and oxidises NADH to NAD+; the other 
membrane-bound domain is involved in ubiquinone reduction.
The matrix (or “peripheral”) domain contains at least 10 subunits, contains 
the NADH binding site, a number of Fe-S centres and at least one flavin 
mononucleotide (FMN), which is non-covalently bound and involved in NADH 
oxidation (reviewed by Friedrich and Bottcher, 2004).
Two ubiquinone binding sites (and at least one reduction site) have been 
proposed to exist close to one another in the membrane domain of complex I (Tormo 
and Estomell, 2000); however their exact positions are as yet unknown. Rotenone is 
a classical and commonly used inhibitor in studies of complex I (Teeter et al., 1969); 
and one which does not compete with ubiquinone binding (Friedrich et al, 1994). 
The neurotoxin MPP+ binds and inhibits complex I at the ubiquinone binding sites. 
These studies have suggested that one site is relatively hydrophilic, while one is 
shielded by a “hydrophobic barrier” on the enzyme (Ramsay et al, 1989, Gluck et 
al, 1994; reviewed in Miyoshi, 2001). Additionally, an inhibitor-binding domain 
between these two ubiquinone sites has also been proposed (Tormo and Estomell, 
2000).
28
Due to the complexity and size of complex I, little is known of the 
mechanism of this enzyme. Electron microscopic analysis has uncovered that the 
two domains of the complex are arranged in an “L” shape in a number of systems 
notably bovine heart (Greighoff, 1998), the red bread mould Neurospora crassa 
(Guenebaut et al., 1997), Yarrowia lipolytica (Freidrich & Bottcher, 2004) and 
Escherichia coli (Guenebaut et al., 1997; although another “U” shaped conformation 
has been described in E.coli by Freidrich & Bottcher, 2004). The peripheral and 
membrane domain are believed to be joined by a stalk of approximately 3nm in 
bovine heart and E. coli (Guenebaut et al., 1997 and Grigorieff, 1998) and this may 
contain the ubiquinone binding sites (Tomo & Estomell, 2000). However, both this 
measurement, and the angle at which each arm lies have been questioned (reveiwed 
in Freidrich & Bottcher, 2004).
It is understood that as a result of NADH oxidation, complex I transfers four 
or five protons from the matrix to the inter-membrane space although the mechanism 
has not been elucidated (reviewed in Heales et al., 2002). The proton-pumping 
action relies upon complex I’s catalysis of the oxidation of NADH to NAD+ yielding 
two electrons, which are proposed to reduce the N-2 Fe-S cluster. This then 
transfers the electrons to ubiquinone (CoQ), reducing it to ubiquinol. CoQ (Fig. 
1.3), described in greater depth later in this chapter, is a lipophilic quinone and this 
substrate-like redox component exists within the inner membrane effectively 
behaving as a homogenous "poor' (Kroger and Klingenberg, 1973). Electrons are 
subsequently passed to complex III of the ETC.
c h 3o
c h 3o
c h 3o
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H
Figure 1.3 The structure o f ubiquione, ubisemiquinone, and ubiquinol
As the lipophilic mobile electron carrier in the ETC, CoQ comprises a six- 
membered carbon ring, and an isoprenyl tail of n repeating units. The specific 
homologue is named according to the number of isoprenyl repeats. Predominantly, n 
in rodents and n = 10 in humans. The addition of 1 electron to the oxidised quinone 
results in partial reduction to ubisemiquinone. Further reduction results in ubiquinol.
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1.1.2. Complex II
Complex II (succinate : ubiquinone reductase; EC. 1.3.5.1) is a four-subunit 
enzyme catalysing the oxidation of succinate from the Krebs cycle to fumarate. The 
subunits are denoted sdhA to sdhD and uniquely in mammalian ETC enzymes, these 
are all encoded by nuclear DNA (Hirawake et al., 1999). SdhA and sdhB are 
hydrophilic, projecting into the matrix, while sdhC and sdhD are membrane-bound 
(Yankovskaya et al, 2003). Another unique feature among respiratory complexes is 
that complex II does not act directly as a proton pump per se: the electrons stripped 
from succinate are transferred to ubiquinone to form ubiquinol without actively 
contributing to the proton gradient. It is also of note that succinate dehydrogenase is 
additionally an integral enzyme of the Krebs cycle; thus this enzyme provides a 
direct link from the matrix-contained Krebs cycle to the ETC.
Although very similar to fumarate reductases, the X-ray structure of 
mammalian mitochondrial complex II has not yet been elucidated. A number of 
high-resolution X-ray structures for have now been proposed for complex II, based 
mostly upon membrane-bound menaquinol : fumarate oxidoreductase (QFR) from 
E.coli (Iverson et al, 1999) and Wolinella succinogenes (Lancaster et al, 1999). 
More recently, the structure of anaerobic succinate : ubiquinone reductase which is 
also analogous to mitochondrial complex II was confirmed in E. coli (Horsefield et 
al, 2003; Yankovskaya et al, 2003), revealing the electron transport pathway from 
succinate to ubiquinone and the existance of the complex as a tightly packed trimer 
(Yankovskaya et al, 2003).
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As with complex I, a matrix domain is responsible for the catalytic reduction 
of the substrate, while electron transfer to CoQ occurs within the membrane via 
generation of ubisemiquinone. It is possible that complex II has 2 CoQ binding sites 
analogous to complex 1, although the finding of Yankovskaya et al. (2003) may 
suggest only a single site in E. coli.
A covalently-bound FAD group in subunit A acts as the primary electron 
acceptor from succinate in complex II, while a number of different Fe-S centres 
allow electron transport to CoQ. SdhB contains three such clusters [2Fe-2S], [4Fe- 
4S] and [3Fe-4S] which ultimately pass electrons to ubiquinone. The sdhC and 
sdhD subunits are anchored within the membrane and contain at least one CoQ 
binding site in the model of Yankoskaya et al. (2003); this is proposed to be 
different to that of QFR .
1.1.3. Complex III
Complex III (ubiquinol : cytochrome c reductase; EC 1.10.2.2) exists as a 
homodimer and catalyses the oxidation of ubiquinol back to ubiquinone; this is 
coupled to direct proton pumping across the inner membrane. Comprising 11 
subunits of which one is mitochondrially encoded, each monomer has a molecular 
mass of 240kDa. Complex III spans the membrane, exposed to both the matrix and 
the inter-membrane space. Electrons from ubiquinol are donated to the hydrophilic 
carrier cytochrome c hydrophilic domain of the inner membrane. Of particular note 
with the regard to complex III is the “Q cycle” theory (proposed initially by 
Mitchell, 1975; Figure 1.4). In addition, for the docking site for cytochrome c,
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Figure 1.4 Complex III and the protonmotive Q cycle
Cytochrome b is shown in green; cytochrome c\ in orange. Initial binding of 
ubiquinol to the Qo site of complex III results in the transfer of one electron (represented in 
this diagram by ) to the mobile 2Fe-2S Reiske complex ) and subsequently
cytochrome c iQ M ^ ). A second electron is then passed via the bi and bw cytochromes to 
ubiquinone bound to the Qi site. This is coupled to the pumping of 2 protons from the 
matrix to the inter-membrane space ( ^  ). Following addition of a second electron from 
another Qo-bound ubiquinol, the Qi ubiquinone becomes fully reduced. It then dissociates, 
with the possibility of binding Qo. A balanced equation for the process is shown above. 
(Adapted from Crofts, 2004)
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crystal structure studies (Xia et al, 1997; Zhang et a l , 1998; Gao et al., 2003) have 
shown that complex III possesses an additional two distinct binding sites: one 
(termed the “Q i” site) for oxidised ubiquone in the vicinity of the matrix side of the 
membrane and another (Qo) for the reduced quinol form closer to the inter­
membrane space side of the membrane. Upon binding fully reduced ubiquinol at the 
Qo site, one electron is passed to the mobile [2Fe-2S] centered “Reiske” protein. 
This can then change conformation from “proximal” to “distil” conformations, 
passing electrons through cytochrome ci and finally to soluble cytochrome c in the 
intermembrane space (Zhang et al, 1998). The other electron from the Q0 site is 
transferred to cytochrome bl, cytochrome bn, and then to the oxidised ubiquinone 
occupying the Qi site, forming ubisemiquinone. The now oxidised ubiquinone at the 
Qo site dissociates, and a second ubiquinol binding Qo results in further reduction of 
soluble cytochrome c and the ubisemiquinone at Qi then becomes reduced to 
ubiquinol. This action requires 2 protons which are taken up from the matrix, 
however the proton pumping action of complex III is not currently well understood 
(see Crofts, 2004 for a review of structure and function). Finally, the fully reduced 
ubiquinol can now bind Qo for the cycle to continue (Mitchell, 1975).
As each turnover requires two ubiquinol molecules to be oxidised at the Qo 
site, two electrons are available to reduce cytochrome c and two to reduce the Qi 
ubiquinone. Subsequently 4 protons are delivered to the inter-membrane space.
34
1.1.4. ComplexIV
Complex IV (cytochrome c oxidase; EC. 1.9.3.1) is the terminal member of 
the ETC proteins and as such binds reduced cytochrome c, using the electrons 
gained to reduce half a molecule of O2 to water. This reaction also allows the 
transfer of protons from the matrix to the inter-membrane space. Crystal studies of 
bovine heart complex IV confirmed a dimerised structure each with 13 subunits and 
a total molecular mass of 204 kDa (Tsukihara et al., 1996, 1998). Subunits I, II, and 
III are mitochondrially encoded (Anderson et al, 1981), forming the central core of 
the protein. The ten remaining subunits are encoded by the nucleus; with likely 
roles in regulation, stabilisation and assembly of the functional protein (reviewed in 
Richter and Ludwig, 2003). However, despite an excellent structural understanding 
of the protein based upon spectroscopic evidence (reviewed in Michel, 1998), 
mutagenesis studies (Haltia et al., 1989; Witt et al., 1997) and more recent 
crystallisation data (Yoshikawa et al, 1998), the molecular mechanism of proton 
translocation and its coupling to the redox steps are still unclear.
The fact that complex IV acts as a proton pump was shown by Wikstrom 
(1977), however, the exact mechanism of the transfer of protons to water and the 
pumping of protons into the inter membrane space remains the topic of debate. 
Proposed mechanisms have been extensively reviewed (Babcock and Wikstrom, 
1992; Michel, 1998; Richter & Ludwig, 2003). Subunit II is likely to act as the main 
docking site for cytochrome c : two coppers in subunit II ( C u a )  are the first to 
receive electrons from cytochrome c, before these are transferred to the centres of 
subunit I, viz. the haem cytochrome a, and then to the binuclear active site
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cytochrome ^/Cub. During the reduction of oxygen at the catalytic site, both metals 
are reduced after the acceptance of two electrons, a state which allows oxygen 
binding and the formation of a peroxy intermediate. A further electron allows the 
formation of water and a ferry 1 intermediate, while one more electron is required to 
form a second water molecule and allow the enzyme to revert back to the oxidised 
state (Han et al., 1990; Babcock and Wilkstrom, 1992). These redox centres are 
located in the middle of the hydrophobic membrane environment (see Reichter & 
Ludwig, 2003). To reduce O2 to H2O requires four protons (from the matrix side), 
an action which also pumps four additional protons across into the inter-membrane 
space. The pumping mechanism may yet be shown to involve conformational 
change at the active site or to occur by a structural change more distil from 
cytochrome a3/ Cub. (reviewed in Richter & Ludwig, 2003)
1.1.5. A TP synthase
The proton motive force, built and maintained by the four complexes, 
drives ATP synthesis by complex V (F1F0-ATP synthase; EC. 3.6.1.34) (Mitchell, 
1961, Mitchell and Moyle, 1969; reviewed in Heales et al., 2002). Complex V binds 
ADP + P„ and proton flux through the complex allows a conformational change of 
the complex to catalyse the conversion to ATP. Subsequent cleavage of the terminal 
phosphate group of this molecule liberates energy to drive cellular biochemical 
functions.
Bovine heart ATP synthase is greater than 500kDA in size, comprises 16 
subunits of which two are encoded by the mitochondrial genome, with 2  distinct
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domains termed ¥\ (matrix subunit) and Fo (membrane domain) (Abrahams et al, 
1994, reviewed in Mueller, 2000). Fj consists of six alternating (3a & 3p) subunits 
arranged around a central “stalk” domain. The so-called (ap )3 domain is nearly- 
spherical ( 8  nm high x 1 0  nm wide) while the stalk is made up of y and e (and 
possibly 6 ) subunits. Nucleotide binding occurs at the a and p subunit interfaces in 
the Fi domain.
The Fo membrane domain is the site of proton translocation and contains 9 
subunits in bovine heart ATP synthase (Abrahams et al, 1994). This domain 
constitutes the “channel” through which protons flow to re-enter the matrix. It is 
thought that protonation of an aspartate residue in the F0 domain causes the rotation 
of the subunit, and subsequent release of this proton to the cytosol. Crucially, this 
rotation also mediates ADP phosphorylation.
In order to stop rotation of the F\ domain during rotation of F0 and the stalk, 
there is also a “stator” linking Fi and F2 (Ogilvie et al, 1997; Wilkens & Capaldi, 
1998). This is believed to anchor the (ap)3 domain, inhibiting it from rotating with 
the y subunit.
The structures of the p subunits of the ¥\ domain have been shown to cycle 
through conformational changes resulting in “open”, “loose” and “tight” substrate 
binding. Additionally, the 3p subunits are always each in a different state. The 
“binding-change mechanism” (Gresser et al, 1982; subsequently reviewed in Boyer, 
1997) proposes that the open conformation has a low affinity for either the substrate 
or product. The loose state allows reversible binding of substrate or product. The 
tight state is a high affinity state for ADP and Pj, such that ATP formation is
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favoured. Following ATP formation in the tight state, it is necessary for another p 
subunit to be in the loose state and bind ADP and Pj. Thus it is likely that 
cooperativity exists between the sites (reviewed in Boyer, 1997).
Dissipation of the proton gradient from the inter-membrane space to the 
matrix through the Fo domain thus induces a rotational movement in the y and e 
subunits of the inner stalk. The 8  subunit may form part of an external stator. 
Rotation induces conformational change and alteration of catalytic activity in the 
nucleotide binding sites of the (ap)3 domain. This allows the phosphorylation of 
ADP with Pj to form ATP.
1.2. Other mitochondrial metabolic processes
While OXPHOS is crucially important for cellular respiration, mitochondria 
are involved in a number of other metabolic processes, some of which are described 
below.
1.2.1. The Krebs cycle
Glycolysis occuring in the cytosol converts glucose to pyruvate and directly 
generates a net of 2 ATP molecules. 2 NADH molecules per glucose are also fed 
into the ETC, and could theoretically generate up to 6  ATP molecules via OXPHOS. 
However, oxidative phosphorylation is not 100% efficient primarily due to proton 
(and electron) leak, and ATP-dependant processes.
The Krebs cycle was elucidated in 1937 (Krebs and Johnson, 1937, and a 
review is given in Scheffler, 1999). Pyruvate enters the mitochondrial matrix via the
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monocarboxylate translocator and is converted to acetyl-CoA by PDHC. Also called 
the citric acid cycle and the tricarboxylic acid (TCA) cycle (Fig. 1.5), the Krebs 
cycle describes the conversion of 6 -carbon citrate to oxaloacetate (a 4 carbon 
molecule) via a number of intermediates: cis-aconitate, isocitrate, a-ketoglutarate, 
succinyl CoA, succinate, fumarate and malate, and then from oxaloacetate to citrate 
via condensation with acetyl-CoA. Including the conversion of pyruvate, these 
reactions may be summarised as:
Pyruvate + Pi + GDP + 4 NAD+ + FAD I 3C02 + 4 NADH + FADH2 + GTP
With each “turn” of the cycle, 2 molecules of CO2 are liberated (one in the 
conversion of 6 -carbon isocitrate to 5-carbon a-ketoglutarate, another with the 
conversion of the latter to 4-carbon succinyl-CoA), both of which also reduce NAD+ 
to NADH. The reaction of succinyl-CoA to succinate phosphorylates GDP to GTP. 
Conversion of GTP to ATP is possible by the enzyme nucleoside diphosphokinase 
(EC. 2.7.4.6). FAD is reduced to FADH2 in the oxidation of succinate to fumarate; 
the electrons used to reduce FADH2 may also be used to reduce CoQ via the electron 
transport flavoprotein. The final oxidation of malate to oxaloacetate reduces a third 
molecule of NAD to NADH. These reducing equivalents thus generated act as 
substrates for the ETC described above.
The 8  major enzymes of the Krebs cycle are shown in Fig. 1.5. All but one 
are soluble matrix enzymes: succinate dehydrogenase (SDH; EC. 1.3.5.1) reviewed 
in Yankovskaya et al., 2003) is notable as a membrane-bound exception. Thus SDH
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Figure 1.5. The Krebs cycle.
Acetyl CoA may be generated by the action of PDHC on pyruvate, itself 
generated by glycolysis in the cytosol. The Krebs cycle generates the reducing 
equivalents NADH and FADH2 which can then become oxidised by the ETC. 
Additionally the conversion of succinyl-CoA to succinate liberates GTP, which can be 
converted to ATP by diphosphonucleotide kinase. Enzymes (#  ): 1: citrate synthase; 2: 
aconitase; 3: isocitrate dehydrogenase; 4: a-ketoglutarate dehydrogenase; 5: succinyl 
CoA synthase; 6: succinate dehydrogenase; 7: fumarase; 8: malate dehydrogenase.
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is a Krebs cycle enzyme directly linked to the ETC, and it is entirely possible that 
this electron-conducting enzyme can pass electrons directly to ubiquinone.
As the matrix is not permeable to NADH, glycolytically produced NADH 
enters the matrix compartment by a shuttle system (see Lehninger, for an overview; 
Rigoulet et al, 2004 for an in depth review) transporting reducing equivalents across 
the inner membrane. The malate-aspartate shuttle carries electrons into the matrix in 
the form of malate (Borst, 1963; Fig 1.6).
In the cytosol, malate is formed by the malate dehydrogenase (MDH; EC. 
1.1.1.37) from oxaloacetate, a reaction coupled to the oxidation of NADH. Malate is 
transported across the inner membrane (by the malate-a-ketoglutarate antiporter), 
whereupon it is converted back to oxaloacetate by mitochondrial MDH (also used in 
the Krebs cycle). This reduces NAD+, generating NADH. In order to complete the 
cycle, oxaloacetate must be transported back to the cytosol. This occurs by 
transamination to aspartate by the reaction of oxaloacetate with glutamate catalysed 
by aspartate aminotransferase (EC. 2.6.1.1; Fig 1.6). This generates a-ketoglutarate 
which can enter the Krebs cycle or leave the mitochondrion (coupled to malate 
entry) via the malate-a-ketoglutarate antiporter. Aspartate returns to the cytosol (via 
the glutamate-aspartate antiporter) and is then converted to oxaloacetate in the 
cytosol by its transamination using a cytosolic aspartate aminotransferase. The 
overall transport mechanism is governed by the level of NAD+ / NADH in the 
matrix; in the presence of high levels of NAD+, transport is inhibited.
A second system, the glycerol-phosphate shuttle uses the cytosolic and 
mitochondrial isoforms of glycerol-3-phosphate dehydrogenase (Glycerol-3-PDH;
NADH
malate
] malate
NADH
FADH
glycerol-3- 
DHAP phosphate
NADH NAD+
Figure 1.6. Mitochondrial reducing equivalent shuttle systems.
As the inner membrane is not permeable to NAD+, NADH, FAD or FADH2, the 
electrons must be passed to substrates which can cross the inner membrane. The upper 
scheme (yellow arrows) depicts the malate-aspartate shuttle for NADH; the lower one 
(green arrows) the glycerol-phosophate shuttle for FADH2. Enzymes ( ^  ) are MDH: 
malate dehydrogenase; AAT: aspartate aminotransferase; G-3-PDH glycerol-3- 
phosphate dehydrogenase, glu = glutamate; asp = aspartate
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EC. 1.1.1.8; Fig 1.6; reviewed in Rigoulet et al., 2004). The cytosolic isoform 
(cGlycerol-3-PDH) uses NADH as a cofactor while the mitochondrial isoform 
(mGlycerol-3-PDH) embedded in the inner membrane uses FAD+ (EC. 1.1.99.5). 
cGlycerol-3-PDH converts dihydroxyacetone phosphate (DHAP) to glycerol-3- 
phosphate (Glycerol-3-P). mGlycerol-3-PDH then reduces FAD+ generating FADH2 
which can donate these electrons to CoQ, in turn oxidised by the ETC (reviewed in 
Rigoulet et al., 2004). Thus less ATP is generated by reducing equivalent entry by 
the glycerol-phosphate then by the malate-aspartate shuttle system (Lehninger, 
2000).
1.2.2. p-oxidation o f fatty acids
Following the hydrolysis of fats to fatty acids, these can subsequently be 
degraded by a number of mechanisms (termed a, p or co oxidation) in peroxisomes 
or mitochondria, p-oxidation of saturated straight chain fatty acids occurs in 
mitochondria and these feed into the Krebs cycle via formation of acetyl CoA. Long 
chain fatty acids over 12 carbons in length utilise free CoA, ATP and a cytosolic 
acyl-CoA synthetase (EC. 6.2.1.3) tethered to the outer membrane of the 
mitchondrion to generate an acyl-CoA thioester (Roe & Coates, 1995). Carnitine 
palmitoyl transferase I (CPT-I; EC. 2.3.1.21) allows transfer of the acyl group to 
carnitine and forms acyl-camitine and free CoA in the cytosol. Given that p- 
oxidation occurs in the matrix (but the inner membrane is not directly permeable to 
long chain fatty acyl-CoA esters) the camitine-acylcamitine translocase exists to 
“shuttle” such molecules into the matrix (reviewed in Brivet et al, 1999). A
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permease in the mitochondrial membrane is responsible for the antiporter action. 
Acyl-camitine is exchanged for carnitine by the antiporter mechanism described. 
Once inside the mitochondrion, the esterfication reverses (via CPT II), forming acyl- 
CoA and free carnitine. Carnitine is subsequently exported to the cytosl via the 
transport mechanism described.
p-oxidation proper involves four enzymatic steps: an initial dehydrogenation, 
hydration, a further dehydrogenation and finally thiolysis to yield acetyl-CoA 
(reviewed in Wanders et al, (1999); Fig 1.7).
An acyl-CoA dehydrogenase (EC. 1.3.99.3) eliminates two hydrogen atoms 
from the acyl-CoA leading to the formation of a double bond between the a & p 
carbons of the acyl chain; the product is termed enoyl-CoA. 4 isoforms of the 
enzyme have been identified, each of which is specific with respect to the length of 
acyl chain which is being saturated. These are the short-chain acyl-CoA 
dehydrogenase (SCAD; EC. 1.3.99.2), medium-chain acyl-CoA dehydrogenase 
(MCAD; EC. 1.3.99.3), long-chain acyl-CoA dehydrogenase (LCAD; EC. 
1.3.99.13) and the very long-chain acyl-CoA dehydrogenase (VLCAD; EC. 
1.3.99.18). The reaction requires FAD as a cofactor and acts to accept electrons from 
the acyl-CoA molecule, becoming reduced to FADH2 . Subsequently, the latter is re­
oxidised to FAD by donation of these electrons to the electron transfer flavoprotein 
(ETF; Crane and Beinert, 1956). These electrons are used to pass electrons to 
ETF:ubiquinone oxidoreductase (EC. 1.5.5.1). This then reduces ubiquinone to 
ubiquinol (Beckmann and Frerman, 1985), which in turn feeds into the ETC as 
described previously.
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Figure 1.7. Mitochondrial p-oxidation o f fatty acids.
Following carnitine shuttling of long chain fatty acids into the mitochondrial matrix, they 
are shortened as described in the text. This generates NADH, FADH2 and acetyl CoA. The 
enzymes involved (signified # )  are 1: acyl-CoA dehydrogenases; 2: enoyl-CoA 
hydratases; 3: 3-hydroxyacyl-CoA dehydrogenases and 4: thiolases. FADH2 generated can 
subsequently reduce the electron tranfer flavoprotein < 4^  ), which can reduce ubiquinone.
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Hydration of enoyl-CoA by enoyl-CoA hydratases (EC. 4.2.1.17) adds a 
water molecule across the double bond, yielding 3-hydroxyacyl-CoA. This is then 
oxidised to p-oxoacyl-CoA; this is the second dehydrogenation step and is catalysed 
by one of at least 2 3-hydroxyacyl-CoA dehydrogenases (EC. 1.1.1.35). The 
enzyme appears to be dependant upon the acyl chain length: maximal activity of 
short-chain hydroxyacyl-CoA dehydrogenase (SCHAD) is for hydroxyacyl 
molecules of lengths between 4 and 10 carbon units. Long-chain hydroxyacyl-CoA 
dehydrogenase (LCHAD) preferentially dehydrogenates hydroxyacyl molecules of 
between 12 and 16 carbons (reviewed in Wanders et al., 1999). The concomitant 
reduction of NAD+ to NADH can thus be used by the ETC for subsequent ATP 
generation via OXPHOS.
Finally, the reaction between 3-oxyacyl-CoA and free coenzyme A results in 
thiolytic cleavage spliting the 3-oxyacyl-CoA (by 3-oxoacyl-CoA thiolase; EC. 
2.3.1.16) into an acyl-CoA ester 2-carbons shorter than the original (which can 
undergo further p-oxidation by re-entering the pathway) and acetyl-CoA (which can 
feed into the Krebs cycle). Thus it can be seen that given a number ‘‘passes” through 
this p-oxidative process, fats offer much greater potential for energy generation than 
carbohydrates.
If however, the fatty acid is unsaturated the mechanism becomes slightly 
more complicated: additional NADPH-dependant isomerases and reductases (whose 
specificity depends upon the number and positions of the double bonds) are 
involved, p-oxidation of fatty acids with an odd number of carbons also requires 
additional steps. The final formation of propionyl-CoA is converted to S-
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methylmalonyl-CoA by the addition of one carbon for which ATP hydrolysis is 
necessary. A racemase converts this isomer to R-methylmalonyl-CoA and a mutase 
requiring coenzyme B12 as a cofactor forms succinyl-CoA; the latter can enter the 
Krebs cycle as described previously.
1.2.3. Ketone Body metabolism
“Ketone bodies” is a term describing acetone, acetoacetate and 3- 
hydroxybutyrate. These metabolites are formed from acetyl-CoA under conditions 
of starvation when oxaloacetate tends to be diverted away from the Krebs cycle for 
use in gluconeogenesis (discussed in Girard et a l, 1992). In such “overflow” 
situations, ketone body metabolism becomes a valuable source of succinate and 
acetyl-CoA for the Krebs cycle, and NADH for OXPHOS (see Mitchell et al., 1995 
for a review). Mitochondrial involvement in this pathway comes from the 
localisation of key enzymes in this organelle in the liver. Two acetyl-CoA 
molecules condense in the presence of mitochondrial acetoacetyl-CoA thiolase (EC. 
2.3.1.9) to form acetoacetyl CoA and free coenzyme A (Fig 1.8). Acetoacetyl-CoA 
then further condenses with another acetyl-CoA in the presence of 3-hydroxy-3- 
methylglutaryl-CoA (HMG-CoA) synthase (EC. 2.3.3.10) to form HMG-CoA. The 
action of HMG-CoA lyase (which is also mitochondrial; EC 4.1.3.4) forms 
acetoacetate and acetyl-CoA. While the latter can enter the Krebs cycle directly, 
mitochondrial 3-hydroxybutyrate dehydrogenase (EC. 1.1.1.30) reduces acetoacetate 
to 3-hydroxybutyrate in the presence of NADH. While the use of ketone bodies as 
an energy source can occur more readily in high energy dependent tissues such as
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Figure 1.8. Ketone body metabolism.
Ketone bodies are formed predominantly in the liver and transported in the 
blood as acetoacetate and 3-hydroxybutyrate. Extra-hepatic tissues (including in 
extreme cases, the brain) can use ketone bodies as a source of acetyl-CoA for the Krebs 
cycle, succinate can enter the Krebs cycle or the ETC; and NADH can be used substrate 
for complex I of the ETC. The enzymes ( • )  are 1: acetoacetyl CoA-thiolase; 2: HMG- 
CoA synthase; 3:HMG CoA lyase; 4: 3-hydroxybutyrate dehydrogenase; 5: 3-keto- 
acyltransferase; 6: acetoacetate decraboxylase
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the heart, in times of extreme starvation, 3-hydroxybutyrate can traverse the blood- 
brain barrier where it is oxidised to acetoacetate and NADH. 3-ketoacyl-CoA 
transferase (EC. 2.8 .3.2) removes CoA from succinyl-CoA forming succinate and 
acetoacetyl-CoA. Free CoA and acetoacetyl-CoA thiolase forms 2 molecules of 
acetyl CoA for subsequent metabolism by the Krebs cycle. The action of 
acetoacetate decraboxylase can convert acetoacetate to the waste product acetone.
It should be noted that the exact localisation of the enzymes described here 
may vary somewhat with tissue and species specificity; additionally, some enzymes 
described as mitochondrial (ie, HMG CoA synthase) also have cytosolic isoforms.
1.2.4. The urea cycle
In order for animals to excrete excess nitrogen (obtained from metabolism of 
amino acids), it is made soluble by its conversion to urea (Krebs & Henseleit, 1932). 
The majority of urea production occurs in the liver, prior to transport to the kidneys 
for excretion in urine. The mitochondrion’s involvement in amino acid metabolism 
is via key steps in the urea cycle (reviewed in Scheffler, 1999). While much of this 
takes place in the cytosol, initial carbamoyl formation (from bicarbonate and 
ammonia utilising ATP) occurs in the mitochondrial matrix, catalysed by carbamoyl 
phosphate synthetase I (CPS I; EC. 6.3.4.16 see Lehninger, 2000 for an overview). 
Within the matrix, ornithine transcarbamoylase (OTC; EC, 2.1.3.3) then converts 
carbamoyl phosphate to citrulline by condensation with ornithine. Citrulline is 
exported to the cytosol, and following condensation with aspartate by 
argininosuccinate synthetase (EC. 6.3.4.5) yielding argininosuccinate. The action of
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argininosuccinase releases fumarate and arginine; the latter releases urea for 
excretion following hydrolysis by arginase (EC. 3.5.3.1). The resultant ornithine can 
then re-enter the mitochondrion, where it condenses with carbamoyl phosphate 
(catalysed by OTC) to begin the cycle again.
1.2.5. Regulation o f the life /  death cycle
From existing knowledge of the respiratory function, and their role in 
generating ATP, mitochondria are essential for eukaryotic life. However, over the 
last two decades it has become apparent that mitochondria are also intimately 
involved in the regulation of apoptosis (Luo et al., 1996; Srinivasula et al., 1998) or 
necrosis (Crompton and Costi, 1988; Nazareth et al., 1991). Additionally CoQ has 
recently been postulated as having a role in the modulation of mitochondrially 
mediated mechanisms of cell death.
As mentioned, mitochondria maintain an electrochemical gradient across the 
inner membrane resulting from proton transport from the matrix to the inter­
membrane space. As cells undergo necrosis, this potential is lost, believed to occur 
as a result of the formation of a pore in the inner membrane; the permeability 
transition (PT) pore. Potential triggers of pore formation include loss of adenine 
nucleotides, elevated P„ increased mitochondrial Ca2+, and oxidative stress. The PT 
is formed by an association of ANT in the inner membrane with the voltage- 
dependant anion channel (VDAC) of the outer membrane at sites of contact 
(reviewed in Crompton, 1999). Cyclophilin D (CyP-D) is generally assumed to be a 
cyclosporine (Cs)-binding matrix protein, and associates with ANT on the matrix
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site (although the physiological function of CyP-D and its role in PT pore formation 
remains to be completely elucidated; Crompton, 1999). CyP-D confers “Cs A- 
sensitivity” to the PT pore by blocking the pore following CsA binding (Szabo and 
Zoratti, 1991; Zoratti and Szabo, 1995). The diameter of the open pore is believed 
to be in the region of 2-2.5 nm, sufficiently large to allow matrix ions, metabolites 
proteins of up to 1500 Da to pass through. While transient pore opening, or very 
brief pore assembly has been proposed to have physiological functions, sustained 
opening of a number of pores will have hugely detrimental effects upon 
mitochondrial integrity: OXPHOS will effectively cease, ATP is further depleted 
due to hydrolysis via reversal of the FiF0 ATP synthase, osmotic swelling of the 
matrix occurs and crucially cytochrome c is released to the cytosol. Cytochrome c 
release has been proposed as a key factor in apoptotic death by promotion of caspase 
activation (Skulachev, 1996; Li et al., 1997). However, apoptosis is an ATP- 
dependant process (Liu et al., 1996). If the cell is ATP-deficient, necrosis may 
occur (reviewed in Martinou & Green, 2001).
Bcl-2 are a family of proteins which can be devided into pro- or anti- 
apoptotic factors. Bcl-2, Bcl-xL are anti-apoptotic whereas the Bax subfamily (Bax, 
Bak and Bok) and the BH3 subfamily (including Bid, Bad and Bim) are conversely 
pro-apoptotic (Martinou and Green, 2001). In a process which is possibly distinct 
from PT pore formation, Bax proteins are also proposed to insert into the outer 
membrane, an action inhibited by the anti-apoptotic members. The insertion of such 
proteins also results in the release of pro-apoptotic factors. Moreover, these proteins 
may also co-operate either positively or negatively with the PT proteins (Marzo et
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al., 1998). Whether cells die by apoptosis or necrosis may depend on upon the 
method mitochondrial disruption, and the cell’s “competence” to undergo apoptosis. 
In this case, cytochrome c and ATP participate in the formation of the 
“apoptosome”, a complex which assembles to activate the caspase cascade, and is 
triggered by cytochrome c.
It is possible that insertion of pro-apoptotic Bcl-2 proteins into the outer 
membrane allows initial maintenance of OXPHOS and thus apoptotic death. On the 
other hand, pathological opening of the PT pore has been suggested to cause matrix 
swelling, loss of membrane potential and thus ATP (Martinou and Green, 2001).
Recently, it has also been proposed that ubiquinone analogues may prevent 
the PT occurring, and thus inhibit cell death (Walter et al., 2000; Armstrong et al., 
2003). In addition, an inhibitor of the Qo site on complex III inhibited ROS 
production, PT formation and cell death (Armstrong et a l, 2003). While it has been 
suggested that this is due to the free-radical scavenging ability of CoQ (Armstrong et 
al., 2003), others propose more direct inhibition of activation by PT pore binding 
site interactions (Walter et al., 2000; Papucci et al., 2003)
Although a number of theories exist, the involvement of the mitochondrion, 
pore formation in the outer membrane and cytochrome c release is certain. 
However, the mechanism of cell death, and modulation of PT pore opening and / or 
formation remains a topic of intense debate.
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1.3. Oxidative and nitrosative stress
1.3.1. ROS and free radicals
Free radicals are reactive molecules which exist independently yet contain 
one unpaired electron. Free radicals occur as byproducts of a number of biological 
reactions, and occur during phagocytosis by neutrophils and macrophages: oxygen is 
reduced by NADPH oxidase in lysosomes to destroy invading bacteria. In addition, 
the cytochrome P 4 5 0  oxygenases also generate radicals (Coon et al.t 1973) as can 
other oxidases such as monoamine oxidase (EC. 1.4.3.4) and xanthine oxidase (EC. 
1.17.3.2; discussed in Halliwell and Gutteridge, 1999).
Gain of an electron by O2 results in the formation of a superoxide radical 
((V  "). O2 ' * molecules can pair up and dismutate to form hydrogen peroxide 
(H2O2), a reaction catalysed by superoxide dismutase (SOD; McCord & Fridovitch, 
1969; Oury et al., 1992). H2O2 can then be fully reduced to water, or partially 
reduced to the hydroxyl radical (OH ). Although H2O2, without any unpaired 
electrons is not strictly a radical, it is included as a reactive oxygen species (ROS). 
This term is used as an umbrella, covering a number of inter-related species such as 
0 2 ‘ \  H2O2, and O H \ The hypochlorite ion (OC1 *), like H2O2 also does not contain 
any unpaired electrons; however given its oxidative ability, it is also included when 
describing ROS.
Such molecules can have deleterious effects on a number of biological 
molecules including nucleic acids, cellular lipids, cytoskeletal proteins and enzymes 
(Halliwell and Gutteridge, 1999).
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1.3.2. Mitochondrial free radical generation
Mitochondria, and specifically the ETC, have been implicated as a major 
source of ROS within the cell (Boveris & Chance, 1973). It has been proposed that 
between 1 and 3% of electrons passing through the ETC form 0 2' ' (from Halliwell 
& Gutteridge, 1999). Thus “electron leak” from respiratory components of the ETC 
contributes markedly to 0 2 * ‘ levels in cells (reviewed in Turrens, 2003). Complexes 
I, II and III in the inner membrane have all been shown to have the ability to reduce 
oxygen to 0 2 * * (reviewed in Turrens, 2003), ubisemiquinol is present in all 
membranes and may pass single electrons to oxygen, whilst in the outer membrane 
monoamine oxidase is capable of producing H2O2. Tissue type may also be a factor: 
while complex III is believed to be responsible for most ROS production in lung and 
heart mitochondria (Turrens & Boveris 1980; Turrens et al., 1982), in the brain, 
complex I may be the major source of 0 2 ' ’ (Barja & Herrero 1998). Additionally, if 
the ETC begins to become reduced (i.e. inhibition of “downstream” carriers causing 
electrons to “back-up”; “State 4 respiration”), then O2 ' ' formation is more likely to 
occur (Scheffler, 1999; Turrens, 2003).
Complex III is often cited as a major producer of ROS within the 
mitochondrion (Boveris et al, 1976; Han et al., 2001; Chen et al, 2003). The 
implication is that following removal of one electron from ubiquinol at the Qo site, 
the resultant semiquinone can become reduced to ubiquinone by passing an electron 
to O2 in the aqueous phase thus generating 0 2 * ' (Nohl and Jordan, 1986; Chen et 
al, 2003).
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1.3.3. Physiological NO generation
Nitric oxide (NO) is formed in a number of tissues including neural, vascular 
and immune cells. Its role as a signaling molecule has been implicated in diverse 
physiological processes such as neurotransmission, memory formation, immune 
response and vasodilatation (reviewed in Lincoln et a l, 1997 and Duncan and 
Heales, 2005). Formed when the guanidino nitrogen of L-arginine reacts with 
molecular oxygen in the presence of nitric oxide synthase (NOS EC. 1.14.13.39), 
various cofactors are necessary including tetrahydrobiopterin (BH4), FMN and 
NADPH. NO is also a free radical, and can react with a number of ROS to produce 
reactive nitrogen species (RNS) such as the nitroxyl and peroxynitrite anion (NO' 
and ONOO' respectively), nitrosonium cation (NO+) and the NO radical itself.
At least three isoforms of NOS are known to exist, denoted NOS I, II, and 
III. NOS I (nNOS) is found as a cytosolic Ca2+-dependant enzyme in central and 
peripheral neurons (Knowles et al., 1989; Gillespie et al., 1989). Intracellular 
calcium above approximately 400nM allows Ca2+-calmodulin binding of NOS. As 
Ca2+ is very rapidly cleared from the cell, calmodulin dissociates from NOS, 
allowing tight control over NO production in neurons (Bredt and Snyder, 1990). 
Given the nature of the molecule, and the products formed in its reaction with ROS, 
it is unsurprising that inappropriate NO generation by NOS I is implicated in a 
number of pathologies (reviewed in Lincoln et al., 1997 and Duncan & Heales, 
2005)
NOS II (iNOS) is also cytoplasmic, and was initially reported in 
macrophages (Marietta, et al., 1988; Hibbs et al., 1988) and is now known to exist in
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a number of immune cell types including astroglia (Simmons and Murphy 1992). 
However, under basal conditions this inducible form of NOS is not expressed. 
Under transcriptional control, (Xie et al., 1993; reviewed by MacMicking et al., 
1997) NOS II activity is not Ca2+-dependant; instead it is already bound to 
calmodulin (Cho et al., 1992). Thus it is able to generate large amounts of NO for 
much longer periods of time that the other constitutive isoforms: whereas NOS I and 
NOS III generate picomolar concentrations of NO, NOS II may generate in the 
nanomolar range (Anggard, 1994). Stimulation of NOS II can be initiated by pro- 
inflammatory mediators such as bacterial membrane products and endogenous 
cytokines including y-interferon (IFNy), interleukin-1 (IL-1), and tumour necrosis 
factor-a (TNFa) (Bolanos et al., 1994; reviewed in Murphy et al., 1993 and 
MacMicking et al., 1997).
It is important that NOS II induction occurs with a concomitant increase in 
the cofactor BH4. If BH4 availability is limiting, NOS II has been proposed to 
preferentially generate O2 ' \  Such a situation would have the potential to generate 
ONOO', a stronger oxidant than either NO or 02’ ’ (Consentino et al., 2001).
NOS III is targeted to cavaeolae, small invaginations in the cell membrane. 
This isoform is, like NOS I, dependant on Ca2+ binding calmodulin and subsequently 
NOS to allow NO synthesis. The main action of NO thus generated is to act as a 
vasodilator in smooth muscle, particularly that allowing fine local control of the 
vasculature such as endothelial cell membranes (for reviews see Moncada et al., 
1991 and Alderton et al., 2001). In the endothelial cell, a major activator of NOS III
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activity is mechanical shear stress resulting from blood flow within the vessel (Buga 
et al., 1991).
A novel isoform of NOS has been reported in mitochondria. Mitochondrial 
NOS (mtNOS) was first proposed a decade ago (Bates et al., 1995, 1996) and was 
proposed as a physiological regulator of the ETC at the level of complex IV. Later 
postulated as a splice variant of NOS I rather than a novel NOS isoform (Kanai et 
al., 2001, 2003), conflictingly mtNOS was found to be reactive to NOS II 
antibodies, but not those for NOS I or III (Tatoyan & Giulivi, 1998). However, 
recent works by Lacza et al. (2003, 2004) and Tay et al., (2004) have refuted the 
hypothesis of the presence of physiologically relevant mtNOS in a number of 
models. Although the subject of a recent review (Haynes et al., 2004), it is likely 
that until a gene encoding a NOS protein with a mitochondrial targeting sequence is 
found, the issue will remain unresolved.
1.4. Introduction to Ubiquinone
1.4.1. Historical background and nomenclature
Ubiquinone (also termed Co-enzyme Q; CoQ) describes a series of 
homologous quinones widely distributed in nature. "Ubiquinone" was first described 
by Festenstein and co-workers in 1955, who used the term to denote the ubiquitous 
nature of a molecule found in many tissues. In 1957, Crane et al. suggested that "Co­
enzyme Q" was a component of the ETC, and the following year Karl Folkers' group 
determined the structure (Fig. 1.3; Wolf et al., 1958) confirming the findings of 
Festenstein et al., (1955). However, it was not until 1975 that the IUPAC-IUB
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Commission of Biochemical Nomenclature deemed that "ubiquinone" be the official 
name of the molecule. (IUPAC-IUB, 1975) However, the fact that ubiquinone 
describes a series of quinones means that in fact CoQ with a numerical subscript is 
probably a more accurate term when describing structural isoforms. Although 
IUPUC nomenclature does not dictate which molecular mass isoform is being 
referred to, it does however give insight into the redox state: ubiquinol describes the 
reduced molecule (C0 QH2), ubiquinone for the oxidised form and ubisemiquinone 
the intermediate (Fig. 1.3).
1.4,2. Structure and biosynthesis
The molecule can be split into two distinct moieties: a six-membered carbon 
ring, with 2 delocalised oxygens at positions 1 and 4 (the quinone), and a "tail" 
section comprising a chain of repeating isoprenyl units. The number of repeats is 
denoted by the numerical subscript used in the nomenclature of CoQ (i.e. C0 Q9, 
CoQ 10).
The biosynthetic pathway was originally determined in bacteria and although 
not fully elucidated, is believed to be similar in mammals. However this assumption 
must be treated with a degree of caution, as although two mammalian genes 
involved in biosynthesis have been identified (Vajo et al., 1999; Johanssen and 
Clarke, 2000) no mammalian enzymes involved in the pathway have as yet been 
purified or cloned (Dallner and Sindelar, 2000; Turunen et al., 2004). The pathway 
has two distinct "arms" (Fig. 1.9): the formation of the six-membered benzoquinone 
ring from tyrosine, and the mevalonate pathway forming the isoprenyl tail from
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Figure 1.9. The CoQ jo biosynthetic pathway.
The benzoquinone nucleus is derived from tyrosine or phenylalanine; the 
mevalonate pathway responsible for the synthesis of the isoprenyl side-chain is better 
understood in mammals. Confirmed enzymes ( Q )  are: 1: acetoacetyl CoA-thiolase; 2: 
HMG-CoA synthase; 3: HMG-CoA reductase; 4: mevalonate kinase; 5:
phosphomevalonate kinase; 6 : mevalonate-PP decarboxylase; 7: famesyl-PP synthase; 
8 : transprenyl transferase; 9: decaprenyl 4-OH-benzoate transferase; 10: squalene 
synthetase. Postulated enzymes ( ^ )  involved in CoQ synthsis are a: tyrosine 
transaminase; b: 4-OH-phenllactate dehydrogenase; c and d represent single or multiple 
enzymes involved in dehydroxylation and p-oxidation respectively.
CoA = coenzyme A; HMG = 3-hydroxy-3-methylglutaryl; PP=pyrophosphate
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acetyl CoA. While these reactions probably occur within the rough endoplasmic 
reticulum, it is the Golgi body in which these two structures undergo a condensation 
reaction, catalysed by a polyprenyl transferase (EC. 2.5.1.39), forming the "ring and 
chain" structure as shown (reviewed by Crane, 2001 and Turunen et a l, 2004). The 
mevalonate pathway is also common for cholesterol synthesis, and is regulated by 
the rate-limiting enzyme 3-hydroxy-3-methyl glutaryl-Coenzyme A reductase 
(HMG-CoA reductase; EC 1.1.1.3.4; Rodwell et al., 1976) and probably also 
transprenyl transferase (Turunen et al., 2004).
Thus although a number of genes for CoQ sysnthesis have been identified in 
bacteria (Vajo et a l, 1999), yeast (Marbois and Clark, 1996; Belogrudov et al., 
2001) and Caenorhabditis elegans (Miyadera et al., 2001), characterisation at the 
protein level using mammalian genes will yield greater understanding of the 
biosynthesis of CoQ.
1.5. Functions o f  Ubiquinone
CoQ has at least three documented physiological roles, acting primarily as an 
electron carrier within the ETC and additionally as a cellular antioxidant (see Emster 
and Dallner, 1995 and Turunen et al., 2004 comprehensive reviews). It has also 
recently been established that CoQ also acts as a cofactor for mitochondrial 
uncoupling proteins (UCPs) (Echtay et al., 2000, 2001).
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1.5.1. CoQ as an antioxidant
Although electron transfer takes place within the inner membrane of the 
mitochondrion, it should be borne in mind that CoQ is found in all cellular 
membranes. In its fully reduced form ubiquinol, the molecule acts as an antioxidant, 
protecting cellular lipids, proteins and DNA against the potentially toxic effects of 
radical damage, usually as a result of nitrosative/oxidative stress. This would appear 
to be particularly relevant in mitochondria, given that the ETC is a major source of 
oxidising species (Liu et a l , 2002, Chen et al., 2003). Within the past decade, it has 
also been shown that ubiquinol can reduce tocopheryl radicals and 
semidehydroascorbate back to a-tocopherol and ascorbate respectively 
(Constantinescu, et al., 1994, Villalba, et al., 1995). Thus CoQ has a significant 
secondary antioxidant function which should not be overlooked.
In many tissues, the quinol form predominates, especially the pancreas where 
none appears to be present in the oxidised form (Aberg et al., 1992). However, 
variability between tissues is evident as the same study also noted that in the brain 
only 23% is present as ubiquinol. Given the susceptibility for this organ to damage 
as a result of oxidative stress, the role of ubiquinone as potential neuroprotective 
agent continues to be investigated by a number of groups (Beal and Matthews, 1997; 
Shults et al., 1997; Di Giovanni et al., 2001; Shults et al., 2002)
CoQ short chain homologues are more effective antioxidants than longer 
chain subtypes in vitro, although side chain length of C0 Q5 through CoQ 10 may have 
little effect on reactivity in vitro (Kagan et a l, 1990). Thus the role of the side chain
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may be to modulate hydrophobicity (and thus the position within the membrane) and 
possibly ETC complex binding.
7.5.2. Electron transfer
The role of CoQ as an electron carrier in the ETC is facilitated by the 
chemical properties of the molecule: it can diffuse freely within the membrane 
without "leaking" into the aqueous phase, and easily cycle between redox states. Its 
lipid nature dictates that ubiquinone binds complex I in a membrane-bound domain. 
Upon accepting electrons from complex I, a single carbonyl group on the six- 
membered ring becomes reduced to the O* (ubisemiquinone) form. A second 
electron will further reduce this to ubiquinol. Similarly, complex II reduces 
ubiquinone to the quinol form, and the carrier subsequently binds to complex III. 
Upon binding the Qo site in its reduced form (and Qi in the oxidised state), the 
electrons are transferred to cytochrome c, and ubiquinone re-generated. Electron 
transfer is directly coupled to the pumping of protons from the matrix to the intra­
membrane space (reviewed in SchefTler, 1999).
It is likely that CoQ populates the membrane as a homogeneous "pool" 
(Kroger and Klingenberg, 1973), although some will remain protein-bound. The 
model proposed by Kroger and Klingenberg represents a freely diffusible pool, 
interacting with the complexes as a result of random Brownian collisions. This has 
recently been challenged by the suggestion of Schagger and Pfiffer (2001) that the 
ETC may exist as a series of supercomplexes. Subsequently, it may be necessary to 
reconsider the nature of the CoQ pool (reviewed in Lenaz, 2001).
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While it is generally believed that ubiquinones with side chains of differing 
length probably have the same physiological role, there is a body of evidence 
accumulating which may suggest the contrary. As a general rule, short-lived animals 
(such as rodents) utilise C0 Q9 while in longer-lived species C0 Q 10 predominates 
(Ramasara, 1985). Given ubisemiquinone's conversion to ubiquinone at complex III 
can reduce molecular oxygen to superoxide (CL) (Liu et al, 2002; Chen et al., 
2003), Lass and co-workers measured O2 ' generation in nine different mammalian 
species with varying C0 Q9 : C0 Q 10 ratios (Lass et al., 1997). It was found that the 
amount of O2" generated by the ETC of sub-mitochondrial particles was directly 
correlated to the amount of C0 Q9 and inversely correlated to the amount of C0 Q 10 
(Fig. 1 . 1 0 ). This group also suggested that C0 Q 10 was a more effective antioxidant 
than C0 Q9. Thus although the molecular structural differences of the two isoforms 
are relatively minor, the difference in hydrophobicities may have an effect on the 
molecule’s position in the bilayer, including the inner mitochondrial membrane. 
The resultant functional differences between C0 Q9 and C0 Q10 have been 
investigated by Edlund et al., 1994. This study infected rat neurons with Sendai 
virus and mumps virus causing cell death in a large proportion of neurons. It was 
noted that following viral treatment, ubiquinone levels were lower than in untreated 
cells. Moreover, C0 Q 10 depletion was more profound than that of C0 Q9 (Edlund et 
al, 1994). Addition of C0 Q 10 but not C0 Q9 conferred protection to those neuronal 
cultures, resulting in increased cell survival. As oxidative stress is implicated in 
neuronal death due to viral infection, it is possible that C0 Q 10 is acting as an 
antioxidant, whereas C0 Q9 does not. This may support the work of Matsura et al,
63
'c<Ds
CL
a .2'E-a
EN “
c
0
c
O
0
0
u i
OX)
E
c
E2
7
horse
,cow
6 goat sheep mouse
rat
5
4
3
;uinea pig
2
1
0
0 1 1.5 2 2.5 3
Rate of 0 2 * generation 
(nmol/min/mg protein)
Fig. 1.10. Relationship between the rates o f  O i generation and the amount o f  CoQ 
extractable from  mitochondria (from Lass et a l 1997).
Data from studies conducted by Sohal and co-workers lends support to the 
hypothesised functional differences between C0Q9 and C0Q10. Here, the rate of O2* 
generation in cardiac sub-mitochondrial particles from nine mammalian species was 
measured, and plotted against the amount of C0Q9 (A ) and C0Q10 ( ■ ) in that species. 
This direct correlation between C0Q9 and the inverse correlation between C0Q10 and O2* 
generation may support a link between the relative abundance of C0Q10 and longevity.
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(1991) who postulate that in Japanese white rabbit liver cells C0 Q 10 acts as a 
mitochondrial antioxidant while C0 Q9 was found to be mostly extra-mitochondrial. 
However, this may contrast their later findings (Matsura et al., 1992) which state 
that C0 Q9 is more effective as an antioxidant in rat hepatocytes.
1.5.3. CoQ as an uncoupling protein co-factor
As mentioned previously, CoQ analogues have been proposed as 
being either positive or negative regulators of the mitochondrial PT pore dependant 
on side chain (Walter et al., 2000), and relatively recently, another role has been 
ascribed to ubiquinone within the mitochondrion. Uncoupling proteins exist in the 
inner membrane of mitochondria to uncouple oxidative phosphorylation 
(Klingenberg et al., 2001). Their well-documented function in brown adipose is to 
allow thermogenesis (reviewed by Kingenberg et al., 2001). Achieved by the 
“futile” dissipation of the proton gradient rather than flow through the ATP 
synthase, UCP’s allow the flow of protons back into the matrix, and the conversion 
of this energy to heat. Thus it is evident that mitochondrial uncoupling must be 
tightly regulated in order to avoid excessive dissipation of the proton gradient and 
subsequent inhibition of ATP synthesis. Oxidised C0 Q 10 has been identified as a 
cofactor for UCP activation for UCP 1 (Echtay et al., 2000), and subsequently for 
UCP2 and UCP3 whose primary functions are not yet completely understood 
(Echtay et al., 2001).
UCP’s have been shown to increase proton conductance in response to 
superoxide O2' generation (Echtay et al., 2002a), and this has been shown to occur
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from the matrix side (Echtay et a l, 2002b). Thus it has been proposed that UCP 2 
and UCP3 open at time of excessive mitochondrial ROS generation to either clear 
intramatrix O2' where they may undergo more rapid dismutation due to the lower pH 
or scavanging by antioxidants (Echtay et al., 2002b) or alternatively by oxidising the 
ETC to decrease ROS production. UCP2 activation was postulated to occur under 
conditions in which the ETC was reduced (by KCN-induced inhibition of complex 
IV); subsequently CoQ will be mostly in the reduced state (Echtay et al, 2002b). 
While these authors proposed that only oxidised ubiquinone would participate in 
UCP1 uncoupling (Echtay et al, 2000), later works suggested the quinol form of 
mitochondrially-targeted CoQ was necessary for uncoupling o f UCP2 (Echtay et al, 
2002b).
7.6. Human Ubiquinone Deficiency
Having considered some aspects of the physiological roles of ubiquinone, its 
key role within the ETC is evident. In man, disruption of the ETC leads to defects 
of mitochondrial respiratory function, leading to a clinical condition termed 
mitochondrial cytopathy (see Wallace, 1999 for a review) Such dysfunctional 
mitochondria are usually the result of inborn errors of metabolism, and the arising 
conditions are considered largely untreatable. However, conditions ascribed to a 
deficiency in ubiquinone may be amenable to therapeutic intervention following 
early and accurate diagnosis (Rotig et a l , 2000).
Human C0 Q 10 deficiency can be dominated by myopathic or cerebellar 
involvement, and usually presents within the first two years of life (Boitier et al,
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1998; Ogashara et al, 1989; Rahman et al, 2001; Van Maldergem et al., 2002). 
Symptoms may include ataxia and dystonia, developmental delay, myopia and visual 
loss possibly due to retinitis pigmentosa and /or optic nerve atrophy. Renal and 
cardiac complications may also be evident, and the symptoms associated with most 
mitochondrial encephalomyopathies are usually progressive. However, 
mitochondrial encephalomyopathies are usually diagnosed by enzymatic assays 
following skeletal muscle biopsy to determine activities of the mitochondrial 
complexes and intermediates (Heales et a l, 1995).
In 2001, Rahman and co-workers reported a case of a neonate presenting 
with ubiquinone deficiency (Rahman et a l, 2001). A baby boy presented at 6 hours 
with "poor feeding, hypothermia and shaking of both arms". Increased peripheral 
muscle tone was evident, MRI scans demonstrated cerebral and cerebellar atrophy, 
and peripheral conditions including renal tubulopathy, cardiac hypertrophy and 
hypokinesia prompted biochemical investigation.
Ubiquinone deficiency in humans can be diagnosed by determination of the 
CoQio concentration of a skeletal muscle biopsy and following determination of the 
enzymatic activities of the mitochondrial complexes, in particular the combined 
activity of complexes II+III as this assay relies upon the presence of endogenous 
ubiquinone (Clark et al, 1994), CoQio determination can achieved by high- 
performance liquid chromatography (HPLC). The patient values are shown in Table
1.1, and it can be seen that while the activities of the separate complexes are within 
the reference range, the linked II+III assay in the absence of exogenous ubiquinone 
(CoQi) was undetectable. In the presence of CoQi, the value of the complex II+III
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Assay Patient Value Paediatric reference range
Complex I 0.163 0.104-0.268
Complex II+III <0.001 0.04-0.204
Complex II+III+CoQi 0.098 0.04-0.204
Complex IV 0.018 0.014-0.340
Complex II 0.151 0.052-0.258
Complex III 0.026 0.008-0.028
CoQio (pmol/ mg protein) 37 140 - 580
Plasma lactate pre-CoQio 
(mmol/L) 7.6 0.9-1.9
Plasma lactate post-CoQio 
(mmol/L) 2.5-2.9
0.9-1.9
Table 1.1. Muscle ETC enzyme activities with ubiquinone concentration and plasma 
lactate values
(From Rahman et al., 2001). Expressed against citrate synthase (CS) activity, 
these values would suggest a ubiquinone deficiency, given the marked increase in the 
complex II+III activity in the presence o f exogenous ubiquinone (CoQi). Plasma 
lactate values before and after CoQio therapy (up to 300 mg/day) are also shown.
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assay fell within the existing reference range. Additionally, elevated plasma lactate 
is not uncommon in patients with suspected ubiquinone deficiency, and as shown in 
Table 1.1, the lactate concentration as measured from this patient was clearly outside 
the accepted reference range.
Following administration of oral CoQio at 11.5 months, (initially 60 mg/day, 
increasing to 300 mg/day), lactate levels decreased from 7.6 mmol/L (at the 
beginning of therapy) to 4.4 mmol/L on day 11, to 2.5 mmol/L by 4 months. 
Unfortunately, the decrease in lactate concentration was not accompanied by a 
clinical improvement of symptoms and the patient died at 2 years. Although the 
observed decrease in plasma lactate may be due to a greater availability of CoQio as 
a result of supplementation, this cannot be confirmed, as consent was not obtained 
for a post-mortem examination (Rahman et al., 2001).
Although CoQ-deficient states may present within the first few years of life, 
some adult cases have been documented (Ogashara et a l, 1986; Van Maldergem et 
al., 2002). The latter publication documents the case of 2 sisters, then aged 31 and 
34 both having previously been diagnosed with Leigh’s Syndrome (LS) as infants 
and displaying a similar catalogue of clinical symptoms. However, CoQio 
deficiency was not detected. In addition to the developmental delay, increased 
lactate : pyruvate ratio and basal ganglial lesions indicative of LS, at 4 years, the 
younger sister displayed ptosis, muscle wasting, spasticity, and required orthopaedic 
shoes to allow her to walk. She later became deaf and failed to undergo puberty. At 
19 years, the only mitochondrial abnormality detected was a mild complex I 
deficiency in fibroblasts; in skeletal muscle biopsy, complex II+III activity was
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normal. At 24 years her general condition worsened, she refused feeding, rapidly 
began to lose weight and became bedridden. A muscle biopsy was again performed 
and this time found decreased complex II+III activity. Following addition of 
exogenous decylubiquinone to the assay reaction mixture, this activity increased 
eightfold bringing the patient values inside the control range. Moreover, 
determination of muscle CoQio concentration in this patient revealed levels around 
5% of the normal mean. Analysis CoQio in lymphoblastoid cultures revealed a 
decrease of around 50% (Van Maldergem et a l, 2002).
Administration of exogenous CoQio (300 mg/day) at age 24 improved her 
clinical profile dramatically. Within 15 days muscle abnormalities had decreased, 
eating resumed and she regained the ability to walk. 7.6kg was gained within 6 
months and she underwent puberty at 26 years. By 29 years, the patient had grown 
20 cm in height in the 5 years since beginning CoQio therapy.
The later biochemical analyses of mitochondrial complex activities of this 
patient suggested a primary CoQio deficiency (Van Maldergem et al., 2002). This 
was supported by the findings of lowered levels of CoQio in both muscle and 
lymphoblastoid cells. Subsequent oral supplementation with exogenous CoQio was 
clearly beneficial in improving her condition.
When considering the role of mitochondria in the neurodegenerative process, 
it is unsurprising that these disorders manifest themselves with neurological 
symptoms. Bearing in mind the neuron's susceptibility to damage following an 
energy deficit, and CoQ's antioxidant properties, individuals who for whatever 
reason become CoQ deficient may not only fail to generate sufficient ATP for
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normal cellular function, the tissue will also be more readily damaged by oxidising 
species. Thus supplementation with oral CoQio may prove useful not only in the 
treatment of patients with ubiquinone deficiency, but also certain neurodegenerative 
conditions associated with oxidative stress and mitochondrial dysfunction.
1.7. Mitochondrial targets in neurological disease
Neurodegenerative diseases, such as Parkinson's Disease (PD) and 
Alzheimer's Disease (AD), are characterised by a progressive loss of neuronal 
function in specific brain regions. Although definate mechanisms are only 
beginning to be elucidated, oxidative/ nitrosative damage has been implicated in the 
pathology of many neurodegenerative conditions (reviewed in Stewart and Heales, 
2003; Duncan and Heales, 2005). For example in PD, elevated levels of nitrosylated 
proteins have been detected (Good et al., 1998; Giasson et al., 2000). This has been 
supported by increases in the CSF concentration of NO breakdown products 
(Quereshi et al., 1998). Post-mortem examination of the brains of patients suffering 
from AD has also shown elevated levels of protein nitrosylation (Smith et al., 1997). 
It has been proposed that damage to mitochondria, and in particular the ETC, 
underlies a component part of neuronal loss in these diseases.
Schapira and co-workers found that complex I activity was decreased in 
post-mortem samples from the substantia nigra of patients with PD (Schapira et al.,
1990). A number of other studies have supported these findings (Cleeter et al, 
1992; Glinka et al., 1996). Additionally, in the same tissue evidence of NOS 
activity, NO radicals and nitrotyrosinated protein residues (suggesting ONOO'
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formation) have all been demonstrated (Hunot et al, 1996; Shergill et al., 1996; 
Good et al., 1998). However, the susceptibility of complex I to ROS / RNS has 
itself been a catalyst for scientific debate within the literature. While NO has been 
reported to inhibit complex I activity in permeabilised hepatocytes (Stadler et al.,
1991), and Radi and colleagues reported ONOO' -mediated decreased complex I 
activity in heart mitochondria (Radi et al., 1994; Cassina and Radi, 1996), these 
findings were not supported by whole cell in vitro studies with NO (Bolafios et al, 
1994) or ONOO' (Bolafios et al., 1995). These differences may be due to the 
differing preparations used in these studies. Reviewed by Brown and Borutaite 
(2004), damage to Fe-S centres in complex I (including removal of iron from and 
disruption of Fe-S centres) has been proposed to account for complex I inhibition by 
RNS. S-nitrosation also represents a reversible mechanism of complex I inhibition 
as reduced thiols (ie. GSH) can reverse such inhibition, as demonstrated in a number 
of models including isolated heart mitochondria (Jekabsone et al., 2003). ONOO' 
has also been suggested to induce complex I inhibition in a neural cell line by 
nitration of tyrosine residues (Yamamoto et al., 2002)
It has been proposed that maintenance of complex I activity in the face of 
ROS / RNS may be due to glutathione (GSH) availability (Barker et al, 1996; 
Clementi et al., 1998). GSH reacts favourably with with ROS / RNS; however 
given a sufficiently high level of oxidative stress upon the cell, it is possible that 
susceptible proteins such as the ETC may become vulnerable to free radical- 
mediated attack. In addition loss of GSH from the substantia nigra is proposed to be 
an early event in PD, preceeding mitochondrial damage (Jenner et al., 1992).
72
Experimental depletion of GSH with the biosynthetic inhibitor L-buthionine 
sulphoximine (L-BSO) has revealed that GSH depletion of astrocytes increase the 
susceptibility of the ETC (particularly at the level of complex I) to ROS / RNS- 
mediated damage (Barker et al, 1996; Bolafios et al., 1996).
The activities of complex II and complex III are often measured as a linked 
assay (King et a l, 1967), and it has been suggested that this system is susceptible to 
RNS (and possibly ROS). Culture of astrocytes in the presence of NO has shown 
decreased activity of complex II+III (Bolafios et al, 1994); this study was 
subsequently supported by the finding of irreversible complex II+III damage as a 
result of ONOO' (Bolafios et a l, 1996). It is possible that complex II (in particular 
SDH) is more susceptible to oxidative/ nitrosative stress in cultured brain cells (Radi 
et a l, 1994; Mitrovic et a l, 1994) and isolated brain mitochondria (Brookes et al, 
1998). Heart sub-mitochondrial particles have been shown as being sensitive to 
H2O2, O2 ' and OH* (Zhang et al, 1990); a finding subsequently confirmed with 
intact brain mitochondria (Gluck et a l, 2002).
Loss of complex IV activity has been reported in AD (Kish et al, 1992), and 
this has been associated with pathogenic P-amyloid generation (Canevari et al, 
1999; 2001). AD represents another condition in which inappropriate NO 
generation and mitochondrial dysfunction have been implicated (Dorheim et al, 
1994; Casley et al, 2001; 2002). This complex has been known to be susceptible to 
the effects of NO for over 60 years (Keilin and Hartree, 1939). Reduced cytochrome 
a3 of complex IV can form a nitrosyl-haem centre in the presence of NO (Brudvig, et 
al, 1980), effictively acting as a competitive inhibitor of the active site. This
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increase in the Km for O2 (and a concomitant decrease in F ^ )  has the potential to 
make ATP generation much more sensitive to oxygen tension (Brown and Cooper, 
1994; Sharpe and Cooper, 1998). Complex IV inhibition has been demonstrated by 
NO using a number of models including cultured cells (Bolafios et al, 1994; 1996), 
isolated mitochondia (Cleeter et al, 1994; Poderoso et al, 1996) and purified 
enzyme (Sharpe and Cooper, 1998).
Thus inhibition of one or more of the mitochondrial complexes can give rise 
to an energy deficit. It is now well known that mitochondria display wide variation 
between cells and cell types, and this is especially true of the heterogeneous 
mitochondrial population in the brain (Davey et a l, 1997). These authors showed 
that <60% inhibition of complex I in non-synaptic mitochondria will not 
compromise ATP synthesis whereas synaptic mitochondria can become ATP 
deficient after only 25% complex I inhibition. Supported by work from the same 
group published the following year using cultured cells, (Davey et al, 1998) 
threshold studies using isolated mitochondria from two cell types examined in vitro 
can be useful in gaining insight into the heterogeneity of mitochondrial populations. 
It is now understood that brain cells which become ATP-compromised will suffer an 
energy deficit, and if this insult is sufficiently severe and/ or prolonged, the ensuing 
cellular and mitochondrial damage may give rise to cell death through either the 
apoptosis or necrosis pathways.
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1.8. Ubiquinone and Neurodegeneration
Disruption of CoQio metabolism has been implicated in various 
neurodegenerative diseases including PD (Matsubara et al, 1991; Shults et al, 
1997; Gotz et al, 2000), Lewy body disease (Molina et al, 2002) and AD 
(Soderberg et al, 1992). In Keams-Sayre Syndrome and other 
encephalomyopathies, altered CoQio metabolism has also been implicated 
(Ogasahara et al, 1986, 1989; Rotig et al., 2000). However a similar number have 
countered much of the evidence presented, finding no change in endogenous CoQio 
levels. (Beal and Matthews, 1997; Jiminez-Jiminez, et al, 2000; Molina et al, 
2000).
It would appear that many different groups have contrasting findings, which 
may in part be due to the variety of methods for determining ubiquinone 
concentration. Whether CoQio levels are measured in serum (Molina et al, 2000), 
muscle (Di Giovanni et al, 2001), brain (Soderberg et a l, 1992), platelets (Gotz et 
al, 2000) or fibroblasts (Rotig et al, 2000) may influence the findings and 
interpretation. Oral CoQio supplementation has been reported to slow the functional 
decline in PD (Shults et al, 2002). However, direct evidence of a CoQio deficit in 
the Parkinsonian brain is currently lacking. Additionally, a number of groups have 
obtained apparently contradictory results with regard to C0 Q9 or C0 Q10 entry to the 
brain following oral supplementation (Matthews et al, 1998; Kwong et al, 2002; 
Bentinger et a l, 2003; Kamzalov et a l, 2003; Gomez-Diaz et al, 2003b); thus the 
reported benefits of CoQ supplementation in neurodegenerative states require further 
investigation to fully understand the mechanisms involved.
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The hypothesis inferring altered C0 Q9 or C0 Q 10 metabolism in cases of 
neurodegeneration may however be supported by the work of Bolanos et al., 1994. It 
was shown in this study that treatment of primary cultures of rat astrocytes with 
lipopolysaccharide (LPS) and y-interferon (IFNy) caused induction of NOS II. The 
elevated levels of NO subsequently generated led to mitochondrial inhibition, 
determined by measurement of the activities of the complexes of the ETC. After 
18h cytokine exposure, complex IV activity was reduced by 25% compared to 
control values. After 36h exposure, complex IV exhibited 56% inhibition, and 
complex II+III activity was reduced by 35%.
The latter phenomenon could be explained by nitrosative/ oxidative damage 
to the complex II subunit, the complex III subunit, or the intermediate electron 
carrier (i.e. CoQ). In isolated brain mitochondria, peroxynitrite (ONOO‘; formed 
from the reaction of NO with O2 ) inhibited complex II activity by 42% (Brookes et 
al, 1998), and in cultured astrocytes and oligodendrocytes NO was shown to inhibit 
SDH activity (Mitrovic et al, 1994). However the effects of NO/ONOO' upon 
C0 Q9 or C0 Q 10 in intact cells were not evaluated in these studies. NO/ONOO' 
mediated depletion of C0 Q9 or CoQ 10 may have fundamentally important 
implications for understanding the mitochondrial component of neurological disease, 
given that in many such conditions, increased NO formation is believed to occur 
(Dawson et a l, 1991; Dawson and Dawson, 1996; Heales et al, 1999; Almeida and 
Bolafios, 2001).
Reports on the reaction of short chain ubiquinol (C0 Q0 and C0 Q2) with NO 
and ONOO*, such as those by the group of Poderoso (Poderoso et al, 1999;
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Schopfer et al, 2000) suggest that in vitro, NO can oxidise ubiquinol to 
ubisemiquinone and finally to ubiquinone, (Poderoso et a l, 1999). A later 
publication (Schopfer et al, 2000) describing the reaction with ONOO' suggests that 
regeneration of the quinone form of the CoQo or C0Q2 (C0Q0H2 and C0Q2H2 
respectively) may protect mitochondria against nitrosative stress. This group 
showed that the reactive intermediates formed by ONOO' decaying to NO3' can be 
quenched by C0Q0H2, which in turn forms ubisemiquinone. Additionally, ONOO' 
promotes O2* formation via reduced oxidation of C0Q0H2 to the ubisemiquinone and 
subsequently CoQo. The presence of C0Q0H2 also protects against ONOO- 
mediated nitration of tyrosine residues in both mitochondrial membranes, and 
supplementation of rats with C0Q10 prevents ONOO'-mediated mitochondrial 
respiratory dysfunction (Schopfer et a l, 2000). Thus it is clear that the antioxidant 
effects of ubiquinols in mitochondrial membranes has the potential to protect against 
respiratory dysfunction as a result of generation by oxidative and nitrosative 
radicals. Subsequently, the implications for neurodegenerative disease may suggest 
that depletion of C0Q9 or C0Q10 would render the mitochondria of neurones and glia 
more susceptible to attack by these oxidising species.
1.9. Lovastatin and disruption o f  CoQ metabolism
1.9.1. GeneraI Pharmacology
In the late 1970s, a fungal metobolite was isolated from Aspergillus terreus 
which was to revolutionise the treatment of hypercholesterolaemia. As an inhibitor 
of the rate-limiting enzyme for cholesterol synthesis, the compound termed ML-
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236B (later known as mevinolin or lovastatin) was shown to have 
hypocholesterolaemic activity in vitro (Endo et al, 1976). Subsequent animal 
studies confirmed that in dogs (Tsujita et a l, 1979) and monkeys (Kuroda et al, 
1979) the drug was effective at lowering plasma cholesterol. Similar in structure to 
HMG-CoA, competetive inhibition of HMG-CoA reductase in hepatocytes results in 
impairment of de novo cholesterol synthesis. This in turn causes an increase in low- 
density lipoprotein (LDL) clearance of cholesterol from the plasma (Bilheimer et al, 
1983; reviewed in Brown & Goldstein, 2004).
Lovastatin is a prodrug; following oral administration, first pass hepatic 
metabolism results in lactonase enzymes cleaving the molecule’s lactone ring by 
hydrolysis of the ester link. The opened P-hydroxy acid of lovastatin has been 
shown to have significantly higher HMG-CoA reductase inhibitory activity than the 
lactone prodrug (Endo et al, 1976; Merck & Co, Inc, 2003).
Inhibition of HMG-CoA reductase by lovastatin is not complete (Merck & 
Co Inc, 2003), thus mevalonate synthesis is not completely blocked at therapeutic 
doses. The “flux diversion hypothesis” also states that squalene synthsase’s 
relatively low affinity for famesyl-pyrophosphate (FPP) allows a decrease in the 
FPP pool to preferentially affect cholesterol (rather than ubiquinone) synthesis. 
Thus the cis- and /raws-prenyltranferases’ higher affinity should theoretically allow 
dolichol and CoQio synthesis to be maintained (Turunen et al, 2004). However 
studies have demonstrated decreased C0 Q9 and C0 Q 10 levels in rats (Willis et al, 
1990) and C0 Q 10 in humans (Folkers et a l, 1990). Thus it is conceivable that such a
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situation may have serious implications of cellular antioxidant status and 
mitochondrial ETC function.
1.9.2. Statin drugs and neurological disease
Statin drugs have been postulated as being of benefit in a number of 
neurological conditions (reviewed in Cucchiara and Kasner, 2001) including glioma- 
type tumours (Prasanna et al, 1996; Soma et al., 1992, 1995), cerebrovascular 
disease (reviewed in Vaughan and Delanty, 1999), Multiple Sclerosis (Stanislaus et 
al, 2001) and AD (Jick et al, 2000; Wolozin et a l, 2000; Simons et al, 2002). In 
addition NO generated due to NOS II induction is implicated in a number of 
neurodegenerative conditions (reviewed in Heales et a l, 1999); however, some work 
has shown that NOS II induction may be inhibited by lovastatin (Pahan et al, 1997; 
Rattan et al, 2003). Lovastatin has also been shown to inhibit lipid oxidation and 
increase SOD levels in plasma of orally treated animals (Chen et al, 1997).
Lovastatin has been used in both animal and cell culture models (Nagasawa 
et al, 2000; Ikeda et al, 2001; Huang et a l, 2003) and although conclusive evidence 
of benefit in neurological disease is lacking, lovastatin is being evaluated by a 
number of groups for the treatment of neurological diseases (reviewed in Cucciara 
and Kasner, 2001).
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1.10. Statement o f  Aims
The aims of this project were to
a) Establish an HPLC method for the determination of different CoQ 
homologues in both human and rodent biological material
b) Determine the CoQ status of glial cell lines, and rat primary astrocyte and 
neuron-enriched cultures
c) Investigate modulation of cellular CoQ availability by RNS, potential 
biosynthetic pharmacological inhibitors and siRNA-mediated 
biosynthetic enzyme knockdown in a number of cell types including glial 
cell lines, and rat primary astrocyte and neuron-enriched cultures.
d) Investigate whether modulation of cellular CoQ availability influences 
respiratory enzyme activities of the ETC (and specifically the complex 
II+III assay) in vitro.
2. MATERIALS AND METHODS
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2. MATERIALS AND METHODS 
2A  Chemicals and Materials
All chemicals, enzymes, coenzymes and reagents were supplied by Sigma-Aldrich 
(Poole, UK) unless otherwise stated, and were of the highest possible grade:
Antibiotic/antimycotic solution (lOOx: 10,000 units penicillin, lOmg streptomycin and 
25pg amphotericin B per ml), Antimycin A, bovine serum albumin, coenzyme Qi, coenyme 
Q9, coenzyme Q 10, Cytosine P-D-arabinofuranoside hydrochloride, deoxyribonuclease I 
(Type IV; from bovine pancrease; DNAse; EC. 3.1.21.1), Earle's Balanced Salt Solution 
(with sodium bicarbonate; EBSS), Hanks Balanced Salt Solution (with sodium bicarbonate, 
without phenol red, calcium chloride and magnesium sulphate; HBSS), L-glutamine, 
Lipopolysaccharide (from E. coli 026:B6; LPS), N6 -(l-Iminoethyl)-L-lysine 
dihydrochloride (L-N1L), Medium 199 (liquid; HEPES modification) Mevinolin (from 
aspergillus; "lovastatin"), Millex GV 0.22p syringe-driven filters, p-nicotinamide adenine 
dinucleotide reduced form (disodium salt; NADH), p-nicotinamide adenine dinucleotide 
phosphate reduced tetrasodium salt (NADPH), poly-D-lysine (lyophilised), poly-L- 
omithine (0.01%), rotenone, sodium perchlorate (anhydrous), trypsin-EDTA solution (lOx, 
0.05% porcine trypsin/ 0.02% EDTA).
Exceptions include the following:
The nitric oxide donor (z)-l-[2-aminoethyl)-N-(2-ammonioethyl) amino] diazen-l-ium-1,2- 
diolate (DETA-NO) was purchased from Alexis Biochemicals (Nottingham, UK)
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Minimal essential medium (MEM; both with and without Phenol Red), Dulbecco's 
modified Eagle medium (D-MEM; 4.5g glucose/1), foetal bovine serum (FBS; heat 
inactivated), and all tissue culture plastics were purchased from Invitrogen (Paisley, UK)
y-interferon (IFNy) was purchased from Calbiochem (Nottingham, UK)
L-lactate dehydrogenase (from rabbit muscle; LDH; EC. 1.1.1.27), nitrate reductase (from 
aspergillus; EC 1.6.6.2) and oxidised cytochrome c (from horse heart) were purchased from 
Roche Diagnostics (Lewes, UK). The Preciset Cholesterol standard (5.17mM) was 
purchased from Boehringer Mannheim, now part of Roche (Lewes, UK).
The Total Cholesterol CHOL-H L-type spectrofluorometric assay kit was manufactured by 
Wako Chemicals and purchased from Alpha Laboratories (Eastleigh, UK).
The BioRad DC Protein Assay Kit was obtained from BioRad, (Hemel Hempstead, UK)
Sephadex G-25M PD-10 desalting columns (elution volume 3.5ml) to remove ascorbate 
from reduced cytochrome c were purchased from Amersham Biosciences (Little Chalfont, 
UK).
Techsphere ODS 5p 150mm HPLC columns and guard columns were purchased from 
HPLC Technolgy (Welwyn Garden City, UK).
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Ethanol and methanol (Hypersolv HPLC grade) perchloric acid (60%) were supplied by 
VWR (Loughborough, UK).
2.2 Tissue Culture
2.2.1 Media and solutions
Minimum Essential Media (MEM; for astrocytes): MEM supplemented with 10% 
(v/v) FBS, 2mM L-glutamine, and 1% (v/v) antibiotic antimycotic (100 units/ml penicillin, 
100 pg/ml streptomycin and 25 ng/ml amphotericin) solution.
MEM (for neurons): as for astrocytes, with the additional supplementation of 25mM KC1.
Medium 199: supplemented with 10% (v/v) FBS, 2mM L-glutamine, and 1% (v/v) 
antibiotic antimycotic solution.
D-MEM: supplemented with 10% (v/v) FBS, 2mM L-glutamine, and 1% (v/v) antibiotic 
antimycotic solution.
EBSS: supplemented with 1% (v/v) antibiotic antimycotic solution.
HBSS: supplemented with 1% (v/v) antibiotic antimycotic solution.
"Solution A": EBSS supplemented with DNAse (75 Kunitz units/ml) and BSA (3mg/ml)
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"Solution B": "Solution A" supplemented with trypsin (27.5 units/ml) and additional 
DNAse (562.5 Kunitz units/ml)
2.2.2. Animals
Pregnant Wistar rats were purchased from A.J. Tuck & Sons (Rayleigh, Essex, UK), 
and the breeding colony within the Institute of Neurology, UCL, UK. Animals were 
maintained on a light/dark 12-hour cycle and fed stock laboratory diet and water ad libitum. 
Preparation of rat primary cortical astrocytes required the use of 1-2 day old pups, which 
were killed by cervical dislocation, while primary neuron culture required the use of 
foetuses removed on the 17th day of gestation (E17).
2.2.3 Preparation o f  astrocyte cultures
Preparation of rat primary astrocyte cultures followed the method of Tabemero et 
al., (1993), but with some minor modifications, i.e. lower concentrations of digestive 
enzymes (DNAse and trypsin) and slower spin speeds to increase the yield of viable cells 
obtained. The animals were decapitated, the cortex carefully removed, and the meninges 
and blood vessels removed by gently rolling the small pieces of tissue along a piece of 
clean dry filter paper. The cleaned tissue was then roughly chopped with small, curved 
edged scissors in EBSS supplemented with DNAse (75 Kunitz units/ml) and BSA 
(3mg/ml). This was termed "Solution A". Then, following mechanical dissociation by 
aspiration with a PI000 Gilson pipette, the cells were spun at 440 g for 5 mins at 4°C, and 
the supernatant discarded. The cells were transferred to petri dish and enzymatically
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digested with "Solution B" (effectively, this was Solution A supplemented with trypsin 
(27.5 units/ml) and additional DNAse (562.5 Kunitz units/ml) for a maximum of 15 mins at 
37°C. The digestion was terminated by the addition of 10% (v/v) FBS. The cell preparation 
was spun and resuspended in fresh Solution A a further two times to achieve a homogenous 
suspension. Finally, the cells were resuspended in L-valine based minimum essential 
media (MEM), supplemented with 10% (v/v) FBS (Invitrogen, Paisley, UK), 2mM L- 
Glutamine and 1% (v/v) antibiotic/antimycotic before being passed through a lOOp pore 
size nylon cell strainer (Becton Dickinson Labware Europe, Le Pont de Claix, France). A 
monolayer of astrocytes was cultured in 80cm2 flasks containing 10ml MEM, and 
maintained in a humidified incubator (95% air/ 5% CO2) at 37°C. Media was changed 
every 3 days, and astrocytes were passaged on the 7th day in vitro (DIV 7), when 
con fluency was reached.
After removal of media, the monolayer was gently washed with HBSS, before 
incubation with 5 ml trypsin/EDTA solution (0.5% (w/v) trypsin, 0.2% (w/v) EDTA for 5 
minutes. Trypsinisation was terminated by the addition of 10% (v/v) FBS, and cells were 
pelleted by centrifugation at 440 g for 5 mins at 4°C. Following resuspension in MEM, the 
astrocytes were divided over a larger area and cultured for a further 6 days, with the media 
changed every 3 days.
At DIV 13, the monolayer was again removed by trypsinisation, pelleted, 
resuspended and the cells counted using a haemocytometer. Astrocytes were then seeded 
into poly-lysine coated (lOpg/ml) 6-well plates at a density of lx l0 5/cm2, in 1 ml medium 
on the day preceding treatment. Figure 2.1 shows a 20x magnification light microscope 
image of the cells obtained after plating on day 13.
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Figure 2.1 Phase contrast light micrograph o f rat primary astrocyte cultures.
Untreated rat primary astrocytes viewed at x20 magnification on DIV 13 of culture 
showing typical cultured astrocyte morphology at confluence.
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2.2.4 Preparation o f neuron cultures
Primary neuron cultures were isolated from Wistar rat E l7 foetuses (Bolafios et al., 
1995; Vicario et a l, 1993). The same basic protocol was followed as for astrocyte 
preparation, except that the MEM was additionally supplemented with 25mM KC1, and on 
the day the preparation was performed, neurons were plated directly onto poly-ornithine 
coated (lOpg/ml) 6-well plates (2.5 x 105 cells/cm2 in 1.5 ml media). On DIV 3, the media 
was changed to one supplemented with cytosine arabinofuranoside (ImM) to inhibit DNA 
synthesis in proliferating cells. Experiments were performed on DIV 6-7.
Figure 2.2 shows a typical 20x magnification light microscope image of the cells 
on DIV 6.
These cells have been previously characterised in this laboratory with regard to 
purity, i.e. immunohistochemical staining against green fibrillary acidic protein (GFAP; 
Bignami et al., 1972) in astrocytes and neurofilament in neurones (Dahl and Bignami, 
1977). A number of recent University of London theses (Stone, 2001; Casley, 2002; Gegg, 
2003; Lam, 2004) and publications from this group (Bolafios et al, 1995; Stewart et al, 
1998; Stewart et al, 2002a) and others (Tabanero et al, 1993; Vicario et al, 1993) have 
repeatedly found >90% GFAP positivity in astrocyte cultures and >85% positivity for 
neurofilament in neuronal cultures.
2.2.5 Preparation o f  cell line cultures
While C0Q9 is the predominant ubiquinone in rodents, humans utilise principally 
CoQio. In order to further investigate this homologue in the human brain, it was necessary
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Figure 2.2 Phase contrast light micrograph o f rat primary neuron cultures.
Untreated rat primary neurons viewed at x20 magnification on DIV6  of culture 
showing typical cultured neuron morphology at confluence.
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to use a human cell line as a readily available source of human cells. However, because of 
possible metabolic and biochemical differences between primary cultures and immortalised 
cell lines, a rodent cell line was also studied. These cell lines, originally derived from rat 
and human brain tumours were originally purchased from the European Collection of Cell 
Cultures (ECACC; Porton Down, UK) and stored in liquid nitrogen until use. Cell line 
recovery, following removal from liquid nitrogen, required rapid defrosting at 37°C for a 
maximum of 2 minutes. The cells (frozen in FBS: media: DMSO at a ratio of 5:3:2) were 
transferred to a 25cm2 tissue culture flask and supplemented with 5 ml of the appropriate 
media. 4 hours later, once the cells had become adherent, the media was changed, and the 
cells split when confluent.
2.2.5.1. Human 1321N1 astrocytoma cultures
The 132IN 1 human astrocytoma line (ECACC No. 86030402.) derives from 
primary human glioma cultures, (Ponten and MacIntyre, 1968; MacIntyre et al., 1972; 
Foster and Perkins 1977) and is well characterised (Brismar, 1995; Stewart et al., 1998). 
These cells were grown in Dulbecco's Modified Eagle Media (DMEM; 4500mg glucose/1) 
supplemented with 10% (v/v) FBS, 2mM L-Glutamine and 1% (v/v) antibiotic/antimycotic.
2.2.5.2. Rat C6  glioma cultures
The rat C6  glioma line (ECACC No. 92090409) originates from a rat glial tumour 
induced by N-nitromethylurea (Breda et al., 1968) and has been widely used for various 
cell biology studies (Feinstein et al., 1994; Cao and Reith (2002) or Brismar, 1995; Barth, 
1998 for reviews). These cells were routinely grown in supplemented media 199 (M l99),
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which consisted of N-2-hydroxylpiperazine-N-2-ethanesulphonic acid (HEPES)-buffered 
M l99 containing 10% (v/v) FBS, 2mM L-Glutamine and 1% (v/v) antibiotic/antimycotic.
Both cell lines were passaged every 3-4 days, (1:6 split), and seeded into 6 -well 
plates at a density of lx l 0 5/cm2 on the day preceding treatment.
2,2.6 Cell treatments
Cells were usually treated in 6 -well well plates. Media was removed, the monolayer 
gently washed with HBSS, and fresh media added containing the necessary supplements for 
the specific treatment. After either 24 or 36 hours, the medium was removed, and usually 
saved and stored at -80°C for later determination of nitrate and nitrite concentration. Cells 
were then washed with HBSS, trypsinised, and gently scraped using a plastic cell scraper, 
then pelleted by centrifugation at 400g for 5 minutes. Following removal of the 
supernatant cells were snap frozen in liquid nitrogen before being stored at -80°C until 
assay. In the case of LDH measurement, a sample of culture media (typically 50 pi) was 
removed before lysis of the cells with Triton X-100 (0.1% v/v). Cells and remaining media 
were then removed, snap frozen in liquid nitrogen and stored at -80°C until assay.
2.2.6.1 Serum withdrawal
In order to examine the effects of serum withdrawal upon cellular CoQ 
levels, some cells were cultured in MEM without FBS for up to 36h. In addition where 
noted, some treatments were also carried out in the presence and in the absence of FBS.
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2.2.6.2 Cytokine + bacterial lipopolysaccharide treatment
Using a protocol based on that of Bolafios et al., (1994), cells were treated with LPS 
(1 pg/ ml) and IFNy (100 U/ml) ± the NOS inhibitor L-NIL; (lOOpM; Moore et al., 1994)
2.2.6.3 Lovastatin treatment
Mevinolin (also known as lovastatin) is a member of the statin class of drugs, used 
clinically to inhibit HMG-CoA reductase the rate limiting enzyme in the cholesterol 
biosynthetic (mevalonate) pathway (Alberts et al, 1980). This fungal metabolite is inactive 
in its prodrug form, although cleavage of the lactone ring to a 5 carbon chain as performed 
in-vivo by lactonase enzymes, converts the prodrug to its bioactive isoform (Endo et al., 
1976, Gerson et al., 1989).
In some experiments lovastatin was dissolved in ethanol, and added to the media at 
1% v/v. It was used at a final concentration of lOpM or lOOpM. However, due to the lack 
of evidence in the literature of the expression of lactonases in cultures, and the fact that 
lovastatin was found to be a more effective inhibitor of HMG-CoA reductase as a sodium 
salt (the p-hydroxy acid; Endo et al., 1976), the prodrug was also converted to the sodium 
salt (as shown in Fig 2.3) by alkaline hydrolysis by dissolution in ethanol containing 1M 
NaOH (Endo et al., 1976). Thus the sodium salt o f lovastatin was also added to the culture 
media at a final concentration of lOpM or lOOpM.
Controls for these experiments were the vehicle (ethanol or 1M NaOH in ethanol) 
added to the culture media at 1% (v/v)
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Figure 2.3. The structures o f  lovastatin and Na-lovastatin.
The natural lactone form of lovastatin (A), was used to generate Na-lovastatin (B), 
following alkaline hydrolysis, as described in section 2.2.63
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2.2.6.4 NO Donor treatment
(z)-l-[2-aminoethyl)-N-(2-ammonioethyl) amino] diazen-l-ium-l,2-diolate (DETA- 
NO) is a slow-release NO donor (Seccia et al., 1996). A 500jiM solution of DETA-NO 
gives sustained release of approximately 1 jiM NO for 24h in astrocyte and neuron MEM 
(Gegg et al., 2003).
Controls for these experiments used degraded DETA-NO. As the half life of this 
compound is in the region of 8 h (Seccia et al., 1996), a stock solution of lOOmM was 
allowed to degrade for 7 days. Thus the compound had passed 21 half lives, at this time 
point released minimal amounts of NO.
2.2.6.5 Combination o f  treatments
In some experiments combinations of the treatments described above were used to 
evaluate the effects of the induction of iNOS in conjunction with lovastatin treatment.
2.3. Spectrophotometric ETC Enzyme assays
2.3.1. NADH:ubiquinone oxidoreductase (Complex I; EC. 1.6.5.3)
Complex I catalyses the oxidation of NADH to NAD+. Thus, electrons are 
transferred from NADH to ubiquinone (which becomes reduced to ubiquinol). 
Subsequently, these electrons are passed to complex III. The activity of complex I was 
determined by the method of Ragan et al., (1987) using a Uvikon XL spectrophotometer 
running at 30°C (NorthStar Scientific Ltd, Bedford, UK) as the rotenone-sensitive decrease 
in NADH (340nm). The sample was three times freeze-thawed (using liquid N2), and 
divided into separate aliquots for each spectrophotometric assay described here. 2 0 pl was
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added to a cuvette with final concentrations of 20mM phosphate buffer (20mM K H 2P O 4 ,  
20mM K 2 P O 4 ,  8 mM MgCl2, pH 7.2), 2.5 mg/ml BSA, 0.15mM NADH and ImM KCN. 
Contents were mixed, and placed in the spectrophotometer for 2 mins to reach 30°C. The 
final volume in the cuvette was 1ml. Addition of 50pM ubiquinone (C0 Q 1) started 
oxidation of NADH, and this was followed for 5 mins. Using the Beer-Lambert Law 
(Abs = e c 1; e = NADH extinction co-efficient = 6 .8 lx l0 3 M' 1 cm '1; c = [NADH]; 1= path 
length = 1 for all calculations) the activity of NADH oxidase in the sample could be 
calculated. After approximately 5 mins, 20pM rotenone (a specific complex I inhibitor) 
was added to inhibit the complex I-dependant component, thus allowing calculation of 
NADH oxidation due solely to complex I; thus complex I activity.
Activity was expressed against the protein content of the sample as nmol/min/mg. 
All sample cuvettes were run against a "blank”, containing sample and all substrates and 
reagents except C0 Q 1. Complex I was proportional to protein between 5 and 25 pg protein 
(R2= 0.994)
2.3.2.Succinate dehydrogenase:cytochrome c reductase (Complex / /+ // / ;  EC.
1.3.5.1+1.10.2.2)
In the ETC, succinate is oxidised by complex II. As a result of this oxidation, 
ubiquinone becomes reduced upon accepting electrons from the Fe-S centres of complex II, 
and subsequently becomes oxidised upon donation of electrons to the cytochrome b of 
complex III. This leads to reduction of the hydrophilic electron carrier cytochrome c. Thus 
the activities of complex II and complex III are often measured as the complex II+III linked 
assay (King et al., 1967); an assay which appears to be dependant upon endogenous
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ubiquinone availability (Rahman et al., 2001). The linked activities of complex II+III are 
followed as the succinate-dependant antimycin A-sensitive reduction of cytochrome c 
(King et al., 1967) at 550nm using a Uvikon XL spectrophotometer running at 30°C 
(NorthStar Scientific Ltd, Bedford, UK). The sample (of volume 20pL) was three times 
freeze-thawed (using liquid N2), and added to a cuvette with final concentrations of lOOmM 
phosphate buffer (lOOmM KH2PO4 , lOOmM K2PO4 , pH 7.4), 0.3mM EDTA ImM KCN 
and 0.1 mM cytochrome c. Contents were mixed, and placed in the spectrophotometer for 
2 mins to reach 30°C. The final volume in the cuvette was 1ml. Addition of 20mM 
succinate started oxidation of NADH, and this was followed for 5 mins. Taking the 
extinction coefficient of cytochrome c at 550 nm as 19.2xl03 M*1 cm'1, the rate of reduction 
of cytochrome c could be calculated. After approximately 5 mins, lOpM antimycin A (an 
inhibitor of complex III) was added to inhibit the reduction of cytochrome c due solely to 
the activity of complex III. Thus calculation of the linked activity of complex II+III was 
possible.
Activity was expressed against the protein content of the sample as nmol/min/mg. 
All sample cuvettes were run against a "blank", containing sample and all substrates and 
reagents except succinate. Complex II+III was proportional to protein between 5 and 25 pg 
protein (R2 = 0.986)
2.3.3. Cytochrome c oxidase (Complex IV; EC. 1.9.3.1)
As previously described, complex III passes electrons to reduce oxidised 
cytochrome c. Reduced cytochrome c then transfers electrons to cytochrome c oxidase 
(complex IV). Determination of complex IV activity used the method of Wharton and
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Tzagoloff (1967), in which the oxidation of reduced cytochrome c is followed at 550 nm. 
Thus it was necessary to prepare freshly reduced cytochrome c for use in this assay.
2.3.3.1 Preparation o f reduced cytochrome c
Ascorbate crystals were added in excess to cytochrome c (0.8mM; horse heart). 
The reduction resulted in a colour change from dark to light red. It was then necessary to 
perform a gel filtration to remove the ascorbate from the solution. This was performed 
using a Sepharex P D j o  gel filtration column previously equilibrated by washing with 
approximately 50ml of lOmM phosphate buffer (lOmM K 2 P O 4 ,  10 mM K H 2 P O 4 ,  pH 7.0). 
In order to determine the concentration of reduced cytochrome c, a 1:20 solution was made, 
and 1ml added to 2 cuvettes. These were placed in the reference and sample carriers in a 
Uvikon XL spectrophotometer, and "zeroed" at an absorbance of 550nm. ImM 
ferricyanide was then added to the reference cuvette to fully oxidise the reference and allow 
determination of the concentration of reduced cytochrome c. The extinction coefficient of 
reduced cytochrome c for this calculation was 19.2xl03 M' 1 cm ' 1
2.3.3.2 Measurement o f Complex IV  activity
Oxidation of cytochrome c was monitored at 550nm at 30°C using a Uvikon XL 
spectrophotometer. In both sample and reference cuvettes, a final concentration of 50pM 
reduced cytochrome c was added to lOmM phosphate buffer (lOmM K 2 P O 4 ,  10 mM 
K H 2 P O 4 ,  pH 7.0). The sample was "zeroed" against the reference, and ferricyanide added 
to the reference to oxidise the cytochrome c. At this point, absorbance increased to 
approximately 1.0. 20pl of sample (previously 3 times freeze-thawed) was addedto the
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sample cuvette and the resultant oxidation of cytochrome c followed for 5 mins. As this is 
a first-order reaction highly dependant upon cytochrome c concentration, activity of 
complex IV was expressed as the first-order rate constant k per minute per mg of protein (k 
min '* mg'1), and was determined by noting the highest absorbance following sample 
addition (to), and every subsequent minute thereafter for 3 mins (tt, t2, and t3). Calculation 
of k necessitated the use of a plot of the natural log of absorbance at the 4 points against 
time. The mean of the slope of the line at ti, t2 and t3 gave the rate constant, which was 
then expressed as k min ' ! ml'1. This was then balanced against the protein concentration of 
the solution, thus the expression of activity as k min '* mg protein' 1 . Complex IV activity 
was shown to be linear between 5 and 25 pg protein (R2 = 0.989)
2.3.4. Measurement o f  citrate synthase activity (EC. 4.1.3.7)
Citrate synthase (CS) is a mitochondrial matrix enzyme which catalyses the 
condensation of oxaloacetate and acetyl CoA resulting in the formation of citrate and free 
CoA. Measurement of citrate synthase was used as an index of mitochondrial enrichment 
within a given sample. Rate of production of CoA was detected by its reaction with 5,5' 
Dithio-bis(2-nitrobenzoic) acid (DTNB) (Shepherd & Garland, 1969) which was followed 
at 412nm at 30°C using a Uvikon XL spectrophotometer. 20pl of sample (previously three 
times freeze-thawed) was mixed in a cuvette containing lOOmM Tris, 0.1% (v/v) Triton X- 
100, 0.1 mM acetyl CoA and 0.2mM DTNB. Addition of 0.2mM oxaloacetate started the 
reaction, and this was monitored for 5 mins. Samples were measured in conjunction with a 
reference blank, which contained all reagents and substrates save oxaloacetate, and the
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extinction co-efficient of DTNB (13.6xl06 M' 1 cm '1) was used to calculate activity. Citrate 
synthase activity was linear between 5 and 25 pg protein (R2 = 0.998)
2.4 Measurement o f  nitrate and nitrite
In this study, the measurement of nitrate and nitrite (NOx; the stable breakdown 
products of reactive nitrogen species) was used as an index of NO generation (Ignarro et 
ah, 1993). In this instance, any NO3' present in the culture media was reduced to NO2' by 
incubation with nitrate reductase (E.C.l.6.6.2; 0.1 U/mL; Roche, Lewes, UK) in the 
presence of NADPH (lOOpM) and FAD (5pM) for 15mins at 37°C. As excess NADPH 
would interfere with the final colourimetric stage in the assay, this was oxidised by addition 
of lactate dehydrogenase (LDH; E.C.l. 1.1.27; 100 U/mL) and sodium pyruvate (lOOmM). 
This allowed the measurement of NO2' (representing total NO2* + NO3 ) by the assay based 
on the Greiss reaction (Green et ah, 1982). Using the method of Green and co-workers, the 
formation of a pink diazo product from the clear colourless solution of phenol red free cell 
culture medium was enabled by the addition of equal quantities of 0 . 1% 
naphthaethylenediamine dihydrochloride, and 1% sulphanilamide/ 5% H3PO4 . Conducting 
the reaction in a 96-well plate allowed higher throughput and ensured consistent results, 
and a SPECTRAmax Plus 96-well Plate Reader (Molecular Devices, Wokingham, UK) was 
used to read absorbance of the reaction mixture at 540 nm.
The method was validated by titrating standard curves of NaNC>2 and NaNC>3 (Fig. 
2.4), showing both linearity to 100 pM and almost complete oxidation of nitrate to nitrite.
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Figure 2.4. NO2 and NO3 standard calibration curve.
N O 2* (♦ )  and N 0 3 (■) standards (the latter reduced to N O 2") were used in the 
determination of in cell culture medium. Absorbance at 540nm is plotted against 
concentration of the standard, showing linearity and conversion of N O 3 '  to N O 2 ’
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2.5 Lactate dehydrogenase measurement
As an index of plasma membrane integrity, LDH was measured in the cell culture 
media. This is often used as an estimate of cell viability (Koh & Choi, 1987, Bolafios et al., 
1995). This was determined using a Uvikon XL spectrophotometer after the method of 
Vassault (1983). During the harvest of cells, 50 pi of media was removed. Following the 
addition of 0.1% (v/v) Triton X-100 which resulted in complete cell lysis, the remaining 
media and cell lysate was removed, centrifuged to pellet any solid material and stored at - 
80°C. LDH assay buffer (lOOmM KH2PO4 , lOOmM K2HPO4 , 170mM pyruvate, pH7.5) 
was added to reference and sample cuvettes. 0.16 mM NADH was the added to both, while 
the absorbance was monitered at 340nm. As it was necessary to measure LDH in the 
culture media both before and after lysis, 2 sample cuvettes were used: one containing 33pl 
of media from unlysed cells, and one containing 33pl of cell lysate. Thus (using an 
extinction co-efficient of 6.22x103M'' cm'1), a percentage of total LDH released into the 
media was calculated:
°/ I DH 1 =  LDH activity in culture media
Se Total LDH activity (lysed cells + media)
The determination of the LDH activity of FBS was carried out in order to account for 
the relative contribution of this serum supplement in the culture media. In this case, a 
“theoretical maximal LDH activity” was calculated by measuring the LDH activity of a 
number of lysed cultures grown in the presence of FBS. The following calculation was 
used:
% LDH contribution from FBS
LDH activity of 10% FBS in cell-free media 
LDH activity of lysed cells in FBS- 
supplemented media
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2.6 Determination o f total cellular cholesterol
Inhibitors of HMG CoA reductase (such as the statin class of drugs) have been 
described as inhibiting synthesis of products of the mevalonate pathway including CoQ and 
cholesterol (Folkers et al., 1990; Alberts et al, 1980). In order to further understand the 
mechanism of action, cholesterol levels were determined as they relate to ubiquinone status.
Cholesterol determination was carried out by means of the Wako Chemicals Total 
Cholesterol CHOL-H L-type spectrofluorometric assay kit (Alpha Laboratories, Eastleigh, 
UK). This 2 reagent diagnostic kit provides a highly reproducible method with which to 
measure total cholesterol in human serum (Richmond, 1973). As this method has not been 
validated by the manufacturer for use in cultured cells, it was necessary to do so by way of 
a series of spiking experiments. Cell homogenates were divided into separate aliquots and 
a known concentration of cholesterol standard was added to half of them. By comparison 
of spiked and unspiked standards, a recovery of 96 ± 3 % was calculated.
Reagent "Rl" consists of a buffered solution of N-(2-hydroxy-3-sulfopropyl)-3,5- 
dimethoxy aniline sodium salt (HDAOS) and cholesterol esterase (CE). The latter 
hydrolyses any cholesterol esters present in the sample to free cholesterol (EQ1).
r ’k n l o c t o r A l  o c f o r  4 - CE _____ k . F r p p  t ' h n l M t p m l  4 -  R f O O H
The second reagent (R2) is a buffered solution of cholesterol oxidase (CO), peroxidase 
(POD) and 4-aminoantipyrine. CO reacts with the total free cholesterol, forming cholest-4- 
en-3-one and hydrogen peroxide (H2O2; EQ2). H2O2 causes 4-aminoantipyrine to undergo
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a quantitative oxidative condensation reaction with HDAOS, catalysed by peroxidase and 
resulting in the formation of a blue pigment (EQ3).
EQ2: Cholesterol + O2 CO -► Cholest-4-en-3-one + H2O2
EQ3: 2H20 2 + 4-aminoantipyrine POD Blue pigment + 3H20
+HDAOS *■
Cell pellets were resuspended in 200 pi isolation buffer (320 mM sucrose, 1 mM 
EDTA, 10 mM Tris; pH 7.4), and 100 pi undiluted homogenate transferred to an 
eppendorf tube. 675 pi of R1 was added and the mixture vortexed and incubated for 10 
mins at 37°C. Addition of 225pl of R2 followed by vortexing and incubation for a further 
10 mins at 37°C allowed formation of the blue reaction product. Absorbance was measured 
at 600nm on a Uvikon XL spectrophotometer (NorthStar Scientific Ltd, Bedford, UK). A 
standard curve for cholesterol showing linearity in the range measured is shown in Fig. 2.5 
(R2 = 0.998). This was prepared in isolation buffer using the Preciset water-soluble 
cholesterol standard solution (5.17 mM) purchased from Boehringer Mannheim 
Biochemicals UK; now part of Roche Diagnostics (Lewes, UK).
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Figure 2.5. Cholesterol standard calibration curve
A serial dilution of Preciset cholesterol standard was made in the range shown. Following 
the protocol as described in the text, absorbance at 600nm was determined and plotted 
against standard concentration showing linearity.
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2.7 Determination o f protein concentration
All biochemical investigations carried out were expressed against a cellular protein 
baseline. The amount of protein in tissue samples was determined by the method of Lowry 
et al, (1951), using the BioRad DC protein assay kit BioRad (BioRad, Hemel Hempstead, 
UK). This kit consists of the two reagents, conveniently pre-mixed and ready for use. 
Solution A consists of alkaline copper tartrate, and solution B is Folin-Ciocalteau reagent. . 
The colour development is mainly due to copper binding to primarily tryptophan and 
tyrosine (although additionally cysteine, cystine and histidine) residues. Subsequent 
copper-mediated reduction of the Folin reagent results in a characteristic blue species. 
Samples were typically diluted 1/20 , 100 pi Solution A was added, 800 pi solution B 
added and the mixture thoroughly vortexed. Absorbance was measured at 750 nm, again 
using the SpectraMax specetrophotometer. Fig. 2.6 shows the linearity of the standard 
curve, prepared with a 0.2 mg/mL solution of bovine serum albumin (BSA) in isolation 
buffer.
2.8 Light micrography o f  cultures
Photographs of cell cultures were obtained using a Nikon 950 CoolPix digital 
camera and Nikon TMS light microscope.
2.9 Statistical A nalysis
Results are presented as mean ± the standard error of the mean, n represents the 
number of independent experiments. While comparisons between two groups were 
analysed using an unpaired Student's t-test, multiple comparisons were made by one-way
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Figure 2.6. BSA standard calibration curve
A serial dilution of 0.2 mg/ml BSA as used in the determination of protein cell 
samples. Absorbance at 750nm is plotted against concentration of protein, showing 
linearity.
ANOVA followed by a least significant difference multiple range test. Where expressed as 
ratios (such as complex activity expressed as a ratio to citrate synthase, or percentages), 
data were first transformed to yield a normal distribution prior to the appropriate analyses 
were performed: = arcsin V (ratio). (Gegg et al., 2003; arcsin = sin'1)
In all cases, p<0.05 was considered statistically significant. Statistics were 
performed using the Statgraphics program. (Rockville, Maryland, USA)
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3. DEVELOPMENT OF AN HPLC METHOD FOR THE DETERMINATION 
OF CoQ IN BIOLOGICAL MATERIAL OF RODENT ORIGIN
3.1. Introduction
C0 Q9 and C0 Q 10 levels in both rodent and human samples are of interest to both 
research and clinical disciplines. It is therefore essential that a reliable method for 
determination o f CoQ derivatives in such tissues is available. While reduced 
ubiquinone (ubiquinol) can be detected using reverse-phase HPLC with electrochemical 
(EC) detection, oxidised ubiquinone is amenable to HPLC followed by ultraviolet (UV) 
detection (Takada et al., 1982).
CoQ, as a hydrophobic component o f lipid membranes, requires organic extraction 
from cellular homogenate. As such extraction can result in losses, in order to 
consolidate such losses, an internal standard must be added to tissue homogenate prior 
to solvent extraction. Existing HPLC methods for the determination of ubiquinone in 
tissues have used various alternative CoQ homologues as internal standards (Ogashara 
et al., 1989; Boitier et al., 1998). However, because most organisms' tissues contain at 
least small amounts of CoQ isoforms not predominant for that species, (Aberg et a l, 
1992, Dalner & Sindelar, 2000), it may be preferable to use an internal standard which 
is not found in nature. Studies involving clinical determination of human ubiquinone 
levels have previously used C0 Q9 as an internal standard (Ogashara et al., 1989), but 
this could be complicated by the presence of small amounts of this homologue in human 
samples due to dietary intake. Additionally, the predominance of C0 Q9 as the major 
homologue in rodents precludes its use as an internal standard when analysing the 
ubiquinone content of tissue of rodent origin. This chapter describes the development 
of a reverse-phase HPLC method using UV detection and a non-physiological diethoxy
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analogue o f C0 Q 10 which can be used as an internal standard in the measurement of 
tissues where either C0 Q9 or CoQ 10 predominate.
3.2 Methods
3.2.1. Tissue Culture
Primary astrocytes were cultured as described in section 2.2
3.2.2. Spectrophotometric measurement o f  ubiquinone standards
The oxidised forms of C0 Q9 and C0 Q 10 absorb UV light maximally at 275 nm 
(Okamoto et al. 1985). In order to confirm this, ubiquinone was dissolved in ethanol 
and a wavelength scan o f absorbance from 200 to 400 nm performed using a Uvikon 
XL spectrophotometer. The Beer-Lambert Law, given molar extinction coefficients of 
14.7 xlO3 M ' 1 cm ' 1 and 14.6 xlO3 M*1 cm ' 1 for C0 Q9 and C0 Q 10 respectively, allowed 
determination of the concentration of ubiquinone standards. Stock solutions dissolved 
in ethanol were stored at -80°C until required. Oxidised ubiquinone standards appeared 
to be unaffected by freezing and storage, as determined by spectrophotometry. In 
addition, the fully oxidised state of CoQ in the standard was confirmed by addition of 
the oxidising agent hexacyanoferrate (Okamoto et al., 1985).
3.2.3. Reverse phase chromatography coupled to UV detection
The reverse-phase HPLC employed was based on the methods of Takada et al. 
(1982) and Boitier et al. (1998), utilising a C l 8  column (150mm x 4mm; ODS 5p; 
Techsphere; HPLC Technology, Welwyn Garden City, UK.) preceeded by a Techsphere 
ODS 5p guard column. A Jasco (Great Dunmow, UK) UV-975 Intelligent UV-Vis
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detector measured absorbance at 275nm. The mobile phase consisted of 7:3 
ethanol:methanol, with 33 mM HCIO4 and 57mM NaClC>4, and samples were injected 
into a 50pl loop through a Rheodyne injector (Thermo Separation Products, Hemel 
Hempstead, UK.). A Jasco PU-1580 pump (flow rate: 0.7 ml/min), Jasco DG-1580-53 
degasser and ChromJet (Thermo Separation Products, Hemel Hempstead, UK.) 
integrator completed the HPLC hardware. A schematic diagram of the apparatus is 
shown in Fig. 3.1.
3.2.4. Synthesis o f  an internal standard used fo r  ubiquinone determination 
by UV- HPLC
Using modifications o f the methods of Edlund, (1988) and Eaton et al. (2000), a 
diethoxy analogue of CoQ 10 (Fig. 3.2) was synthesised. CoQ 10 ( 1 0 0  mg) was dissolved 
in 1 ml hexane, and sonicated to ensure dissolution. This solution was then dissolved in 
4ml dry ethanol and transferred to a separating funnel. The substitution of the methoxy 
groups with ethoxy groups was catalysed with the addition of NaOH in ethanol (1M; 
100 pi). After 20 mins, the addition of glacial acetic acid (1M; 100 pi) acidified the 
mixture and terminated the reaction. 1 0  ml o f hexane was added, and the reaction 
mixture was twice washed with 10 ml H2O. The aqueous layer was run off, leaving the 
solvent, which was then dried with excess Na2SC>4 . Approximately 2ml of the resultant 
yellow, oily liquid was removed and centrifuged at 19,000g for 3 mins to check for and 
remove any particles. Supernatant was then aliquotted and stored at -80°C. This neat 
mixture was diluted by approximately 1 : 8000 when added to samples for use as an 
internal standard
I l l
Direction 
of flow
Guard
Column
UV
Detector
II N>——
nm
Mobile Degasser Pump Injector 
Phase 0.7 ml/min
Reverse-phase 
HPLC column
Waste
Integrator
Figure 3.1. Schematic diagram o f  HPLC apparatus used to determine ubiquinone by 
reverse-phase HPLC and ultraviolet detection.
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Figure 3.2. The structure o f  diethoxy-CoQio.
This diethoxy analogue was synthesised from C0 Q 10 for use as an internal 
standard for HPLC. The removal o f two methoxy groups from the benzoquinone ring 
and their subsequent replacement with ethoxy groups was achieved as described in 
Chapter 3. When added to cell homogenates prior to extraction, it allowed 
consolidation of losses, and more accurate determination of ubiquinone concentration in 
the tissue. It eluted from the column around 90 sec after CoQio in this system.
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3,2.5. Sample preparation fo r  ubiquinone determination by UV-HPLC
Rat primary astrocytes were harvested as described in section 2.2.6, and the 
pellet resuspended in 200 pi ice-cold isolation medium (320 mM sucrose, 1 mM EDTA, 
10 mM Tris; pH 7.4). 40 pi was removed for protein determination, and 20 pi of 
internal standard added to the remaining 160 pi. Following thorough vortexing to 
distribute the internal standard, disruption o f the mitochondrial membrane was achieved 
by freeze-thawing three times using liquid nitrogen and a 37°C water bath. 600 pi of 
extraction medium (hexane:ethanol; 5:2) was added to the tissue homogenate, and the 
mixture was vortexed again before centrifugation at 16,000 g for 4 mins. The solvent 
layer was removed and saved, another 600 pi of extraction medium added to the 
homogenate and the extraction process repeated a further two times. Subsequently, 
approximately 1 0 0 0  pi o f supernatant organic solvent was obtained, in which was 
dissolved the endogenous C0 Q9 and CoQ 10. This was then dried under a stream of 
nitrogen gas and the residue reconstituted in 160pl ethanol. This was passed through a 
Millex 0.22p syringe-driven filter to remove protein and cellular debris directly before 
injection onto the column. In some cases, hexacyanoferrate was added to the extract 
immediately prior to filtration in order to ascertain that CoQ was fully oxidised when 
extracted by this method (Okamoto et al., 1985).
3.3. Experimental protocol
3.3.1. Chromatography and UV absorbance properties o f CoQ
Following confirmation of absorption spectra maxima of C0 Q9 and C0 Q 10 at 
275nm, concentrations were calculated using the Beer Lambert Law. These standards 
were then combined in known concentrations. This mixture was then resolved by 
HPLC into 2 peaks showing C0 Q9 and CoQ 10.
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3.3.2. Validation o f  the internal standard
Validation experiments in which a known amount of internal standard was subjected 
to three times freeze-thawing, followed by extraction, reconstitution and filtering steps 
were performed. As the internal standard's UV-HPLC properties were unchanged 
following these procedures, rat brain homogenate was prepared ( 1 0 % w/v) in ice-cold 
isolation buffer (320 mM sucrose, 1 mM EDTA, 10 mM Tris; pH 7.4), and the C0 Q9 
concentration of this homogenate determined (using CoQ 10 as an internal standard). 
The homogenate was then divided into six parts, and internal standard added to all. In 
addition, three of the six samples also had 50% of the original amount of C0 Q9 added. 
Ubiquinone was then extracted from these samples, and the concentration measured by 
HPLC analysis as described in the previous section. These allowed determination of a 
percentage recovery, and comparison with existing methods using other CoQ analogues 
as internal standards.
3.3.3. Determination o f  CoQ in rat astrocytes using the internal standard
Internal standard was added to rat astrocytes prior to freeze-thawing and solvent 
extraction as described in Section 3.2.5. These samples were then analysed by UV- 
HPLC as described in section 3.2.2.
3.4. Results
3.4.1. Chromatography and UV detection o f  ubiquinone
The absorption of UV light by C0 Q9 and C0 Q 10 in the range 200 nm - 400 nm was 
measured. This is shown in figures 3.3 & 3.4 respectively. In addition to a peak at 275 
nm a stronger peak was evident at 205 nm. However, due to the absorbance of a
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Figure 3.3. Wavelength scan o f C 0 Q 9  in ethanol showing maximal absorption at X- 205 
and 275nm.
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Figure 3.4. Wavelength scan o f CoQ]0 in ethanol showing maximal absorption at X - 205 
and 275nm.
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number of molecules at this wavelength, determination of ubiquinone was carried out at 
275nm.
An established HPLC method (Takada et a l, 1982) has been used as the basis 
for the development of a method allowing determination of both C0 Q9 and CoQ 10 in 
rodent and human tissue samples. Commercially available CoQ was prepared as 
standards and used initially to confirm a viable and robust method. Both C0 Q9 and 
C0 Q 10 have been shown to give a linear response as shown in Figures 3.5 and 3.6 
respectively. In addition, the presence of hexacyanoferrate to oxidise CoQ caused no 
increase in peak height with either standards or biological samples. A typical 
chromatogram of C0 Q9 and C0 Q 10 standards is shown in Figure 3.7. Detection of C0 Q9 
and C0 Q 10 was linear between 50 and 1 0 0 0  nM. R2= 0.999 for both C0 Q9 and C0 Q 10.
3.4.2. Development and characterisation o f  an internal standard
Synthesis of diethoxy-CoQio as an internal standard allowed the calculation of 
and compensation for losses occurring as a result of solvent extractions. A spectral scan 
between 200 - 400 nm is shown in Figure 3.8. Addition of the internal standard to 
biological samples before the extraction did not interfere with the existing CoQ 
chromatography (Fig. 3.9). Spiking experiments resulted in a calculated recovery of 
107 ±2% .
3.4.3. Ubiquinone levels in cultured astrocytes
Following extraction as described in section 3.2.5, detection of both C0 Q9 and 
CoQ 10 in the extract was possible (Fig 3.8). Cellular CoQ levels were calculated by 
measuring the peak height of the extract, and comparing it to the standard. The 
concentration of CoQ in the extract was divided by the percentage recovery of the
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Figure 3.5. C0 Q9 standard calibration curve.
Detector settings were as follows:
Absorption X = 275 nm 
Range = 0.005 
Response speed = standard 
Mode = normal
Integrator settings were as follows:
Chart speed = 0.25 cm/sec 
Attenuation = 16
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Figure 3.6. CoQio standard calibration curve.
Detector settings were as follows:
Absorption X = 275 nm 
Range = 0.005 
Response speed = standard 
Mode = normal
Integrator settings were as follows:
Chart speed = 0.25 cm/sec 
Attenuation = 16
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Figure 3.7. Chromatogram o f250 nM CoQ9 and 250 nM CoQ,0 standards.
Settings as described previously except attenuation = 4 .
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Figure 3.8. Wavelength scan o f diethoxyCoQjo in ethanol showing maximal absorption 
at X= 216 and 280nm.
Internal
Standard
Figure 3.9. Typical HPLC chromatogram obtained from analysis o f rat astrocytes.
Settings as described previously, except integrator attenuation is in this case = 
This figure shows C0Q9 and C0Q10 as extracted from rat primary astrocytes, with the 
internal standard.
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internal standard. Finally, this concentration (in nmol/1) was expressed against a 
protein baseline (pmol CoQ/ mg protein). C0 Q9 levels in these astrocytes was 
calculated as 174.2 ± 10.8 pmol C0 Q9 /mg protein. C0 Q 10 was less abundant at 37.9 ±
1 .6  pmol /mg protein (n = 1 2  independent cell culture preparations for both 
observations). Variability was calculated as 6.5%, observed when a single astrocyte 
homogenate was extracted and CoQ determined 3 times. Additionally, 3 separate 
astrocyte preparations resulted in an inter-assay variability of 4.8%. The limit of 
detection was found to be in the region of 5 nM CoQ in the extract, which relates to 
cellular levels in the pmol range/ mg protein The extraction process yielded CoQ in its 
fully oxidised state, as there was no increase in CoQ detected when exposed to 
hexacyanoferrate immediately prior to analysis.
Although a large solvent front was observed, this did not interfere with the 
chromatography of C0 Q9 or CoQ 10. If ubiquinone homologues of molecular mass lower 
than that of C0 Q9 were to be considered, this may prove problematic.
3.5 Discussion
Previously, C0 Q9 has been routinely used as an internal standard in clinical 
determination of human ubiquinone levels. However, this is clearly unsuitable for 
species in which this homologue is the predominant isoform. Appendix I describes the 
analysis of a human sample using the diethoxy internal standard. A muscle biopsy 
received by the Neurometabolic Unit of the National Hospital for Neurology and 
Neurosurgery, London, UK for analysis. This case of suspected ubiquinone deficiency 
was analysed using the internal standard described here.
As rodents utilise primarily C0 Q9, and CoQ 10 accounts for approximately 18% 
of the total ubiquinone extracted from rat primary astrocytes, an alternative internal
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standard was necessary. The modification of C0 Q 10 to its diethoxy analogue caused an 
increase in retention time on this HPLC system when compared to C0 Q 10 itself. Initial 
experiments had shown diethoxy-CoQio to be stable, and subsequent spiking 
experiments using tissue homogenates gave a recovery of close to 100%. Time has 
shown that this internal standard does not revert back to C0 Q 10 in measurable amounts 
when stored at -80°C and handled with the same precautions as ubiquinone. The 
internal standard has been used previously to assess the ubiquinone content of human 
plasma (Eaton et al., 2000) but not in rodent tissue.
Edlund et al. (1994) calculated the C0 Q9 level in cultures of rat dorsal root 
ganglion neurons as 680 pmol/ mg, and CoQ 10 levels in the region of 400 pmol/ mg. 
However, the findings of Kamzalov, et al. (2003) describing CoQ levels in homogenate 
of rat brain report C0 Q9 levels of 2 0 0  pmol/ mg protein with CoQ 10 present at 
approximately 100 pmol/ mg. Albano et al. (2002) measured C0 Q9 and C0 Q 10 in rat 
foetal mixed cultures, and report levels of approximately 250 pmol/ mg protein for each 
homologue. Thus it can difficult to make comparisons to previous findings for a 
number of reasons: the results described here, are from monocultures of neonatal rat 
primary astrocytes expressed against a protein baseline. The literature databases yield 
no publications discussing CoQ levels in rat astrocyte cultures. Differences may occur 
as a result o f in vivo experiments compared to ex vivo cell culture techniques. Species 
differences will alter the ratio of C0 Q9: CoQ 10, and possibly the amount of total CoQ. 
Finally, it is possible that a failure to use, or differences in, internal standards could 
account for some of the variability of CoQ levels encountered when searching the 
literature.
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3.6 Conclusion
It was necessary to develop this HPLC method to measure C0 Q9 and CoQ 10 in 
biological material of rodent origin with a novel internal standard as the use of other 
CoQ homologues may affect results obtained. This method has employed an internal 
standard which is not a naturally-occurring CoQ homologue. Thus the peak obtained 
are distinct from those of the analytes. The method is highly reproducible with a low 
co-efficient of deviation and excellent recovery.
In addition, this internal standard can also be used in the determination of CoQ 10 in 
human samples, which may contain small but measurable amounts of C0 Q9 . As 
described in subsequent chapters, this HPLC method has been used in to determine CoQ 
levels in a number of neural cell types exposed to various potentially oxidative and 
nitrosative stresses. It has also been used to determine the amount of CoQ 10 in human 
muscle biopsy samples (Appendix I). As ubiquinone has been postulated as being 
neuroprotective (Edlund et al., 1994; Matthews et al., 1998; Cammer, 2002) and 
alterations in ubiquinone metabolism have been described in some neurodegenerative 
conditions, (Soderberg et a l, 1992; Shults et al., 1997; Molina et al, 2002) this method 
can be used to elucidate whether C0 Q9 or CoQ 10 levels are altered in response to 
oxidative/ nitrosative stimuli in brain cell culture models of oxidative and nitrosative 
stress.
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4. CoQ9 AND C0 Q10 STATUS OF RAT AND HUMAN BRAIN CELL LINE
CULTURES; EFFECTS OF NO, LIPOPOLYSACCHARIDE + y-
INTERFERON & LOVASTATIN EXPOSURE
4. L  Introduction
C0 Q9 is the predominant ubiquinone homologue in rodents. In humans, a higher 
molecular mass isoform with 1 0  repeating units forming its polyprenyl tail is the most 
abundant CoQ molecule (Ramasara, 1985). Most mammals have a small percentage of 
a second isoform comprising their total ubiquinone (reviewed in Szkopinska, 2000). 
C0 Q9 and CoQ 10 were initially assumed to perform the same physiological role in 
different species. Thus, in earlier studies, little attention was paid to potential 
physiological differences between the different molecular mass homologues. However 
the ratio of C0 Q9 : CoQ 10 varies between species and tissues examined, and it has 
subsequently been proposed that separate isoforms may be employed in differing 
physiological roles. The findings o f Matsura et al. (1991), supported by the findings of 
Battino et al. (1995 and 2001) suggest that C0 Q 10 acts as an electron carrier in the ETC, 
while C0 Q9 may be expected to function primarily as an antioxidant (Matsura et al., 
1991). Lass et al., (1997) reported that C0 Q 10 generated less superoxide than C0 Q9, and 
subsequent studies raised the possibility of this being due to a lower degree of 
mitochondrial protein binding of C0 Q9 (Lass and Sohal, 1999).
Additionally, the role of CoQ 10 in the human brain has provoked much discussion 
within the literature. Putative neuroprotective actions of CoQ 10 towards cultured cells 
(Edlund et al., 1994; Cammer 2002; Sandu et al., 2003), or as a therapy for diseases 
such as PD (Shults et al., 2002), HD (Huntingdon Study Group, 2001), and animal
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models of ALS (described in Beal, 1999) and cerebral ischemia (Ostrowski, 2000) have 
increased interest in CoQio as a human therapeutic agent.
In order to further investigate this homologue using human brain cells, it was 
necessary to use a human neural cell line. This chapter describes investigations carried 
out using the human-derived 1321N1 astrocytoma cell line. Cultures were exposed to a 
number of treatments by supplementation of their culture media.
For comparison, data derived from the human cell line were compared to those 
obtained from the rat C6  glioma cell line.
Lovastatin inhibits HMG-CoA reductase, the rate-limiting enzyme for cholesterol 
synthesis (Alberts et a l, 1980). Due to commonality between the biosynthetic 
pathways for cholesterol and CoQ, statin drugs are also proposed to potentially inhibit 
C0 Q9 and C0 Q 10 synthesis leading to decreased C0 Q9 and C0 Q 10 levels in rats (Willis et 
a l, 1990) and serum C0 Q 10 in humans (Folkers et a l, 1990).
A combination of lipopolysaccharide and y-interferon (LPS+IFNy) induces iNOS in 
astrocytes (Galea et a l, 1992; Bolaiios et a l, 1994) and some astrocyte-derived cell 
lines (Feinstein et a l, 1994). The C6  glioma line is reported to be capable of inducing 
iNOS when treated for 24h with LPS+IFNy (Feinstein et al., 1994). CoQ is reported to 
be susceptible to attack by NO or its metabolites (Kalen et al, 1989; Schopfer et al, 
2000). Thus the effects of NO and lovastatin upon C0 Q9 and C0 Q 10 status were 
examined in these cultures. In addition, lovastatin is proposed to induce cytokine- 
mediated iNOS expression in rat and human brain transformed cell lines (Rattan et al, 
2003), thus combinations treatments examined the effects of NO production in 
lovastatin-treated cultures.
4.2. Aims
•  To determine the basal levels of C0 Q9 and CoQ 10 in rat C6  glioma and 
human 1321N1 astrocytoma cultures.
•  To examine the effects o f lovastatin (in both the prodrug and active 
isoform) upon such cultures
•  To examine the effects o f iNOS induction / exogenous NO on these cells, 
and the effects of lovastatin upon iNOS-mediated NO generation.
4.3. Methods
4.3.1. Tissue culture
1321N1 human astrocytoma cells (ECACC no. 86030402) were recovered from 
cryostat liquid nitrogen storage as described in section 2.2.5. Culture conditions were 
maintained as per section 2.2.5.1. Rat C6  glioma cultures (ECACC no. 92090409) were 
also investigated, and cultured as described in sections 2.2.5. and 2.2.5.2. Cultures were 
exposed to a range of treatments for 24h in the absence o f serum and the cells collected 
as a pellet as described in sections 2 .2 .6 .
4.3.2. CoQ measurement by HPLC
Following extraction of cellular lipids as described in section 3.2.5, the 
concentrations o f C0 Q9 and CoQ 10 were measured by reverse-phase UV-HPLC as 
described in section 3.2.3.
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4.3.3. NOx determination in tissue culture media
The concentration o f nitrate+nitrite (NOx) in the cell culture medium was 
determined as an index of NO generation as per section 2.4.
4.3.4. Protein determination
All measurements were expressed against a protein baseline. Protein content of 
samples was determined by the method of Lowry et al. (1951) as in section 2.7.
4.4. Experimental protocols
4.4.1. Exposure o f  human 1321N1 and rat C6 cells to lipopolysaccharide + 
y-interferon
Human 1321N1 and rat C6  cultures were exposed to media supplemented with 
LPS (lpg/ml) and IFNy (100 U/ml) for 24h and the cellular CoQ levels measured. L- 
N6 -(l-iminoethyl)lysine hydrochloride (L-NIL) is an inhibitor of iNOS (Moore et al., 
1994), and in some cases this was used in conjunction with LPS+IFNy. In order to 
determine whether LPS+IFNy elicited NO generation in these cultures, NOx 
concentration in the media was determined.
4.4.2. Exposure o f  rat C6 cells to DETA-NO
Following experiments in which both cell lines were exposed to LPS+IFNy, the 
nitric oxide donor DETA-NO (500pM) was used to expose the rat-derived cell line to 
exogenously generated NO. NO generation was confirmed by the measurement in the 
cell culture media of NOx. In some cases, DETA-NO was allowed to degrade for at 
least 7 days at 37°C, and was used as a negative control where appropriate.
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4.4.3. Exposure o f human 1321N1 and rat C6 cells to lovastatin
Lovastatin is an inhibitor of HMG Co-A reductase (Alberts et al., 1980). It has 
been reported that lactonase enzymes increase the efficacy of lovastatin in vivo (Endo, 
1976; Gerson et al., 1989). As expression of such lactonases in these cells was 
unconfirmed, the lactone ring was cleaved by conversion of lovastatin to its sodium salt 
(Na-lovastatin; Endo et al, 1976). Thus lovastatin (lOpM) was added to cell culture 
media in both the natural lactone form and as Na-lovastatin (see figure 2.3 for 
structures). In order to measure whether iNOS was induced in response to either the 
treatment or the appropriate controls (ethanol (1% (v/v)) for the lactone or 1M NaOH in 
ethanol (1% (v/v) for the sodium salt), NOx concentration in the cell culture media was 
determined.
4.4.4. Simultaneous exposure o f  human 1321N1 and rat C6 cells to 
lipopolysaccharide + y-interferon and lovastatin
Both cell types were exposed to media supplemented with Na-lovastatin (10 
pM) in addition to LPS+IFNy used at the concentrations described previously. Media 
were collected and NOx measured to evaluate the effects of lovastatin upon NO 
generation in these cells.
4.4.5. Simultaneous exposure o f  rat C6 cells to DETA-NO and lovastatin
Rat C6  cultures were exposed to media supplemented with both DETA-NO (500 
pM) and Na-lovastatin (10 pM). NOx was also measured in the cell culture media in 
order to confirm generation of NO by the NO donor.
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4.4.6. Simultaneous exposure o f  rat C6 cells to DETA-NO and 
lipopolysaccharide + y-interferon
The dual insult of exogenous NO generation by DETA-NO (500 jiM) combined 
with LPS and IFNy (as previous concentrations) was examined to determine the effect 
upon CoQ levels and resultant NO generation in the cell culture media.
4.5. Results
4.5.1. CoQ levels in human 132IN I astrocytoma and rat C6 glioma cells
4.5.1.1. Human 132IN I astrocytoma
The predominating ubiquinone homologue was found to be CoQio (33.8 ± 7.6 
pmol/ mg protein). C0 Q9 accounted for approximately 9% of the total (3.3 ± 1 .6  pmol/ 
mg protein; Fig 4.1 A).
4.5.1.2. Rat C6 glioma
In contrast to the human cell line, in these rat-derived cultures C0 Q9 was found 
to be the most abundant isoform (114.3 ± 15.7 pmol/ mg protein). In this case, C0 Q 10 
accounted for approximately 13% of the total cellular CoQ (17.8 ± 3.3 pmol/ mg 
protein; Fig 4 .IB).
4.5.2. The effect o f  lipopolysaccharide + y-interferon on CoQ status o f  
human 132INI astrocytoma and rat C6 glioma cells
4.5.2.1. Human 132IN I astrocytoma
Exposure of 132INI cultures to LPS+IFNy for 24h did not significantly alter the 
amount of either C0 Q9 or C0 Q 10 detected in these cells (C0 Q9 : control = 3.3 ± 1.6 pmol/ 
mg protein; LPS+IFNy = 3.7 ± 3.1 pmol/ mg protein; C0 Q 10: control = 33.8 ± 7.6
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Figure 4.1. Ubiquinone levels in untreated human 1321N1 astrocytoma and rat C6  
glioma cultures.
Human 132INI astrocytoma (A) and rat C6  glioma cells (B) were grown for 
24h in 6 -well culture plates without FBS as described in sections 2.2.4 and 2.2.5. Data 
are mean ± SEM values of five independent culture preparations.
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pmol/mg protein; LPS+IFNy = 30.4 ± 8.7 pmol/ mg protein; Fig. 4.2A). The level of 
NOx in the cell culture media did not change following LPS+IFNy exposure. 
Following treatment, NOx levels were determined in the extracellular media as 12.8 ±
1 .1  nmol/ mg protein as compared to 14.0 ± 1 .1  nmol/ mg protein in untreated controls.
4.5.2.2.Rat C6 glioma
Cultures of C6  cells underwent identical exposure of LPS+IFNy. Under these 
conditions, in contrast to the human cell line, C0 Q9 levels increased by approximately 
55% (control = 114.3 ± 15.7 pmol/ mg protein; LPS+IFNy = 177.1 ± 20.6 pmol/ mg 
protein; Fig. 4.2B). Moreover, the inhibitor of iNOS, L-NIL, abolished this increase, as 
co-incubation with the inhibitor caused no significant increase compared to controls 
(LPS+IFNy+L-NIL = 126.1 ± 8.7 pmol/ mg protein). While the increase in C0 Q9 
following 24h exposure to LPS+IFNy was statistically significant, the modest increase 
in C0 Q 10 was not (control = 17.8 ± 3.3 pmol/ mg protein; LPS+IFNy = 22.6 ± 3.8 pmol/ 
mg protein; Fig. 4.2B). Although analysis o f the media used for these experiments 
showed a trend towards increased NOx in the extracellular environment, (control: 10.8 
± 2.1 nmol NOx/ mg protein compared to LPS+IFNy: 15.5 ± 0.7 nmol/ mg protein) this 
increase was not statistically significant.
4.5.3. The effect o f  DETA-NO on CoQ status o f  rat C6 glioma cells
The NO donor DETA-NO increased NOx in the cell culture media by 
approximately 11-fold (untreated control = 10.8 + 2.1 nmol/ mg protein; DETA-NO = 
119.4 ± 18.2 nmol/ mg protein Fig. 4.3). No significant change was observed against 
control values for either C0Q9 (control = 99.1 ± 7.8 pmol/ mg protein; DETA-NO = 
88.5 ± 2 . 2  pmol/ mg protein; Fig 4.4) or C0Q10 (control = 16.4 + 2 .1  pmol/ mg protein;
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Figure 4.2. The effect o f  LPS+IFNy, and L-NIL treatment upon the CoQ status o f  
human 132IN I astrocytoma and rat C6  glioma cultures.
A: Human 132INI astrocytoma cells were incubated for 24h in 6 -well
culture plates in the absence (control) or presence of LPS + IFNy (lpg/ml; 100 U/ml, 
respectively) as indicated. ■  = C0 Q9; ■  =CoQio. Data are mean ± SEM values of four 
to five independent culture preparations.
B: Rat C6  glioma cells were incubated for 24h in 6 -well culture plates in the
absence (control) or presence of LPS + IFNy (lpg/ml; 100 U/ml, respectively). L-NIL 
(100 pM)was included as indicated. ■  = C0 Q9; ■  =CoQio- Data are mean ± SEM 
values of four to five independent culture preparations. * signifies /?<0.05 analysed by 
one-way ANOVA.
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Figure 4.3. The effect o f  DETA-NO treatment upon levels o f  NOx in the media o f rat 
C6  glioma cultures.
Rat C6  glioma cells ( ■  ) were incubated for 24h in 6 -well culture plates 
in the absence (control) or presence of DETA-NO (500pM). Cell culture medium was 
collected and analysed as described in section 2.4. Data are mean ± SEM values of four 
to six independent culture preparations. * signifies p<0.05 analysed by one-way 
ANOVA.
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Figure 4.4. Ubiquinone levels in rat C6  glioma cultures treated with DETA-NO.
Rat C6  glioma cells were grown for 24h in 6 -well culture plates without FBS in 
the absence (control) or presence of DETA-NO (500pM) as indicated. ■  = C0 Q9; ■  
=CoQio. Data are mean ± SEM values of four to six independent culture preparations.
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DETA-NO = 13.1 ±0 . 6  pmol/ mg protein; Fig. 4.4). . Thus despite having confirmed 
generation of NO, levels of C0 Q9 or CoQ 10 as measured under these conditions were not 
significantly different. (Fig. 4.4).
4.5.4. The effect o f  lovastatin on human 1321N1 astrocytoma and rat C6 
glioma cells
4.5.4.1. Human 1321N1 astrocytoma
Neither the C0 Q9 nor the CoQ 10 levels in the human cell line altered 
significantly following 24h exposure to lovastatin (C0 Q9: control = 5.2 ± 2.9 pmol/ mg 
protein; lovastatin = 5.1 ± 1.7 pmol/ mg protein; C0 Q 10: control = 19.5 ± 3.0 pmol/mg 
protein; lovastatin = 24.9 ± 2.3 pmol/ mg protein; Fig. 4.5A). This treatment resulted in 
a modest increase of NOx in the cell culture media and in this case statistical 
significance was achieved (control = 10.6 ± 1.0 nmol/ mg protein; lovastatin = 13.4 ± 
0.3 nmol/ mg protein Fig. 4.6A). Na-lovastatin caused a statistically significant 
decrease in the amount of cellular C0 Q9 (control = 8.7 ± 1 . 2  pmol/ mg protein; Na- 
lovastatin = 1.7 ± 1.1 pmol/ mg protein; Fig. 4.5B) but not C0 Q 10 (control = 24.4 ± 2.3 
pmol/ mg protein; Na-lovastatin = 29.5 ± 6.0 pmol/ mg protein; Fig. 4.5B). Under these 
conditions however, the amount of NOx in the cell culture media did not change 
(control = 12.0 ± 0.5 nmol/ mg protein; Na-lovastatin = 12.8 ± 1.1 nmol/ mg protein; 
Fig. 4.6B)
4.5.4.2. Rat C6 glioma
In response to 24h exposure to lovastatin, C0 Q9 status of rat C6  cultures 
decreased by 33% (control = 105.9 ± 10.5 pmol/ mg protein; lovastatin = 71.2 ± 7.8 
pmol/ mg protein Fig. 4.7A). The sodium salt of lovastatin had a similar effect (control
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Figure 4.5. The effect o f  lovastatin and its sodium salt (Na-Lovastatin) treatment 
upon the CoQ status o f  human 1321N1 astrocytoma cultures.
A: Human 132INI astrocytoma cells were incubated for 24h in 6 -well
culture plates in ethanol (1% (v/v); control) or lovastatin (lOpM) as indicated. ■  = 
C0 Q9; ■  =CoQio. Data are mean ± SEM values of three to five independent culture 
preparations.
B: Human 1321N1 astrocytoma cells were incubated for 24h in 6 -well
culture plates in 1M NaOH in ethanol (1% (v/v); control) or Na-lovastatin (lOpM) as 
indicated. ■  = C0 Q9; ■  =CoQio. Data are mean ± SEM values of three to five 
independent culture preparations. * signifies /?<0.05 analysed by one-way ANOVA.
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Figure 4.6. The effect o f  lovastatin and its sodium salt (Na-Lovastatin) treatment 
upon the NOx levels in the media o f  human 132 IN I astrocytoma cultures.
A: Human 132INI astrocytoma cells were incubated for 24h in 6 -well
culture plates in ethanol (1% (v/v) control) or lovastatin (lOpM) as indicated. Data are 
mean ± SEM values of three to four independent culture preparations. * signifies p<0.05 
analysed by one-way ANOVA.
B: Human 1321N1 astrocytoma cells were incubated for 24h in 6 -well
culture plates in 1M NaOH in ethanol (1% (v/v); control) or the sodium salt of 
lovastatin (lOpM) as indicated. Data are mean ± SEM values of three to four 
independent culture preparations.
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Figure 4.7. The effect o f  lovastatin and its sodium salt (Na-Lovastatin) treatment 
upon the CoQ status o f  rat C6  glioma cultures.
A: Rat C6  glioma cells were incubated for 24h in 6 -well culture plates in
ethanol (1% (v/v); control) or lovastatin (lOpM) as indicated. ■  = C0 Q9; ■  =CoQio. 
Data are mean ± SEM values of three to five independent culture preparations. * 
signifies /K0.05 analysed by one-way ANOVA.
B: Human 132INI astrocytoma cells were incubated for 24h in 6 -well
culture plates in 1M NaOH in ethanol (1% (v/v); control) or Na-lovastatin (lOpM) as 
indicated. ■  = C0 Q9; ■  =CoQio. Data are mean ± SEM values of three to five 
independent culture preparations. * signifies p<0.05 analysed by one-way ANOVA.
Control Lovastatin
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= 106.0 ± 9.2 pmol/ mg protein; Na-lovastatin = 75.7 ± 7.0 pmol/ mg protein Fig. 4.7B). 
However, the change observed in the amount of CoQio in these cells was not significant 
(lovastatin treatment: control = 14.1 ± 1.5 pmol/ mg protein; lovastatin = 10.6 ± 1 . 0  
pmol/ mg protein; Na-lovastatin treatment: control = 13.4 ± 1.3 pmol/ mg protein; Na- 
lovastatin = 11.4 ± 1.1 pmol/ mg protein; Fig. 4.7). Measurement of NOx in the cell 
culture medium uncovered no change following exposure to either lovastatin (control =
12.0 ± 1.8 pmol/ mg protein; lovastatin = 13.0 ± 1.6 nmol/ mg protein; Fig. 4.8A) or its 
sodium salt (control = 10.3 ± 1.0 pmol/ mg protein; Na-lovastatin = 11.7 ± 1.0 nmol/ 
mg protein; Fig. 4.8B).
4,5.5. The effect o f  simultaneous exposure o f  human 1321N1 astrocytoma 
and rat C6 cells to lipopolysaccharide + y-interferon and Na-lovastatin
4.5.5.1. Human 132 IN I astrocytoma
Following treatment of 132INI astrocytoma cells for 24h with LPS+IFNy+Na- 
lovastatin, C0 Q9 levels decreased by 50% (control = 8.7 ± 1.2 pmol/ mg protein; 
LPS+IFNy+Na-lovastatin = 4.4 ± 0.2 pmol/ mg protein). However in this case, when 
analysed by one-way ANOVA, significance was not achieved. C0 Q 10 status remained 
unchanged (control = 24.5 ± 2.3 pmol/mg protein; LPS+IFNy+Na-lovastatin = 25.6 ±
6.2 pmol/ mg protein; Fig. 4.9A). In addition, the levels of NOx were not significantly 
affected (control = 12.0 ± 0.5 nmol/ mg protein; LPS+IFNy+Na-lovastatin = 10.3 ± 0.5 
nmol/ mg protein; Fig. 4.10A).
4.5.5.2. Rat C6 Glioma
Exposure of rat C6  cultures to LPS+IFNy+Na-lovastatin caused a decrease of 
approximately 37% in C0 Q9 levels when compared to controls (control = 106.0 ± 9.2
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Figure 4.8. The effect o f  lovastatin treatment upon levels o f  NOx in the media o f  rat 
C6  glioma cultures.
Rat C6  glioma cells were incubated for 24h in 6 -well culture plates, either 
A: In the presence of the ethanol (1% (v/v) control) or lovastatin (IOjiM), or
B: In the presence of 1M NaOH in ethanol (1% (v/v); control) or Na-lovastatin (lOpM). 
Culture medium was collected and used for NOx analysis as described in section 2.4. 
Data are mean ± SEM values of five independent culture preparations..
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Figure 4.9. The effect o f  simultaneous exposure o f  LPS+IFNy, and the sodium salt o f  
lovastatin upon the CoQ status o f  human 1321N1 astrocytoma and rat C6  glioma 
cultures.
A: Human 1321N1 astrocytoma cells were incubated for 24h in 6 -well
culture plates in the presence of 1M NaOH in ethanol (1% (v/v); control) or LPS+IFNy 
as previously, with the addition of Na-lovastatin as indicated. ■  = C0 Q9; ■  = C0 Q10. 
Data are mean ± SEM values of three to four independent culture preparations.
B: Rat C6  glioma cells were incubated for 24h in 6 -well culture plates in the
presence of 1M NaOH in ethanol (1% (v/v); control) or LPS+IFNy as previously, with 
the addition of Na-lovastatin as indicated. ■  = C0 Q9; ■  = CoQ 10. Data are mean ± 
SEM values of five to six independent culture preparations. * signifies p<0.05 analysed 
by one-way ANOVA.
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Figure 4.10. The effect o f  LPS+IFNy in combination with the sodium salt o f  
lovastatin (Na-Lovastatin) upon the NOx levels in the media o f human 1321N1 
astrocytoma and rat C6  glioma cultures.
A: Human 1321N1 astrocytoma cells were incubated for 24h in 6-well
culture plates in the presence of 1% 1M NaOH in ethanol or LPS+IFNy as previously 
but with the addition of Na-lovastatin (10pM). Culture medium was collected and used 
for NOx analysis as described in section 2.4. Data are mean ± SEM values of three to 
four independent culture preparations.
B: Rat C6 glioma cells were incubated for 24h in 6-well culture plates in the
presence of 1M NaOH in ethanol (1% (v/v); control) or LPS+IFNy as previously but 
with the addition Na-lovastatin (lOpM). Culture medium was collected and used for 
NOx analysis as described in section 2.4.as indicated. Data are mean ± SEM values of 
three to four independent culture preparations. * signifies p<0.05 analysed by one-way 
ANOVA.
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pmol/ mg protein; LPS+IFNy+Na-lovastatin = 67.4 ± 1.6 pmol/ mg protein; Fig. 4.9B). 
CoQio status was unaffected (control = 13.4 ± 1.3 pmol/ mg protein; LPS+IFNy+Na- 
lovastatin = 11.7 ± 2.5 pmol/ mg protein; Fig. 4.9B). Under these conditions, the NOx 
concentration of the media increased significantly (control = 10.3 ± 1.0 nmol/ mg 
protein; LPS+IFNy+Na-lovastatin = 14.3 ± 0.8 nmol/ mg protein; Fig. 4.1 OB).
4.5.6. The effect o f  simultaneous exposure o f  rat C6 cells to DETA-NO and 
Na-lovastatin
DETA-NO in combination with Na-lovastatin was added to the C6  cell culture 
medium for 24h. The increased concentration of NOx in the media was confirmed 
(untreated control = 10.3 ± 1.0 nmol/ mg protein; DETA-NO+Na-lovastatin = 82.5 ±
13.2 nmol/ mg protein; Fig. 4.11). These conditions resulted in a 38% decrease in C0 Q9 
while C0 Q 10 levels remained unchanged (C0 Q9 : control = 106.0 ± 9.2 pmol/ mg protein; 
DETA-NO+Na-lovastatin = 65.9 ± 2.9 pmol/ mg protein; C0 Q 10: control = 13.4 ± 1.3 
pmol/mg protein; DETA-NO+Na-lovastatin = 12.8 ± 0.7 pmol/ mg protein; Fig. 4.12).
4.5.7. The effect o f  simultaneous exposure o f  rat C6 cells to 
lipopolysaccharide + y-interferon + DETA-NO
The combination of LPS + IFNy in conjunction with exogenous NO generation did 
not significantly alter C0 Q 10 levels, however C0 Q9 decreased by 29% (C0 Q9 : control =
99.1 ± 7.8 pmol/ mg protein; LPS+IFNy+DETA-NO = 70.5 ± 2.7 pmol/ mg protein; 
C0 Q 10: control = 16.4 ± 2.1 pmol/mg protein; LPS+IFNy+DETA-NO = 13.3 ± 0.7 
pmol/ mg protein; Fig. 4.13). NOx in the media, was no greater than that from DETA- 
NO alone (untreated control = 10.8 + 2.1 nmol/ mg protein; DETA-NO = 119.4 ± 18.2 
nmol/ mg protein; LPS+IFNy+DETA-NO = 118.2 ± 18.6 nmol/ mg protein; Fig 4.14)
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Figure 4.11. The effect o f  DETA-NO in conjunction with Na-lovastatin upon levels o f  
NOx in the media o f  rat C6  glioma cultures.
Rat C6 glioma cells ( ■  ) were incubated for 24h in 6-well culture plates in the 
presence of 1M NaOH in ethanol (1% (v/v); control) or DETA-NO (500pM) with Na- 
lovastatin (lOpM). Cell culture media was removed for analysis of NOx. Data are 
mean ± SEM values of five to six different culture preparations. * signifies p<0.05 
analysed by one-way ANOVA.
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Figure 4.12. The effect o f  simultaneous exposure o f  DETA-NO in conjunction with 
the sodium salt o f  lovastatin upon the CoQ status o f  rat C6 glioma cultures.
Rat C6  glioma cells were incubated for 24h in 6 -well culture plates in the 
presence of 1M NaOH in ethanol (1% (v/v); control) or DETA-NO (500 pM) in 
conjunction with Na-lovastatin (10 pM). ■  = C0 Q9; ■  = C0 Q10. Data are mean ± SEM 
values of five to six different culture preparations. * signifies /?<0.05 analysed by one­
way ANOVA
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Figure 4.13. The effect o f  simultaneous exposure o f  DETA-NO in conjunction with 
LPS+IFNy upon the CoQ status o f  rat C6 glioma cultures.
Rat C6  glioma cells were incubated for 24h in 6 -well culture plates in the 
presence of degraded DETA-NO (control) or fresh DETA-NO (500 pM) in conjunction 
with LPS+IFNy (concentrations as previously). ■  = C0 Q9; ■  = C0 Q10. Data are mean 
± SEM values of five to six independent culture preparations. * signifies p< 0.05 as 
analysed by one-way ANOVA compared to control values. # signifies p< 0.05 as 
analysed by one-way ANOVA compared to values for LPS+IFNy.
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Figure 4.14. The effect o f  DETA-NO in conjunction with LPS+IFNy upon levels o f  
NOx in the media o f rat C6 glioma cultures.
Rat C6  glioma cells ( ■  ) were incubated for 24h in 6 -well culture plates in the 
absence (control) or presence of DETA-NO(500pM) and LPS+IFNy (used as 
previously). Data are mean ± SEM values of five to six independent culture 
preparations. * signifies p< 0.05 as analysed by one-way ANOVA.
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4.6.Discussion
In human cells C0 Q 10 predominates; in the 132INI astrocytoma cultures C0 Q9 
accounted for approximately 9% of the total ubiquinone. Conversely, C0 Q 10 comprised 
approximately 13% of the total in the rat C6  glioma cultures. With regard to total 
ubiquinone (C0 Q9 + C0 Q 10), the rat-derived cultures were found to contain 
approximately 3.5-fold more than the human cultures. While the reason for this is not 
apparent, it could be due to species differences due to human and rat origins. 
Interestingly, alterations of cellular C0 Q9 status occurred mostly in the rat cultures. It is 
possible that a larger CoQ “pool” may allow cellular levels in the rat cultures to be less 
tightly regulated and can thus more readily altered.
Activation of iNOS by cytokines can generate NO in a number of cell types 
including rat primary glial cultures (Galea et a l, 1992; Bolanos et al., 1994), rat C6  
glioma cells (Feinstein et a l, 1994) and certain astrocytoma lines (Vigne et al, 1993; 
Mollace et a l, 1993). However the specific stimuli required for NO generation, can 
vary between cell types; for example in C6  cells, NO generation was substantially 
increased by co-incubation with tumour necrosis factor-a (TNFa; Feinstein et a l, 1994).
Following treatment with LPS+IFNy, no change was observed in cellular levels 
of either C0 Q9 or CoQ 10 or media NOx from the human astrocytoma cells. However, 
although rat C6  glioma cells did not increase NOx under the same conditions (in 
agreement with Feinstein et al, 1994) a 55% increase in the amount of C0 Q9 was 
observed. Moreover, co-incubation of these cultures with L-NIL abolished this increase 
suggesting the involvement of iNOS, but not NO. The presence of DETA-NO did not 
alter cellular CoQ levels; however DETA-NO in conjunction with LPS+IFNy appeared 
to inhibit the LPS+IFNy-mediated increase in C0 Q9, reducing C0 Q9 levels to a value 
significantly below control levels.
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Under conditions where either L-arginine (L-arg) or tetrahydrobiopterin (BH4) 
are limiting, it has been proposed that iNOS may preferentially generate superoxide (O2' 
Heinzel et al., 1992; Consentino et al., 2001). Given that there is no detectable increase 
in NOx in the cell culture media, these findings raise the possibility that iNOS- 
generated 0 2 ' rather than NO could mediate such an increase in C0 Q9 in rat cells. In 
addition, it is conceivable that inclusion of exogenous NO could scavange 0 {  forming 
the potentially more deleterious species ONOO'. This may explain the subsequent 
decrease in C0 Q9 under these conditions.
Lovastatin can inhibit C0 Q9 and CoQ 10 synthesis as a result of HMG-CoA 
reductase inhibition in cell culture models (Maltese and Aprille, 1985), humans (Folkers 
et a l, 1990) and rats (Willis et a l, 1990). In this study a decrease in C0 Q9 was 
observed following exposure of the human cell line to Na-lovastatin, but not the 
prodrug form. In contrast to the human cell line, the rat glioma cultures showed 
profound decreases in C0 Q9 levels following treatment with both lovastatin and Na- 
lovastatin respectively. These findings would suggest that the p-hydroxy acid form of 
lovastatin can be used to decrease cellular C0 Q9 status after 24h incubation of rodent 
and human-derived cells. In both cell types, CoQ 10 appears to be preserved.
Studies by Yamamoto et a l  (1989) and Gomez-Diaz et a l (2003b) have 
proposed that an interconversion may exist between C0 Q9 and C0 Q10. If this were the 
case, it is also conceivable that if the period of exposure were increased, following 
C0 Q9 depletion, C0 Q 10 levels would subsequently begin to fall. A similar effect may be 
seen if C0 Q 10 were directly synthesised from C0 Q9 (i.e. by the addition of a single 
isoprenyl unit), as proposed by Yamamoto et a l  (1989) using perfused rat heart 
preparations.
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These data would also imply that rodent cells are capable of converting the 
prodrug to the active isoform. Lactonase activity conferred by paraoxonase-like 
enzymes have been described in rat liver microsomes (Ozols, 1999); it is conceivable 
that the rat C6  glioma cell line may possess a similar enzyme which could convert 
lovastatin to the p-hyroxy form.
Inclusion of LPS+IFNy with Na-lovastatin in the media of both cell types did 
not have a different effect compared to the statin alone. However, under these 
conditions, the increase in C0 Q9 obtained when rat glioma cultures were treated with 
LPS+IFNy alone was abolished, thus it is possible that Na-lovastatin decreased C0 Q9 
via biosynthetic inhibition while blocking any iNOS / 0 2 ’ -mediated increase in CoQ.
Conflicting reports in the literature suggest that lovastatin may augment (Ikeda 
et a l, 2001; Rattan et al., 2003) or inhibit (Pahan et al., 1997; Huang et al., 2003) iNOS 
induction. These studies examined a diverse range of cell types: neonatal rat cardiac 
myocytes (Ikeda et al., 2001) C6  glioma, T98G and A172 human astrocytoma, 
neuroblastoma and immortalised rat astrocytes (Rattan et al, 2003), rat primary 
astrocytes (Pahan et a l, 1997), and murine macrophages (Huang et al., 2003). 
Although in the current study, the human cells exposed to the natural lactone form of 
lovastatin alone elicited an increase in the amount of NOx in the cell culture media, this 
was not reflected with Na-lovastatin. Neither was it consistent with the rat cell line 
exposed to either form of lovastatin.
The simultaneous inclusion of LPS+IFNy with Na-lovastatin in the media of the 
human cell line failed to alter NO generation. However in the rat-derived cultures, the 
presence of Na-lovastatin caused an increase in NOx in the media of almost 40%. This 
statin-mediated increase in the apparent sensitivity of iNOS has been previously 
described by Ikeda et al. (2001) and Rattan et al., (2003). Thus it is evident that
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metabolic differences existing between various cell types and species can have profound 
effects upon cellular responses, in particular lovastatin metabolism and the mechanism 
by which iNOS is induced.
While exogenous NO alone did not significantly decrease C0 Q9 or CoQ 10 in rat 
C6  glioma cultures, the inclusion o f Na-lovastatin with DETA-NO elicited a decrease in 
C0 Q9 greater than that which occurred in response to Na-lovastatin alone. Thus it may 
be the case that inhibition of CoQ biosynthesis at the level of HMG Co-A reductase is 
more profound in the presence of NO possibly as a result of increased turnover.
4 .7. Conclusion
These data would suggest that the rat glioma cultures are capable of 
metabolising the prodrug lovastatin to the active p-hydroxy acid form; while human 
astrocytoma cells cannot. It is conceivable that this may be due to the presence of a 
lactonase enzyme in the rat cells, possibly absent in the human cells.
In addition, although human 1321N1 astrocytoma cells contain less total 
ubiquinone, they may conserve both their C0 Q9 and CoQ 10 status in response to 
treatments causing profound alterations in C0 Q9 status in rat C6  glioma cells. Although 
C0 Q9 predominates in the rat, and CoQ 10 is more abundant in the human, C0 Q9 levels 
(particularly in the rat-derived cell line) appeared more susceptible to manipulation.
As all but one of the effects manifest as alterations in C0 Q9 status, it is possible to 
hypothesise that the experimental conditions used here generally influence only C0 Q9 
metabolism, but not C0 Q 10. This could suggest a "sparing effect" in that C0 Q 10 levels 
are maintained at the expense of C0 Q9 .
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5. CoQ 9 AND CoQjo LEVELS IN PRIMARY CULTURES OF RAT
ASTROCYTES; THE EFFECTS OF SERUM WITHDRAWAL
5.1. Introduction
Previous studies have detected small but significant amounts of CoQio in rodent- 
derived tissue (Edlund et a l, 1994; Lass & Sohal 1999; Tang et al, 2004). However, 
reports in the literature are currently lacking with respect to C0 Q9 and CoQ 10 levels in 
primary cultures o f rat cortical astrocytes. Primarily, this chapter evaluates the 
ubiquinone status of these cells, and describes the effects of removal of serum ffom the 
cell culture medium for up to 36h prior to harvest.
Serum is a complex mixture of numerous biomolecules. Foetal bovine serum (FBS) 
is commonly used in cell culture media as a source of anti-apoptotic, hormonal and 
growth factors, attachment and spreading factors, binding proteins, enzymes, 
lipoproteins, antioxidants and minerals. Usually, optimum cell growth requires serum 
in the culture medium between 5 to 20% (v/v) (Maurer, 1986). It has been widely 
accepted that unless supplemented with the necessary growth, survival and other 
extracellular factors, cell populations may begin to undergo a number of responses 
including programmed cell death unless continuously signalled not to either by 
neighbouring cells, or factors within the culture medium (Raff et al, 1983; Ishizaki et 
al, 1995). Thus although not all mechanisms are yet understood, serum withdrawal has 
been used to induce apoptosis, oxidative stress and affect expression of numerous 
cellular proteins (Ishizaki et a l, 1995; Palazzotti et al, 1999; Koshimura et a l, 2000; 
Rossler et a l , 2004).
Although the composition of sera used to supplement cultures has not been fully 
elucidated, FBS is known to be a source of exogenous CoQ (although the CoQ
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homologue was not specified; Maltese & Aprille 1985) and cholesterol (Quesney- 
Huneeus et al., 1979). It is also possible that proteins present in FBS such as bovine 
serum albumin could affect cellular uptake of compounds from the culture media 
(Maranga et al., 2002; Selleri et al., 2003; Mundy et al, 2004). Previous chapters have 
involved supplementation of the culture media with lovastatin in serum-free media to 
avoid effects resulting from the presence of CoQ in the serum; subsequent chapters will 
involve supplementation with lovastatin in the presence of serum. However, this drug 
binds plasma proteins such as albumin in vivo, and its cellular uptake involves a carrier- 
mediated system (Nagasawa et al., 2000). The effects of simvastatin (a close structural 
analogue of lovastatin) have been shown to decrease with increasing concentration of 
FBS in the culture media (Kikuchi et al., 1997). It is possible that protein-bound 
lovastatin may be unable to enter cells resulting in decreased bioavailability or lower 
efficacy in this cell culture model. Alternatively, the binding of lovastatin to albumin in 
FBS could conceivably facilitate entry to the cells. Thus it is necessary to investigate 
serum withdrawal in these cells prior to the use of lovastatin in order to control for any 
cellular effects due to incubation in the absence of serum.
C0 Q9 and CoQ 10 synthesis involves the mevalonate pathway, another end product of 
which is cholesterol (Turunen et al., 2004; see also figure 1.9). Acetyl Co A is 
converted to famesyl pyrophosphate, a common substrate for the synthesis of both CoQ 
and cholesterol. The rate limiting enzyme (HMG CoA reductase) is thus believed 
common for both cholesterol and CoQ homologues (reviewed in Dallner and Sindelar, 
2000 and Turunen et al., 2002). However, as the latter stages of C0 Q9 and CoQ 10 
synthesis in mammals are not well characterised, the relationship between relative 
amounts of these molecules in rat primary astrocytes was investigated.
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5.2.Aims
• To determine the levels of C0 Q9, C0 Q 10 and cholesterol in FBS
• To determine the levels o f C0 Q9, CoQ 10 and cholesterol in primary 
cultures of rat cortical astrocytes.
• To investigate the effects o f serum withdrawal for up to 36h upon the 
cellular levels of C0Q9, CoQ 10 and cholesterol.
5.3.Methods
5.3.1. Tissue culture
Primary cultures of rat astrocytes were prepared and maintained as described in 
section 2.2.3. On DIV 14, cells were subcultured in 6 -well plates for 24h or 36h in the 
presence or absence of serum and the cells collected as a pellet as described in sections 
2 .2 .6 .
5.3.2. CoQ measurement by HPLC
Cellular lipids were extracted as described in section 3.2.5, and the 
concentrations of C0 Q9 and CoQ 10 were measured by reverse-phase UV-HPLC as in 
section 3.2.3.
5.3.3. Cholesterol determination
Determination of total cellular cholesterol in the cell pellet was carried out by 
spectrophotometry. This is described in section 2.6.
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5.3.4. Lactate dehydrogenase determination
As an index of cell stress, LDH release from the astrocyte cultures was measured 
after 36h growth in 6  well plates, and expressed as a percentage of the total LDH 
activity of the culture following complete lysis using Trition X-100 (0.1% v/v). This is 
described in section 2.5. In order to account for LDH present in FBS supplements 
(Haslam et al., 1999), the LDH activity o f FBS itself was measured in cell-free culture 
systems and these values subtracted from total LDH activities of serum-containing 
cultures
5.3.5. Protein determination
For those findings expressed against a protein baseline, the protein content of 
samples was determined by the method of Lowry et al. (1951) as in section 2.7.
5.4. Experimental protocol
5.4.1. Determination o f  CoQ content o f  Foetal Bovine Serum
Lipid extraction was performed (similar to that described in section 3.2.5) by the 
addition of 600 pi of hexane/ethanol (5:2) to 160pl of FBS. This was vigorously 
vortexed, centrifuged at 16,000g, and the non-polar supernatant removed. This was 
repeated twice more, the supernatants pooled and evaporated to dryness under a stream 
of nitrogen gas. The lipids extracted were resuspended in ethanol (160 pi), and passed 
through a 0.22p filter prior to injection into the HPLC system.
5.4.2. Determination o f  cholesterol content o f  Foetal Bovine Serum
As per section 2.6, 100 pi of FBS (10%, v/v) was added to 675 pi of reagent 1 
(R l) from the CHOL-H L-type spectrofluorometric assay kit (Alpha Laboratories,
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Eastleigh, UK). Following incubation for 10 mins at 37°C, 225 pi of R2 was added, the 
mixture vortexed and incubated as previously. Subsequently, the total cholesterol 
content of FBS was determined by spectrophotometric measurement at 604 nm. In 
order to ensure concurrent results across batches, 3 separate batches of serum were 
used.
5.4.3. Serum withdrawal from  astrocyte cultures
Primary cultures of rat astrocytes were plated and maintained in media 
supplemented with FBS (10% v/v) and media without FBS for either 24h or 36h. 
Cellular CoQ and cholesterol levels were measured as described.
5.4.4. LDH activity o f  media from  astrocyte cultures
Following removal of 50 pi of culture media, Triton X-100 (0.1%; v/v) was used 
to lyse the cells. The LDH activity of these samples was determined and the viability of 
the culture expressed as a “percentage leakage” as previously described in section 2.5.
Additionally, the LDH activity of FBS was determined and expressed as a 
percentage of the theoretical maximum. The theoretical maximum was obtained by 
determining the mean of the activity of the cultures following lysis.
5.5. Results
5.5.1. CoQ concentration o f  Foetal Bovine Serum
Lipid extraction of FBS followed by HPLC analysis resulted in the 
determination of the concentration of ubiquinone in FBS as C0 Q9 = 253.1 ± 7.6 nM and 
CoQ 10 = 54.6 ±3 .2  nM. This was determined by separate observations on 3 batches of 
serum.
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5.5.2. Cholesterol concentration o f  Foetal Bovine Serum
Cholesterol content of FBS was measured as in section 2.6. This was 
determined using 3 separate batches of serum (in duplicate) as 805.8 ± 26.9 pM.
5.5.2. CoQ levels in primary cultures o f  rat astrocytes
Figure 5.1 A shows that basal levels in rat primary astrocytes cultured in the 
presence of FBS for 24h were determined as C0 Q9 = 173.6 ±19.1 pmol/ mg protein; 
CoQ 10 = 35.4 ± 2.7 pmol/ mg protein (Fig 5.1 A). The same cells under similar 
conditions, but with incubation time extended to 36h in the presence of FBS, were 
found to have slightly higher cellular C0 Q9 and CoQ 10 levels of C0 Q9 = 183.1 ± 16.4 
pmol/ mg protein and C0 Q 10 = 41.2 ± 4.4 pmol/mg (Fig 5.1 A). This was not 
significantly different to the C0 Q9 or C0 Q 10 levels after 24h.
5.5.4. The effect o f  serum withdrawal on cellular CoQ levels
Cells cultured in the absence of serum for 24h did not contain significantly 
different amounts of C0 Q9 or CoQ 10 to those cultured in media supplemented with FBS 
(C0 Q9 = 174.2 ± 10.8 pmol/ mg protein; C0 Q 10 = 37.9 ± 1 .6  pmol/ mg protein; Fig 
5.IB).
However, extension of the period of serum withdrawal to 36h gave rise to a 
statistically significant (/?<0.05) increase in C0 Q9 (23%) and C0 Q 10 (18%) when 
compared to the cells cultured for 24h in the absence of FBS (C0 Q9 = 214.8 ± 6 . 8  pmol/ 
mg protein; C0 Q 10 = 44.9 ± 3.2 pmol/ mg protein; Fig 5.IB).
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Figure 5.1. The effect o f  serum withdrawal upon the CoQ status ofprimary cultures 
o f  rat astrocytes.
A: Rat astrocytes cells were incubated in the presence of FBS (10% v/v) for
24h or 36h in 6 -well culture plates as indicated. ■  = C0 Q9; ■  =CoQio. Data are mean 
± SEM values of between six and twelve independent culture preparations.
B: Rat astrocytes cells were incubated in the absence of FBS for 24h or 36h
in 6 -well culture plates as indicated. ■  = C0 Q9; ■  =CoQio. Data are mean ± SEM 
values of between six and ten independent culture preparations (* signifies p < 0.05).
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5.5.5. The effect o f  serum withdrawal on media lactate dehydrogenase 
release
LDH release from astrocytes cultured for 36h in both the presence and absence 
of serum was investigated. Media obtained from untreated controls harvested after 36h 
in the presence of serum appeared to display greater LDH activity than media from 
those cells deprived of serum for 36h (+FBS=7.4 ±1.3 %; -FBS=3.6 ± 0.6 %). These 
data achieved statistical significance following percentage transformation of the data 
and analysis by unpaired t-test (p<0.05).
The mean LDH activity of 3 batches of FBS (10% v/v) was equal to 6.5 ± 0.8% 
of the total lysed (cells + serum-supplemented media) value.
5.5.6. The effect o f  serum withdrawal on cellular cholesterol levels
In order to assess whether cellular cholesterol content is affected by serum 
withdrawal, cholesterol levels in the cultures were determined after 24h and 36h in 
culture (section 2 .6 ).
Total cellular cholesterol in untreated astrocytes cultured in the presence of FBS 
for 24h was determined as 62.0 ± 7.2 nmol/ mg protein, while extension of the period to 
36h caused little difference (57.4 ± 18.6 nmol/ mg protein; Fig 5.2A). Serum 
withdrawal for 24h results in a cholesterol level of 74.5 ± 10.6 nmol/ mg protein, 
however, extension of withdrawal to 36h results in a statistically significant decrease of 
around 6 6 % (36h withdrawal: 26.8 ± 5.0 nmol/ mg protein; /?<0.01; 5.2B).
164
A: + FBS
B: - FBS
Figure 5.2. The effect o f  serum withdrawal upon the total cholesterol status o f  
primary cultures o f  rat astrocytes.
A: Rat astrocytes cells were incubated in the presence of FBS (10% v/v) for
24h or 36h in 6 -well culture plates as indicated. Data are mean ± SEM values of three 
to four independent culture preparations.
B: Rat astrocytes cells were incubated in the absence of FBS for 24h or 36h
in 6 -well culture plates as indicated. Data are mean ± SEM values of three to four 
independent culture preparations (** signifies p < 0 .0 1 ).
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5.6.Discussion
C0Q9 and CoQ 10 are detectible in primary cultures of rat cortical astrocytes by 
UV-HPLC following lipid extraction of a cell culture homogenate. As these cultures 
are rodent-derived, it follows that C0Q9 is the predominant homologue in this species 
(Ramasara, 1985); C0Q10 comprised approximately 17% of the total.
Following 36h culture in the presence of FBS, cellular levels of C0 Q9 and C0 Q 10 
were not significantly different to levels after 24h. Similarly, the amount of cholesterol 
in these cells did not change as a result of the increased period in culture. Thus it is 
clear that given the presence of FBS in the cell culture media, these products of the 
mevalonate pathway are not affected by their time in culture for up to 36h.
Although withdrawal of serum from the culture medium for a period of 24h did 
not alter cellular levels of C0 Q9 and CoQ 10, the significant increase of both isoforms 
observed after 36h may be clarified in the context of previous studies. Increased CoQ 
content of the plasma membrane following serum withdrawal has been previously 
described by Barroso et al. (1997). This group found that the CoQ content of the 
plasma membrane of HL-60 cells increased by 40% following 48h serum deprivation. 
Although the homologue was not specified, presumably this refers to CoQ 10 given the 
human source of the cell line. It was proposed by the authors that this may represent a 
stress response induced by serum withdrawal. Additionally, it has been noted that the 
substitution of FBS in primary astrocyte cultures with lipoprotein-depleted serum 
resulted in an approximately two-fold increase in both HMG-CoA reductase activity 
and sterol synthesis (Langan et al., 1987). Such a mechanism may account for the 
milder increase observed with these whole-cell primary astrocyte preparations after 36h 
serum-withdrawal.
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24h serum withdrawal resulted in a slight increase in cellular levels of total 
cholesterol. However, extension of the period of withdrawal to 36h resulted in 
profound depletion of cellular cholesterol to approximately 6 6 % of the 24h serum- 
withdrawn group. It has not been determined as to whether this is due to the withdrawal 
of exogenous cholesterol per se (present in FBS) or another component (i.e. loss of a 
precursor compound) in serum. It may additionally be due to as yet unknown inherent 
metabolic alterations as a result of serum withdrawal.
These findings show that serum supplementation of the cell culture media is 
necessary in order to maintain cholesterol, but not C0 Q9 or C0 Q10 status, in astrocytes. 
It is possible that this reflects the requirement of an exogenous source of cholesterol, but 
not C0 Q9 or CoQ 10. Indeed, this requirement may be reflected by the relative 
concentrations of cholesterol and CoQ found in FBS. When considering a 10% (v/v) 
FBS-supplementation of cell culture media, these represent a cholesterol concentration 
of approximately 80 pM, while C0 Q9 would be present at approximately 25nM, and 
C0 Q 10 at 5nM.
Analysis of the activity of media LDH would initially suggest increased 
permeability of the plasma membrane in the presence of serum. However, the greater 
LDH activity of media from cells cultured in the presence of FBS may be explained by 
LDH within sera (Haslam et a l, 1999). A 10% (v/v) solution of FBS contained 6.5 ± 
0.8% of the total LDH activity o f the lysed cells and media. Thus it is likely that the 
higher LDH activity observed in the serum-supplemented cultures is not the result of 
increased membrane permeability, but instead reflects the LDH activity of the serum. It 
is therefore necessary to take into account the contribution from FBS when considering 
the amount of LDH in culture media. The difference between the serum-supplemented 
cultures (7.4 ± 1.3%) and the contribution from FBS alone (6.5 ± 0.8%) would suggest
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that LDH release from the cytoplasm of those cultures was in the region of 0.9%. 
Given that in the absence of serum, LDH in the cell culture media was 3.6% ± 0.6%, 
these data would suggest that the presence o f FBS in the culture media was beneficial 
with regard to cellular viability, and that the absence of serum for 36h increased release 
of cytoplasmic LDH.
5.7. Conclusion
This chapter has shown that it is possible to detect the major and minor 
homologues of CoQ in primary cultures of rat cortical astrocytes. As such, this system 
can be employed to study factors influencing C0 Q9 and CoQ 10 metabolism.
Given that these cells are rodent-derived, C0Q9 was found to predominate. 
Following 24h serum withdrawal, no change was evident in cellular levels of C0Q9 or 
CoQ 10. Neither did cholesterol levels alter significantly. Thus it is feasible to culture 
these cells for 24h without serum and not affect C0Q9 or CoQ 10 metabolism. 
Subsequently, drugs such as lovastatin which may be highly bound to serum proteins 
can be evaluated in the absence of potential effects due to removal of serum for up to 
24h.
36h culture in the absence of serum resulted in significantly increased levels of 
C0 Q9 and CoQ 10 while cholesterol levels were profoundly decreased. These differential 
effects may suggest that the requirements for the maintenance of cellular levels of these 
two molecules are different. It is possible that primary astrocyte cultures require the 
presence of exogenous cholesterol (or precursors) from serum-supplemented media to 
maintain cellular levels. While removal of serum has been reported to increase the 
activity of HMG-CoA reductase (Langan et al., 1987), the half life of CoQ turnover has 
been calculated as approximately 40-fold higher than that of cholesterol in rat brain
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tissue (Andersson et a l 1990). Thus following inhibition of cholesterol synthesis 
resulting from serum withdrawal, induction of HMG-CoA reductase activity may be 
more apparent with regard to C0 Q9 or CoQ 10 levels than total cholesterol.
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6. THE EFFECTS OF LOVASTATIN UPON C0 Q9 AND C0 Q10 LEVELS IN 
PRIMARY CULTURES OF RAT ASTROCYTES
6.1. Introduction
Lovastatin inhibits HMG-CoA reductase in a number of models (Alberts et a l, 
1980; Maltese & Aprille, 1985, Folkers et a l, 1990). A large body of work over more 
than two decades exists within the literature relating to the effects of lovastatin; in 
addition this drug appears to be widely-used in a number of cell culture models (Pahan 
et a l, 1997; Laufts et a l, 1998; Nagasawa et a l, 2000; Ikeda et al, 2001; Huang et al, 
2003). The drug is well characterised, and its lipophilic properties mean that while it is 
necessary to first dissolve it in ethanol before its addition to aqueous media, it could 
readily cross hydrophobic barriers such as the plasma membrane and the blood-brain 
barrier (Tsuji et a l, 1993; Merck & Co. Inc. 2003).
Lovastatin is predominantly bound to plasma proteins such as albumin in vivo 
(Merck & Co. Inc. 2003). Thus, it is highly likely that it would bind similar proteins in 
FBS-supplemented cell culture media. Such a situation has previously been reported to 
lower the bioavailability of some compounds added to cell cultures (Maranga, et al, 
2002; Selleri et a l, 2003; Mundy et a l, 2004); it is therefore conceivable that the 
bioavailability o f lovastatin may be decreased by the use of FBS in the culture media. 
While the p-hydroxy acid form has been proposed to enter bovine brain capillary 
endothelial cells via the monocarboxylic acid transporter (Tsuji et al, 1993), and rat 
mesangial cells by way of a carrier-mediated mechanism (Nagasawa et a l, 2000), the 
prodrug form may enter by non-specific diffusion (Nagasawa et al, 2000). However 
albumin is known to bind and transport multiple bioactive substances (Peters, 1985). 
Thus rather than decrease bioavailability, it is also possible that the entry of lovastatin to
1
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cells could be facilitated by albumin carriage, following binding to proteins in FBS. 
Alternatively, while lactonase activity in FBS has not been described, lactone 
hydrolysing enzymes have been described in other mammalian sera (Roth et al., 1967; 
Teiber et a l, 2003). Subsequently, results obtained following addition of lovastatin to 
the culture media may be altered by the presence or absence of serum in the media.
As discussed in previous chapters, HMG-CoA reductase inhibition is conferred 
by its in vivo conversion to its p-hydroxy acid (such as the sodium salt of lovastatin; 
here denoted Na-lovastatin) by cleavage of the lactone ring (Endo et al., 1976). This is 
shown in Figure 2.3.
As the ability of astrocytes to metabolise lovastatin to this p-hydroxy acid isoform 
was unknown, both lovastatin and Na-lovastatin were added to cultures in the presence 
or absence o f serum. Lovastatin has been reported to decrease total ubiquinone 
(C0Q9+10) levels in cultured murine neuroblastoma cells, following addition to the cell 
culture media (Maltese & Aprille, 1985). Given the commonality of the C0Q9, C0Q10 
and cholesterol biosynthetic pathways, the status of these compounds was determined in 
order to address the effect o f lovastatin and Na-lovastatin on primary astrocyte cultures.
As this study examines cellular, rather than mitochondrial CoQ levels, in order to 
gain insight into the function of C0 Q9 and C0 Q 10 within the ETC, the activities of the 
mitochondrial reparatory chain were determined. It has been suggested that the activity 
of complex II+III may be dependant upon the endogenous level of C0 Q9 or C0 Q10 in the 
inner mitochondrial membrane (Clark et al., 1994; Rahman et al., 2001). This 
hypothesis is further supported by the work of Fernandez-Ayala et al (2005) which 
found that supplementation of human promyelocytic HL-60 cells with C0 Q 10 increases 
levels in mitochondria, and that this lead to increased complex II+III activity.
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6.2.Aims
• To investigate the effects of lovastatin and Na-lovastatin upon cellular 
levels of C0 Q9, CoQ 10 and cholesterol in rat primary astrocytes.
• To examine the effects of serum withdrawal in conjunction with the 
addition of lovastatin and Na-lovastatin
• To ascertain whether alterations in cellular CoQ status influence the 
complex II+III activity in vitro.
6.3.Methods
6.3.1. Tissue culture
Primary cultures o f rat astrocytes were prepared and maintained in culture as 
described in section 2.2.3. Cultures were exposed to a number of culture conditions for 
24h or 36h in the presence or absence of serum and the cells collected as a pellet as 
described in sections 2 .2 .6 .
6.3.2. CoQ measurement by HPLC
Cellular lipids were extracted as described in section 3.2.5, and the 
concentrations of C0Q9 and CoQ 10 were measured by reverse-phase UV-HPLC as in 
section 3.2.3.
6.3.3. ETC enzyme assays
The activities of the enzymes of the respiratory chain were assayed in the 
samples as described in section 2.3
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6.3.4. Lactate dehydrogenase determination
As an index o f cell stress, LDH release from the astrocyte cultures was measured 
after 36h growth in 6  well plates, and expressed as a percentage of the total LDH 
activity of the culture as described in section 2.5. Previously, it has been observed that 
FBS in culture media is responsible for a proportion of total LDH activity. Thus 
activity attributable to FBS was subtracted from the activity of each sample of culture 
media containing FBS prior to calculation (section 2.5).
6.3.5. Cholesterol determination
Determination of total cellular cholesterol was carried out as described in section
2 .6 .
6.3.6. Protein determination
For those findings expressed against a protein baseline, the protein content of 
samples was determined by the method o f Lowry et al. (1951) as in section 2.7.
6.3.7. Astrocyte morphology
Cells were photographed as described in section 2.8, using a Nikon CoolPix 950 
digital camera and Nikon TMS phase contrast light microscope.
6.4. Experimental protocol
6.4.1. Exposure o f  astrocyte cultures to lovastatin
Primary cultures of rat astrocytes were exposed to media containing lovastatin 
for 24h or 36h. The (3-hydroxy acid of lovastatin (“Na-lovastatin”) was generated from 
the lactone form by dissolution in 1M NaOH in ethanol. Nucleophilic attack of the p
174
carbon and subsequent alkaline hydrolysis resulted in formation of Na-lovastatin. 
While absolute quantification of the concentration of Na-lovastatin was not obtained, 
this established method of conversion has been used by a number of groups previously 
(Endo et al., 1976; Alberts et a l, 1980; Maltese & Aprille, 1985), and was shown to 
have greater inhibitory activity of HMG-CoA reductase by Endo et al. (1976) and in the 
manufacturer’s product monograph (Merck and Co. Inc., 2003)
Both lovastatin and Na-lovastatin were added to the media in two 
concentrations; either lOpM or lOOpM. FBS (10% v/v) was added to the media in some 
experiments, while in others, cells were deprived o f serum for up to 36h before being 
harvested. In control experiments, only the appropriate vehicle was added without 
lovastatin, as described in section 2.2.6.3. In the case of lovastatin, the control vehicle 
is ethanol (present at 1% (v/v) in the cell culture media), while Na-Lovastatin used 
NaOH in ethanol (lOmM; 1% (v/v) final concentration). A 1% (v/v) solution of ethanol 
amounts to an absolute concentration of 171mM.
6,5. Results
6.5.1. The effect o f  lovastatin exposure in the presence o f  serum
6.5.1.1. Ubiquinone and cholesterol status
Cultured with FBS, exposure of astrocytes for 24h to lOpM lovastatin did not 
alter levels o f either C0 Q9 or C0 Q 10 in the presence o f FBS (10% v/v; control: C0 Q9 = 
2 0 2 . 8  ± 18.4 pmol/ mg protein; C0 Q 10 = 40.3 ± 3.0 pmol/ mg protein; 1 0  pM lovastatin: 
C0 Q9 = 198.8 ± 3 1 .8  pmol/ mg protein; C0 Q 10 = 42.1 ± 5.3 pmol/ mg protein; Fig 
6.1 A). lOOpM lovastatin caused a statistically significant decrease in cellular C0 Q9 
status of 52% in cells cultured in the presence o f FBS (/?<0.05). In contrast, C0 Q 10
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Figure 6.1. The effect o f lovastatin exposure upon the CoQ status ofprimary cultures 
o f rat astrocytes.
A: Rat astrocytes cells were incubated for 24h in 6 -well culture plates in the
presence of lovastatin (10pM or lOOpM) and FBS (10% v/v) as indicated (■  = C0 Q9; 
■  =CoQio). Data are mean ± SEM values of five to seven independent culture 
preparations.
B: Rat astrocytes cells were incubated for 36h in 6 -well culture plates in the
presence of lovastatin (10 or lOOpM) and FBS (10% v/v) as indicated (■  = C0 Q9; ■  
=CoQio). Data are mean ± SEM values of four to six independent culture preparations. 
* signifies p  < 0.05, analysed by one-way ANOVA.
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levels were unaffected (lOOpM lovastatin: C0 Q9 = 97.9 ± 14.9 pmol/ mg protein; C0 Q 10 
= 40.3 ± 9.1 pmol/ mg protein; Fig 6.1 A). Extension of the period of incubation from 
24h to 36h in the presence of serum gave a similar pattern of results to those obtained at 
24h. Under these conditions, no decrease was observed with lOpM lovastatin (control: 
C0 Q9 = 187.7 ± 2 1 . 2  pmol/ mg protein; C0 Q 10 = 42.7 ± 4.2 pmol/ mg protein; 1 0  pM 
lovastatin: C0 Q9 = 169.1 ± 5.9 pmol/ mg protein; C0 Q 10 = 42.4 ± 3.0 pmol/ mg protein; 
Fig. 6 . IB). However, the use of lovastatin at a concentration of lOOpM lead to a 
significant decrease in the amount o f C0 Q9 but not C0 Q 10 (C0 Q9 = 118.8 ± 13.1 pmol/ 
mg protein; C0 Q 10 = 43.3 ± 5.7 pmol/ mg protein; Fig. 6 . IB).
In the presence o f FBS, lovastatin did not significantly alter cholesterol levels 
compared to the control vehicle (control: 51.5 ± 6 . 8  nmol/ mg protein; 10 pM 
lovastatin: 64.3 ± 9.2 nmol/ mg protein; 100 pM lovastatin: 67.1 ± 6 . 6  nmol/ mg 
protein; Fig 6.2A). Extension o f exposure to 36h did not alter this finding (control: 53.7 
± 7.8 nmol/ mg protein; lOpM lovastatin: 65.7 ± 14.6 nmol/ mg protein; lOOpM 
lovastatin: 49.8 ± 5 .4  nmol/ mg protein; Figure 6.2B).
6.5.1.2.Mitochondrial enzyme activity
As shown in Table 6.1, lovastatin treatment for 24h or 36h did not significantly 
affect CS activity. The activities o f the enzymes of the ETC were not affected by 
lovastatin treatment at either 10 pM or 100 pM for up to 36h expressed against a protein 
baseline.
Table 6.2 reports the activities of the ETC enzymes expressed as a ratio of CS. 
It can be seen that against a ratio o f CS activity, complex IV activity decreased by 26% 
following 36h incubation with 100 pM lovastatin. This was the only observed decrease; 
all other activities were not significantly different from their control values.
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Figure 6.2. Cholesterol levels in astrocytes treated with lovastatin
Rat astrocytes were incubated for 24h (■ ) or 36h (■ ) in 6 -well culture plates in 
the presence of FBS (10% v/v). Cell culture media was supplemented as indicated, and 
cells harv ested following 24h or 36h incubation. Data are mean ± SEM values of three 
to four independent culture preparations expressed against a protein baseline.
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24 h 36 h
control 10 pMlovastatin
100 pM
lovastatin control
10 pM
lovastatin
100 pM
lovastatin
C x i
(nmol/min/mg) 24.3 ± 5.6 21.5 ±6.5 24.7 ± 2.7 22.4 ±2.1 29.5 ± 11.2 25.6 ± 5.5
Cx II+III
(nmol/min/mg) 11.9± 1.9 16.6 ± 2.1 7.5 ± 0.6 7.6 ±2.7 5.3 ± 0.5 7.3 ± 0.9
Cx IV
(k/min/mg) 1.28 ±0.20 1.39 ±0.07 0.78 ±0.12 1.29 ± 0.15 0.95 ± 0.34 0.92 ± 0.07
CS
(nmol/min/mg) 98.0 ± 9.3 117.0 ±4.1 84.0 ± 5.3 87.0 ±5.3 90.0 ± 10.4 105.2 ±8.5
Table 6.5. The effect o f lovastatin exposure upon the mitochondrial complex activities 
o f primary cultures o f  rat astrocytes in the absence o f  serum.
Rat astrocytes cells were incubated for 24h or 36h in 6 -well culture plates in the 
presence of Na-lovastatin (10 pM or 100 pM). Mitochondrial complex activity was 
determined as described. Data are mean ± SEM values of three to four independent 
culture preparations, expressed against a protein baseline. Yellow highlighting represents 
a statistically significant difference compared to control values {p < 0.05).
24 h 36 h
control 10 pMlovastatin
100 pM
lovastatin control
10 pM
lovastatin
100 pM
lovastatin
C x i 0.27 ± 0.09
0.19 ± 
0.06
0.30 ± 
0.04
0.26 ± 
0.02
0.31 ± 
0.11
0.24 ± 
0.04
Cx II+III 0.12 ± 0.01
0.14 ± 
0.02
0.09 ± 
0.01
0.09 ± 
0.03
0.06 ± 
0.01
0.07 ±0.01
Cx IV
(k/nmol)
0.013 ± 
0.001
0.012 ± 
0.001
0.009 ± 
0.001
0.015 ± 
0.003
0 .0 1 0  ± 
0.002
0.009 ± 
0.001
Table 6.6. The effect o f lovastatin exposure upon the mitochondrial complex activities 
o f primary' cultures o f  rat astrocytes in the absence o f  serum.
Complex activities were determined as described above, and expressed as a ratio 
of citrate synthase activity.
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6.5.1.3. LDH release and astrocyte morphology
As an index of membrane integrity, gaining insight into cell viability, LDH 
activity in the cell culture media was determined. The inclusion of ethanol (1%) in the 
culture medium resulted in 3.7% greater release than the untreated controls (untreated 
control: 0.9 ± 0.6%; ethanol vehicle: 4.6 ± 1.3%). However, lovastatin appears to 
increase this in a statistically significant manner by approximately an additional 5% and 
9% for 10 pM and 100 pM lovastatin respectively (10 pM: 9.2 ± 2.1%; 100 pM: 13.6 ± 
2 .2%).
Typical polygonal in-vitro astrocyte morphology is shown in figure 6 .3A, in 
contrast to the stellation observed in the majority o f cells treated with lovastatin 
(lOOpM; Fig. 6.3B). No changes were observed in astrocyte morphology following 
serum withdrawal or the addition o f control vehicles; stellation occurred following 1 0  
pM or 100 pM lovastatin exposure for 24 or 36h.
6.5.2. The effect o f  Na-lovastatin exposure in the presence o f  serum
6.5.2.1. Ubiquinone and cholesterol status
The sodium salt o f  lovastatin (Na-lovastatin; lOpM) did not change the amount 
o f either C0 Q9 or C0 Q 10 extracted from rat astrocytes in the presence of FBS (control: 
C0 Q9 = 153.3 ± 14.2 pmol/ mg protein; C0 Q 10 = 34.5 ± 4.1 pmol/ mg protein; 10 pM 
Na-lovastatin: C0 Q9 = 159.9 ± 2 2 . 6  pmol/ mg protein; C0 Q 10 = 38.3 ± 4.8 pmol/ mg 
protein; Fig 6.4A). However, increasing the concentration of Na-lovastatin to 100 pM 
elicited a statistically significant (p = 0.05) decrease of 31% in C0 Q9 levels (100 pM 
Na-lovastatin: C0 Q9 = 106.6 ± 14.0 pmol/ mg protein; C0 Q 10 = 33.3 ± 5.5 pmol/ mg 
protein; Fig 6 .4 A). C0 Q 10 levels did not change significantly.
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Figure 6.3. Astrocyte morphology in the absence and presence o f  lovastatin
Light micrographs (x 40 magnification) showing typical polygonal astrocyte 
morphology in vitro (A) and stellation following incubation with lovastatin for 36h (B). 
Following serum withdrawal for up to 36h, no changes in morphology were evident. 
Stellation occured as a result o f treatment with 10 pM or 100 pM lovastatin or Na- 
lovastatin in the presence or absence of serum.
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Figure 6.4. The effect o f  Na-lovastatin exposure upon the CoQ status o f primary 
cultures o f  rat astrocytes.
A: Rat astrocytes cells were incubated for 24h in 6 -well culture plates in the
presence of Na-lovastatin (10 pM or 100 pM) and FBS (10% v/v) as indicated 
(■  = C0 Q9; ■  =CoQio). Data are mean ± SEM values of eight independent culture 
preparations.
B: Rat astrocytes cells were incubated for 36h in 6 -well culture plates in the
presence of Na-lovastatin (10 or lOOpM) and tFBS (10% v/v) as indicated (■  = C0 Q9; 
■  =CoQio). Data are mean ± SEM values of four to six independent culture 
preparations.
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After 36h, the decrease in C0 Q9 levels observed following treatment with lOOpM Na- 
lovastatin did not achieve significance (control: C0 Q9 = 165.9 ± 16.7 pmol/ mg protein; 
C0 Q 10 = 45.0 ± 5.5 pmol/ mg protein; lOpM Na-lovastatin: C0 Q9 = 163.5 ± 28.9 pmol/ 
mg protein; C0 Q 10 = 42.0 ± 6 . 6  pmol/ mg protein; lOOpM Na-lovastatin: C0 Q9 = 125.6 
± 9.9 pmol/ mg protein; C0 Q 10 = 44.4 ± 4.0 pmol/ mg protein; Fig 6.4B).
In the presence o f FBS, 10 pM Na-lovastatin exposure for 24h resulted in a 
modest increase in cholesterol levels (control: 50.6 ± 8.2 nmol/ mg protein; 10 pM Na- 
lovastatin: 57.1 ± 8.4 nmol/ mg protein; Fig 6 .5A). However, lOOpM Na-lovastatin 
exposure resulted in a 64% increase in the amount o f cholesterol in these cultures when 
compared to their appropriate control (100 pM Na-lovastatin: 83.2 ± 7.6 nmol/ mg 
protein; Fig 6 .5A); this difference was statistically significant. 36h treatment with 10 
pM or 100 pM Na-lovastatin resulted only in relatively small and non-significant 
increases over control values (control: 43.0 ± 8.4 nmol/ mg protein; 10 pM Na- 
lovastatin: 51.7 ± 10.3 nmol/ mg protein; 100 pM Na-lovastatin: 61.0 ± 11.6 nmol/ mg 
protein; Fig 6.5B).
6.5.2,2. Mitochondrial enzyme activity
Na-lovastatin incubation for up to 36h in the presence of FBS did not give rise to 
statistically significant differences in the activities of citrate synthase or the respiratory 
enzymes as shown in tables 6.3 and 6.4.
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Figure 6.5. Cholesterol levels in astrocytes treated with Na-lovastatin
Rat astrocytes were incubated for 24h (■ ) or 36h (■ ) in 6 -well culture plates in 
and the presence of FBS (10% v/v). Cell culture media was supplemented as indicated, 
and cells harvested following 24h or 36h incubation. Data are mean ± SEM values of 
three to four independent culture preparations expressed against a protein baseline.
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24 h 36 h
control
10 pM
Na-
lovastatin
100 pM
Na-
lovastatin
control
10 pM
Na-
lovastatin
100 pM
Na-
lovastatin
Cx I
(nmol/min/mg) 25.8 ± 3.6 31.0 ± 7 .0 32.6 ± 2.4 19.0 ± 8 .7 23.0 ±4.5 30.9 ± 2.4
Cx II+III
(nmol/min/mg) 9.80 ± 1.48 11.54 ±2.57 8.79 ± 0.97 8.17 ± 2 .0 9.90 ± 2.92 6.68 ± 1.14
Cx IV
(k/mia'mg) 1.36 ±0.11 1.15 ± 0.14 1.10 ± 0.12 1.07 ±0.29 0.88 ±0.17 0.78 ± 0.24
CS
(nmol/min/mg) 93.7 ± 12.3 122.8 ± 11.7 114.4 ±9.1 83.6 ± 22.5 99.9 ± 14.3 102.1 ±7.6
Table 6.3. The effect o f  Na-lovastatin exposure upon the mitochondrial complex 
activities o f  primaryr cultures o f  rat astrocytes in the presence o f  serum.
Rat astrocytes cells were incubated for 24h or 36h in 6 -well culture plates in the presence 
of Na-lovastatin (10 pM or 100 pM) and FBS (10% v/v). Mitochondrial complex 
activity was determined as described. Data are mean ± SEM values of three independent 
culture preparations, expressed against a protein baseline.
\ 24 h 36 h
\ control
10 pM
Na-
lovastatin
100 pM
Na-
lovastatin
control
10 pM
Na-
lovastatin
100 pM
Na-
lovastatin
C x i 0.30 ± 0.06
0.27 ± 
0.08
0.35 ± 
0.07
0.21 ± 
0.05
0.23 ± 
0.02
0.37 ± 
0.08
Cx II+III 0.10±0.01
0.09 ± 
0.01
0.11 ± 
0.01
0.10±
0.01
0.10±
0.03
0.07 ± 
0.01
Cx IV
(k/nmol)
0.011 ± 
0.001
0.010±
0.001
0.015 ± 
0.002
0.013 ± 
0.004
0.009 ± 
0.001
0.008 ± 
0.002
Table 6.4. The effect o f  Na-lovastatin exposure upon the mitochondrial complex 
activities o f  primary cultures o f  rat astrocytes in the presence o f  serum.
Complex activities were determined as described in the table above, and 
expressed as a ratio of citrate synthase activity.
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6.5.2.3. LDH release
10 pM Na-lovastatin increased LDH release in the region of 5% of the 
maximum above controls (vehicle: 5.0 ± 1.2%; lOpM lovastatin: 10.4 ± 3.0%). This 
was not statistically significant. 100 |iM  Na-lovastatin caused LDH release 
approximately 10% o f the maximum above control levels (14.6 ± 5.4%); this was 
statistically significantly different compared to control vehicle values.
6.5.3. The effect o f  lovastatin exposure in the absence o f  serum
6.5.3.1. Ubiquinone and cholesterol status
C0 Q9 and C0 Q 10 levels were determined as previously, but astrocytes were 
cultured for 24h or 36h in the absence o f serum. Following 24h culture under these 
conditions with the natural lactone form o f lovastatin, C0 Q9 and C0 Q 10 levels were 
found not to be significantly different (control: C0 Q9 = 173.3 ± 23.6 pmol/ mg protein; 
C0 Q 10 = 36.0 ± 3 .5  pmol/ mg protein; lOpM lovastatin: C0 Q9 = 193.3 ± 24.7 pmol/ mg 
protein; C0 Q 10 = 41 ± 5.3 pmol/ mg protein; 1 0 0  pM lovastatin: C0 Q9 = 142.3 ± 2 1 . 2  
pmol/ mg protein; C0 Q 10 = 48.9 ± 8 . 6  pmol/ mg protein; Fig 6 .6 A).
The same experimental conditions maintained for 36h again resulted in no 
significant difference in the C0 Q9 status o f these cultures (control: C0 Q9 = 224.8 ± 22.7 
pmol/ mg protein; 1 0  pM lovastatin: C0 Q9 = 258.2 ± 26.6 pmol/ mg protein; 100 pM 
lovastatin: 227.6 ± 3.5 pmol/ mg protein; Fig. 6 .6 B). However, it was observed that 36h 
exposure o f the 100 pM lovastatin caused a statistically significant increase in the 
amount o f C0 Q 10 (control: C0 Q 10 = 51.9 ± 3.1 pmol/ mg protein; 1 0  pM 
lovastatin:CoQ 10 = 59.8 ± 5.1 pmol/ mg protein; C0 Q 10 = 80.0 ± 8.3 pmol/ mg protein; 
Fig 6 .6 B).
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Figure 6.6. The effect o f  lovastatin exposure upon the CoQ status o f primary cultures 
o f rat astrocytes in the absence o f  serum.
A: Rat astrocytes cells were incubated for 24h in 6 -well culture plates in the
presence of lovastatin (10 pM or lOOpM) but in the absence of FBS as indicated 
(■  = C0 Q9; ■  =CoQio). Data are mean ± SEM values of six to seven independent 
culture preparations.
B: Rat astrocytes cells were incubated for 36h in 6 -well culture plates in the
presence of lovastatin (10 or lOOpM) but in the absence of FBS as indicated 
(■  = C0 Q9; ■  =CoQio). Data are mean ± SEM values of four to eight independent 
culture preparations. * signifies p  < 0.05, analysed by one-way ANOVA
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These conditions did not cause statistically significant differences in cellular 
cholesterol concentration after 24h (control: 78.6 ± 13.4 nmol/ mg protein; lOpM 
lovastatin: 91.0 ± 22.1 nmol/ mg protein; 100 pM lovastatin: 68.1 ± 22.3 nmol/ mg 
protein; Fig 6.7A), or 36h (control: 42.2 ± 9.7; 10 pM lovastatin 35.7 ± 10.8 nmol/ mg 
protein; 100 pM lovastatin = 42.8 ± 3.2 nmol/ mg protein; Fig 6.7B).
6.5.3.2. Mitochondrial enzyme activity
Culture in the absence o f serum and simultaneous treatment with lovastatin for 
24h did not profoundly affect CS activity, and no significant differences in ETC enzyme 
activities were observed when compared to controls (Table 6 .6 ). Against protein, 
complex IV showed a significant decrease of 39% after 24h incubation with 100 pM 
lovastatin (p< 0.05). However, this inhibition was not observed after 36h incubation 
(Table 6.5).
6.5.3.3.LDH release
Lovastatin in the absence o f serum did not increase LDH release from astrocytes 
in a statistically significant manner at 10 pM; however 100 pM caused an increase in 
release of approximately 10% o f the maxamal value (vehicle: 6.0 ± 3.2%; 10 pM 
lovavatatin: 12.6 ± 2.9%; 100 pM lovastatin: 17.5 ± 6.4%). The latter was statistically 
significant.
6.5.4. The effect o f  Na-lovastatin exposure in the absence o f  serum
6.5.4.1. Ubiquinone and cholesterol status
Exclusion of FBS and simultaneous supplementation of culture media with 10 
pM Na-lovastatin did not profoundly alter the amount of C0 Q9 or COQ10 extracted from
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Figure 6.7. Cholesterol levels in serum  - deprived astrocytes treated with lovastatin
Rat astrocytes were incubated for 24h (■ ), or 36h (■ ) in 6 -well culture plates in 
the absence of FBS as indicated. Cell culture media was supplemented as indicated, 
and cells harvested following 24h or 36h incubation. Data are mean ± SEM values of 
three to four independent culture preparations expressed against a protein baseline.
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24 h 36 h
control 10 pMlovastatin
100 pM
lovastatin control
10 pM
lovastatin
100 pM
lovastatin
Cx I
(nmol/min/mg) 24.3 ± 5.6 21.5 ± 6.5 24.7 ± 2.7 22.4 + 2.1 29.5+11.2 25.6 ± 5.5
Cx II+III
(nmol/min/mg) 11.9± 1.9 16.6 + 2.1 7.5 ± 0.6 7.6 ± 2.7 5.3 ±0.5 7.3 + 0.9
Cx IV
(k/min/mg) 1.28 ± 0.20 1.39 + 0.07 0.78 + 0.12 1.29 + 0.15 0.95 ± 0.34 0.92 ± 0.07
CS
(nmol/min/mg) 98.0 ± 9.3 117.0 + 4.1 84.0 ± 5.3 87.0 + 5.3 90.0+10.4 105.2 + 8.5
Table 6.5. The effect o f lovastatin exposure upon the mitochondrial complex activities 
o f primary cultures o f rat astrocytes in the absence o f serum.
Rat astrocytes cells were incubated for 24h or 36h in 6-well culture plates in the 
presence of Na-lovastatin (10 pM or 100 pM). Mitochondrial complex activity was 
determined as described. Data are mean ± SEM values of three to four independent 
culture preparations, expressed against a protein baseline. Yellow highlighting represents 
a statistically significant difference compared to control values (p < 0.05).
24 h 36 h
control 10 pMlovastatin
100 pM
lovastatin control
10 pM
lovastatin
100 pM
lovastatin
C x i 0.27 + 0.09
0.19 + 
0.06
0.30 + 
0.04
0.26 + 
0.02
0.31 ± 
0.11
0.24 + 
0.04
Cx II+III 0.12 + 0.01
0.14 + 
0.02
0.09 + 
0.01
0.09 + 
0.03
0.06 + 
0.01
0.07 + 0.01
Cx IV
(k/nmol)
0.013 + 
0.001
0.012 + 
0.001
0.009 + 
0.001
0.015 + 
0.003
0.010 + 
0.002
0.009 + 
0.001
Table 6.6. The effect o f lovastatin exposure upon the mitochondrial complex activities 
ofprimary' cultures o f  rat astrocytes in the absence o f serum.
Complex activities were determined as described above, and expressed as a ratio 
of citrate synthase activity.
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these cultures (control: C0 Q9 = 159.8 ± 16.1 pmol/ mg protein; C0 Q 10 = 39.3 ± 5.1 
pmol/ mg protein; 10 pM Na-lovastatin: C0 Q9 = 167.2 ± 15.7 pmol/ mg protein; C0 Q 10 
= 45.5 ± 7.1 pmol/ mg protein; Fig 6 .8 A). With lOOpM Na-lovastatin, a decrease 
observed in C0 Q9 levels did not achieve statistical significance; neither were C0 Q 10 
levels altered (lOOpM Na-lovastatin: C0 Q9 = 117.5 ± 30.2 pmol/ mg protein; C0 Q 10 =
37.8 ± 9.2 pmol/ mg protein; Fig 6 .8 A).
Similarly, 36h incubation did not elicit statistically significant changes in C0Q9 
or C0Q10 status, although C0Q9 and C0Q10 levels were generally higher when compared 
to those cultures grown in the presence o f serum (control: C0Q9 = 249.2 ±41.2  pmol/ 
mg protein; C0Q10 = 56.9 ± 6.5 pmol/ mg protein; lOpM Na-lovastatin: C0Q9 = 253.6 ±
30.9 pmol/ mg protein; C0Q10 = 63.0 ± 6.7 pmol/ mg protein; lOOpM lovastatin: C0Q9 
= 178.0 ± 28.2 pmol/ mg protein; C0Q10 = 59.4 ± 1 1.4 pmol/ mg protein; Fig 6 .8 B).
With regard to cholesterol, 24h exposure did not significantly alter cellular 
levels (control: 72.7 ± 10.4 nmol/ mg protein; 10 pM Na-lovastatin: 75.9 ± 12.3 nmol/ 
mg protein; 100 pM Na-lovastatin: 83.3 ± 13.2 nmol/ mg protein; Fig 6.9A). While no 
change was observed following 36h exposure to 10 pM Na-lovastatin (control: 35.2 ± 
5.4 nmol/ mg protein; 10 pM Na-lovastatin: 35.9 ± 3.5 nmol/ mg protein; Fig 6.9B) 
lOOpM Na-lovastatin in the absence o f serum resulted in an approximate doubling of 
total cellular cholesterol after 36h (lOOpM Na-lovastatin: 72.0 ± 6.5 nmol/ mg protein; 
Fig 6.9B), and this result was statistically significant (p < 0.05).
6.5.4.2. Mitochondrial enzyme activity
As shown in tables 6.7 and 6 .8 , Na-lovastatin incubation during 24h or 36h 
culture without FBS did not lead to statistically significant alterations in CS or ETC 
enzyme activity against either protein or CS.
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Figure 6.8. The effect o f  Na-lovastatin exposure upon the CoQ status ofprimary 
cultures o f  rat astrocytes in the absence o f  serum.
A: Rat astrocytes cells were incubated for 24h in 6 -well culture plates in the
presence of Na-lovastatin (10 pM) but in the absence of FBS as indicated 
(■  = C0 Q9; ■  =CoQio). Data are mean ± SEM values of seven to eight independent 
culture preparations.
B: Rat astrocytes cells were incubated for 36h in 6 -well culture plates in the
presence of Na-lovastatin (10 or lOOpM) and the absence of FBS as indicated 
(■  = C0 Q9; ■  =CoQio). Data are mean ± SEM values of four to six independent 
culture preparations.
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Figure 6.9. Cholesterol levels in serum - deprived astrocytes treated with Na- 
lovastatin
Rat astrocytes were incubated for 24h (■ ), or 36h (■ ) in 6 -well culture plates in 
the absence of FBS as indicated. Cell culture media was supplemented as indicated, 
and cells harvested following 24h or 36h incubation. Data are mean ± SEM values of 
three to four independent culture preparations expressed against a protein baseline.
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24 h 36 h
control
10 pM
Na-
lovastatin
100 pM
Na-
lovastatin
control
10 pM
Na-
lovastatin
100 pM
Na-
lovastatin
C x i
(nmol/min/mg) 24.7 + 6.1 24.1 ± 3 .6 26.6 + 3.7 20.4 ± 3.0 26.9 ± 3.7 23.1 + 1.4
Cx II+III
(nmol/min/mg) 10.6+ 1.6 12.8+ 1.6 7.6 ± 0 .5 9 .9+  1.6 10.4 + 2.7 4.6 ± 2.6
Cx IV
(k/min/mg) 1.50 + 0.27 1.00 + 0.09 0.92 + 0.12 0.89 ± 0.20 1.44 + 0.31 0.65+ 0.25
CS
(nmol/min/mg) 96.7 ± 6.0 112.7 + 4.2 97.1 ± 12.2 86.5 ± 7.4 100.4+ 12.8 83.7 ±17.1
Table 6.7. The effect o f  Na-lovastatin exposure upon the mitochondrial complex 
activities ofprimary cultures o f  rat astrocytes in the absence o f  serum.
Rat astrocytes cells were incubated for 24h or 36h in 6 -well culture plates in the 
presence of Na-lovastatin (10 pM or 100 pM). Mitochondrial complex activity was 
determined as described. Data are mean ± SEM values of three independent culture 
preparations, expressed against a protein baseline.
24 h 36 h
control
10 pM
Na-
lovastatin
100 pM
Na-
lovastatin
control
10 pM
Na-
lovastatin
100 pM
Na-
lovastatin
C x i 0.26 + 0.06
0.22 + 
0.03
0.36 + 
0.13
0.23 + 
0.01
0.27 + 
0.03
0.30 + 
0.06
Cx II+III 0.11 ± 0.02
0.11 ± 
0.02
0.10 + 
0.03
0.12 + 
0.03
0.10 + 
0.02
0.06 + 
0.03
Cx IV
(k/nmol)
0.016 + 
0.003
0.009 + 
0.001
0.012 + 
0.002
0.010 + 
0.003
0.014 + 
0.003
0.007 + 
0.002
Table 6.8. The effect o f  Na-lovastatin exposure upon the mitochondrial complex 
activities ofprimary cultures o f  rat astrocytes in the absence o f  serum.
Complex activities were determined as described in the table above, and 
expressed as a ratio of citrate synthase activity.
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6.5.4.3, LDH release
Again when cultured in the absence o f serum, 10 pM Na-lovastatin did not 
significantly increase LDH release. 100 pM Na-lovastatin however, caused a 
statistically significantly release compared to the control vehicle (control: 7 .1  ± 2 .6 %; 
10 pM Na-lovastatin: 9.7 ± 5.6%; 100 pM Na-lovastatin: 16.3 ± 1.4%).
6.6. Discussion
Lovastatin treatment has previously been described as inhibiting biosynthesis of 
both cholesterol (Alberts et a l, 1980; Bradford et a l, 1994) and CoQ^io (Maltese and 
Aprille, 1985). In addition, lower levels o f these end-products have been described 
following treatment with lovastatin (Alberts et a l, 1980; Willis et a l, 1990; Folkers et 
a l, 1990). Thus primary cultures o f rat astrocytes were treated with lovastatin and 
cholesterol, C0 Q9 and C0 Q 10 and ETC enzyme activities measured. While plasma 
protein binding could possibly limit bioavailability (Selleri et a l, 2003; Mundy et a l, 
2004), albumin carriage as a result o f lovastatin binding to proteins in FBS could 
enhance uptake, or a lactonase activity o f FBS could enhance conversion to the active 
isoform. Thus lovastatin was added in culture media in the presence or absence of FBS 
( 10%).
As Na-lovastatin has been established as being more effective at inhibiting 
HMG-CoA reductase than the lactone form (Endo, et a l, 1976; Alberts et a l, 1980; 
Merck & Co. Inc., 2003), both lovastatin and Na-lovastatin were added to the culture 
medium for up to 36h in the presence or absence o f FBS.
While lovastatin exposure significantly decreased C0 Q9 levels after 24h when 
used at a concentration of 100 pM (Fig 6.1 A), the decrease observed with Na-lovastatin 
under the same conditions (although still statistically significant) was markedly smaller
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(Fig 6.4A). In both cases, the absence o f serum resulted in smaller non-significant 
decreases suggesting that the presence o f FBS may facilitate the entry of lovastatin to, 
or otherwise increase the efficacy o f the drug in these primary astrocyte cultures.
A number of mammalian sera have lactonase activity (Roth et al., 1967; Teiber 
et al., 2003). In human serum, lovastatin can be converted to the activated form by 
serum, although the serum-dependant component accounts for only 15% of the total 
lovastatin conversion, which primarily occurs in the liver (Tang and Kalow, 1995). 
Serum lactonase activity metabolising lovastatin has been ascribed to paraoxonase 1 
(PON1; EC. 3.1.8.1, formerly 3.1.1.2; Billecke et al., 2000), while rabbit serum contains 
PON3 (Draganov et al., 2000). Thus while literature searches do not confirm the 
presence o f PON isoforms in FBS, it is possible that the 10% supplementation of culture 
media with FBS could convert the prodrug to the active form.
Notably, given that no changes in either C0 Q9 or C0 Q 10 levels were observed 
following 10 pM exposure to lovastatin or Na-lovastatin.
Lovastatin (100 pM) inclusion in serum-containing media for 36h resulted in a 
significant decrease o f in C0 Q9 but not C0 Q 10 in comparison to control levels, mirroring 
the findings o f the 24h experiment (Fig 6 . IB). Again the absence of serum in these 
experiments abolished the decrease in C0 Q9 levels. However, despite the decreases in 
C0 Q9, C0 Q 10 status was unaffected. Although a modest increase in C0 Q 10 levels was 
observed in one case in the absence o f FBS (Fig. 6 .6 B), the reasons for this are unclear. 
Taken in light o f the finding of decreased C0 Q9 levels while C0 Q 10 is maintained, these 
data may support the proposition of distinct metabolic pathways for synthesis of C0 Q9 
and C0 Q 10, where levels of one may be amenable to modulation whilst maintaining 
concentration o f the other homologue.
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Rather than displaying increased potency, Na-lovastatin appeared to be less 
effective in modulating cellular CoQ levels: the decreases observed in C0 Q9 
concentration with Na-lovastatin were generally smaller in either the presence of 
absence o f serum.
While C0 Q9 levels were seen to decrease, cholesterol levels were maintained 
with lovastatin treatment in the presence o f serum. Cholesterol levels were elevated 
following Na-lovastatin treatment (100 pM) in the presence of serum for 24h (while 
C0 Q9 decreased) and after 36h incubation in the absence of serum (when C0 Q9 levels 
did not change significantly). The reasons for this are unclear; however the increases in 
cholesterol may be attributable to the induction o f rat HMG-CoA reductase synthesis 
following competitive inhibition by lovastatin, as described in animal studies by 
(Edwards et al., 1983; Yamauchi et al., 1991). As ubiquinone synthesis in rat brain 
slices is approximately 20-fold slower than that o f cholesterol yet the half life CoQ 
turnover is 90h compared to approximately 4000h for cholesterol (Andersson et al., 
1990), it is possible such induction o f HMG-CoA reductase may not be sufficient to 
maintain C0 Q9 levels following initial inhibition. Additionally, serum lipoprotein 
withdrawal has also been described as an inducer of HMG-CoA reductase activity in 
primary cultures o f rat glia (Langan et al., 1987).
It is therefore evident that decreases in C0 Q9 did not correlate to a loss of 
cellular cholesterol and the differential effects upon C0 Q9 , C0 Q 10 and cholesterol 
(which may share a common biosynthetic pathway) therefore remains to be resolved. 
However as the biochemisty o f CoQ synthesis has yet to be fully elucidated in 
mammals, it is possible that distinct CoQ homologues and cholesterol, as the end 
products o f the mevalonate pathway, are regulated independently.
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While the LDH data would suggest increased membrane permeability of 
cultures treated with lovastatin, these findings must be treated with caution. As 
described by Keilhoff & Wolf (1993), increased LDH activity in cell culture medium 
may not necessarily correlate with decreased cell viability. These authors suggest that 
LDH may be better used as a marker o f cell stress than cell death. Finally, the observed 
decreases in C0 Q9 were unlikely to be attributable to cell death given that CoQ 10 status 
did not change.
In order to gain further insight into the consequences of depletion of cellular 
C0 Q9 resulting from lovastatin and Na-lovastatin treatment, the activities of the ETC 
enzymes were determined. As can be seen, only complex IV was affected, with 
significant decreases in activity observed in 100 pM lovastatin-treated cultures grown in 
the absence of serum for 36h and expressed against CS activity (Table 6.2). This 
appeared to correspond to decreased C0 Q9 levels, but not CoQ 10 or cholesterol. Given 
the antioxidant nature of CoQ, and the susceptibility o f complex IV to oxidative stress 
and free radical-mediated inhibition (Brown and Cooper, 1994; Bolaflos et a l, 1994; 
Bolafios et al., 1996, reviewed in Heales et al., 1999), it is conceivable that decreased 
antioxidant defences at the levels o f either C0 Q9 or CoQ 10 could result in decreased 
complex IV activity. However a statistically significant decrease in complex IV was 
also observed with 24h lovastatin treatment in the absence FBS. Under these conditions 
no changes in C0 Q9 , CoQ 10 or cholesterol metabolism were observed; subsequently it is 
unclear as to whether complex IV activity was decreased as a result of alterations in the 
cellular levels C0 Q9 .
The complex II+III assay may be dependent upon endogenous CoQ 
homologues in the ETC (Clark et al., 1994; Rahman et al., 2001); thus a marked loss of 
at least one o f these homologues could potentially manifest as a decreased activity of
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this linked assay (Shults et al., 1997; Van Maldegerm et a i, 2002). However, the 
decreases in C0 Q9 observed with 1 00 pM lovastatin and 100 pM Na-lovastatin after 24h 
and 36h (Figs 6.1 and 6.4A) did not translate to statistically significant decreases in 
complex II+III activity in vitro. A number o f possibilities can be considered: while 
mitochondrial complex II+III activity was used as a putative index of C0 Q9 or C0 Q 10 
function in the inner mitochondrial membrane, this study addressed total cellular levels 
o f these species. It may be that changes in other membranes’ C0 Q9 or C0 Q 10 status are 
not related to levels in the inner mitochondrial membrane. Thus alterations in 
mitochondrial C0 Q9 or C0 Q 10 may not be evident in whole cell measurements. It is also 
possible that a much greater decrease in C0 Q9 or C0 Q 10 may be necessary to elicit 
decreased levels o f complex II+III activity. However, it may be important that under 
these conditions, C0 Q 10 levels were maintained. Thus the possibility exists that while 
cellular levels o f C0 Q9 are decreased, it is C0 Q 10 which is functionally active as an 
electron carrier within the inner mitochondrial membrane.
6 .7. Conclusion
It was found that 100 pM lovastatin or Na-lovastatin had the ability to decrease 
cellular levels o f C0 Q9 (but not C0 Q 10) following 24h or 36h exposure. A lower 
concentration of the statin (10 pM) did not alter CoQ status. Decreases observed in the 
absence of serum were less profound than those observed in the presence of serum. 
Thus albumin carriage may be a factor in cellular uptake of lovastatin; alternatively 
these effects may be attributed to lactonase activity of the FBS.
Total cellular cholesterol did not decrease under comparable conditions. In 
these cases, Na-lovastatin appeared to be more effective in eliciting an increase in 
cellular cholesterol than was lovastatin. Whether the differential effects observed on
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CoQg and cholesterol are due to differences in cellular turnover and biosynthetic rate of 
these molecules, or another mechanism remains to be elucidated.
Complex II+III activity did not correlate with the increases or decreases 
observed in C0 Q9 or C0 Q 10. These findings may support the hypothesis that the major 
and minor isoforms o f CoQ are involved in differing physiological functions in discreet 
subcellular locations.
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7. C o Q 9 a n d  c o q 10 l e v e l s  in  p r im a r y
CULTURES OF RAT ASTROCYTES AND 
NEURONS; EFFECTS OF EXPOSURE TO
NITRIC OXIDE
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7. CoQ9 AND C0 Q 10 LEVELS IN PRIMARY CULTURES OF RAT 
ASTROCYTES AND NEURONS; EFFECTS OF EXPOSURE TO NITRIC 
OXIDE
7.7. Introduction
With regard to the effects upon astrocytes and neurons, a number of differential 
effects of reactive nitrogen species (RNS) have been reported (reviewed in Heales et al., 
2004).
RNS acting upon the ETC have been shown to inhibit complexes II+III and 
complex IV in primary cultures o f astrocytes (Bolafios et al., 1994, Stewart et al., 
1998b). The neuronal ETC however, appears to be less robust (Bolafios et al., 1995; 
Gegg et al., 2003).
GSH status o f such astrocytes almost doubles upon 24h exposure to DETA-NO; 
neurons however, exposed to the same conditions for 18h decrease their GSH content 
by almost 50%, (Gegg et al., 2003). Moreover, while in cultured astrocytes and neurons 
RNS exposure does not readily inhibit complex I (Bolafios et al., 1994, 1995, 1996), 
following GSH depletion with L-BSO, complex I becomes susceptible to RNS- 
mediated inhibition (Barker et al., 1996).
Monocultured neurons contain approximately 70% less GSH than neurons 
cultured in the presence of astrocytes (Bolafios et al., 1996). Induction of iNOS for 24h 
in these astrocytes cocultured with neurons results in significant neuronal mitochondrial 
damage; however, cell death does not occur at this timepoint (Stewart et al., 1998b). In 
contrast, direct exposure of monocultured neurons to RNS causes cell death associated 
with mitochondrial damage (Bolafios et a l, 1995, 1996).
2 0 2
Cocultured neurons with NO-generating astrocytes increase their GSH levels, 
and subsequently maintain ETC activities. If the astrocytes are previously depleted of 
GSH, nearby neurons are unable to upregulate GSH sysnthesis; subsequently complex 
II+III and complex IV activity decreases (Gegg et al., 2005).
RNS exposure does not immediately cause cell death of astrocytes (Bolafios et 
al. 1994, 1995). However, neurons have been shown to be vulnerable to RNS-mediated 
damage. This differential is in part due to the ability of astrocytes to maintain ATP 
synthesis (and thus prevent ATP hydrolysis as a reversal of the ATP synthase) by an 
upregulation of glycolysis (Bolafios et al., 1994, Almeida et al., 2004).
Although a number o f differential effects resulting from RNS exposure to 
astrocytes and neurons have been documented, the C0 Q9 and C0 Q 10 status under such 
conditions has not yet been examined. This chapter describes the effects of iNOS 
induction in astrocytes, and DETA-NO exposure in astrocytes and neurons with regard 
to cellular levels o f C0 Q9 and C0 Q 10.
7.2.Aims
• To investigate the effects o f iNOS activation for up to 36h upon cellular 
levels of C0 Q9 , and C0 Q 10, and the activities of the enzymes of the ETC 
in astrocyte cultures.
•  To investigate the effects o f DETA-NO as an exogenous source of NO in 
this cell culture system.
• To characterise the C0Q9 and C0Q10 status of neurons, and their 
responses to exogenous NO as a result o f DETA-NO addition to the 
culture medium.
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7.3.Methods
7.3.1. Tissue culture
7.3.1.1. Primary astrocyte cultures
Primary cultures of rat astrocytes were prepared and maintained as described in 
section 2.2.3. On DIV 13, as described in section 2.2.6, cultures were exposed to LPS 
(1 pg/ ml) and IFNy (100 U/ml) for 24h or 36h in the absence of serum to induce iNOS- 
mediated NO generation (Bolafios et al., 1994). L-NIL (100 pM) was used as an 
inhibitor o f iNOS (Moore et al., 1994). Exogenous NO was generated in cell culture 
media by the addition of the NO donor DETA-NO (500 pM). Cells were collected as a 
pellet as described in sections 2 .2 .6 .
7.3.1.2.Primary neuron cultures
Neuron-enriched cultures were prepared as described in section 2.2.4. On DIV 
6 , cultures were maintained in the absence of serum for 24h. In experiments 
investigating the effect of endogenous NO, DETA-NO (500 pM) or the degraded 
control was added to the culture medium (section 2.2.6.4).
7.3.2. CoQ measurement by HPLC
Cellular lipids were extracted as described in section 3.2.5, and the 
concentrations o f C0 Q9 and C0 Q 10 were measured by reverse-phase UV-HPLC as in 
section 3.2.3.
7.3.3. ETC enzyme assays
The activities of the enzymes of the respiratory chain were assayed in the 
samples as described in section 2.3
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7.3.4. Lactate dehydrogenase determination
As an index of cell stress, LDH release from the astrocyte cultures was measured 
after 36h o f growth in 6  well plates, and expressed as a percentage o f the total LDH 
activity of the culture. This is described in section 2.5.
7.3.5. Measurement o f  NOx in culture media
The generation o f NO2* and NCV (NOx) species in the culture media was used 
as an index of NO generation. Determination o f NOx used the Greiss assay (based on 
the method of Green et al., 1982); wherein a pink diazo product was formed from the 
reaction between naphthaethylenediamine dihydrochloride, and sulphanilamide/ H3PO4 . 
This has previously been described in section 2.4.
7.3.6. Protein determination
CoQ levels in cells and ETC activities were expressed against a protein baseline, 
the protein content o f samples was determined by the method of Lowry et al. (1951) as 
in section 2.7.
7.4. Experimental protocol
7.4.1. Exposure o f  astrocyte cultures to LPS + IFNy
Primary cultures of rat astrocytes were exposed to media supplemented with 
LPS (1 pg/ ml) and IFNy (100 U/ml) for 24h or 36h. This has previously been 
described to induce the iNOS protein (Bolafios et al., 1994), leading to NO generation 
and subsequent elevation of NOx in culture medium. Control experiments used 
untreated cells incubated for the same time. Some experiments used L-NIL (100 pM) in 
addition LPS + IFNy to inhibit activation of iNOS.
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7.4.2. Exposure o f  astrocyte cultures to DETA-NO
DETA-NO (500pM) in this astrocyte and neuron culture medium has previously 
been calculated to release a steady state concentration of approximately 1 pM NO for 
24h (Gegg et al., 2003). This compound was used to expose astrocytes to exogenous 
NO. In control experiments, media was supplemented with the same concentration of 
degraded DETA-NO. This had been previously incubated at 37°C for 7 days. Given 
that the half life of DETA-NO is approximately 8 h (Seccia et al., 1996), negligible NO 
will be generated by the addition of the degraded compound to cell culture media. The 
CoQ status and ETC enzyme activities o f astrocyte cultures exposed to NO of 
exogenous or endogenous origin were reported.
7.4.3. CoQ status o f  neuronal cultures and exposure to DETA- NO
C0 Q9 and CoQ 10 status o f these neuron-enriched cultures was determined as 
conducted previously with other cell types: section 3.2.5 describes the extraction and 
sample preparation for the determination o f CoQ by UV-HPLC. C0 Q9 and CoQ 10 
levels were measured in untreated cells and following the inclusion for 24h o f either 
fresh DETA-NO (500 pM) in the cell culture media, or degraded DETA-NO as a 
control.
7,5. Results
7.5.1. CoQ status o f  astrocyte cultures following LPS + IFNy exposure 
Incubation of astrocytes with LPS + IFNy for 24h generated significant amounts of NO 
in the culture media as witnessed by the measurement of NOx (Fig. 7.1 A). This was 
abolished by the use of the inhibitor of iNOS, L-NIL (control: 26.8 ± 3.2 nmol
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Fig 7.1 NOx levels in culture media from  rat primary astrocytes
Rat primary astrocytes were incubated for 24h (A: ) or 36h (B: ■ ) in 6 -well
culture plates in the absence (control) or presence of LPS (1 pg/ ml) and IFNy (100 
U/ml), with and without the inhibitor of iNOS L-NIL (100 pM) or alternatively DETA- 
NO (500pM) as indicated. Data are mean ± SEM values of three to four independent 
culture preparations. * signifies /?<0.05 compared to control values following analysis 
by one-way ANOVA.
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NOx/ mg protein; LPS+IFNy: 99.1 ± 12.5 nmol NOx/ mg protein; +L-NIL: 28.9 ± 5.2 
nmol NOx/ mg protein; Fig. 7.1 A).
24h incubation with LPS+IFNy did not affect the amount of either C0Q9 or 
C0Q10 extracted from the cultures (control: C0Q9 = 174.2 ± 10.8 pmol/ mg protein; 
CoQio = 37.9 ± 1.6 pmol/ mg protein; LPS+IFNy: C0Q9 = 191.5 ± 20.6 pmol/ mg 
protein; C0Q10 = 42.0 ± 5.6 pmol/ mg protein; +L-NIL: C0Q9 = 144.1 ± 12.7 pmol/ mg 
protein; C0Q10 = 32.0 ± 2.6 pmol/ mg protein; Fig. 7.2A).
However, maintained under the same conditions for 36h, similar levels of NOx 
were detected in media (control: 33.5 ± 2.3 nmol NOx/ mg protein; LPS+IFNy: 100.1 ±
13.8 nmol NOx/ mg protein; Fig 7 .IB), but these cultures contained 22% less C0 Q9 (p = 
0.05) than controls. Under the same conditions, CoQ 10 levels were not significantly 
affected (control: C0 Q9 = 214.8 + 6 . 8  pmol/ mg protein; CoQ 10 = 44.9 ±3 .2  pmol/ mg 
protein; LPS+IFNy: C0 Q9 = 168.2 ± 11.6 pmol/ mg protein; C0 Q 10 = 38.1 ± 3.5 pmol/ 
mg protein; +L-NIL: C0 Q9 = 222.0 ± 24.5 pmol/ mg protein; C0 Q 10 = 45.1 ± 5.2 pmol/ 
mg protein; Fig 7.2B). The increased NOx and the decreases in C0 Q9 were abolished 
by the inclusion o f L-NIL in the culture medium (+L-NIL: 31.6 ± 2.5 nmol NOx/ mg 
protein Fig 7 .IB).
7.5.2. CoQ status o f  astrocyte cultures following DETA-NO exposure
DETA-NO generated NOx in cell culture media compared to untreated controls 
(DETA-NO: 128.6 ± 7.5 nmol NOx/ mg protein; Fig 7.1). After 24h, this resulted in 
C0 Q9 and C0 Q 10 levels which were significantly decreased compared to controls 
(control: C0 Q9 = 193.3 ± 28.2 pmol/ mg protein; C0 Q 10 = 55.3 ± 7.1 pmol/ mg protein; 
DETA-NO: C0 Q9 = 130.5 ± 7.0 pmol/ mg protein; C0 Q 10 = 31.2 ± 3.1 pmol/ mg 
protein; Fig 7.3A). However, extension of this incubation with DETA-NO to 36h while
A: 24h
■  C0Q9 
H C0Q10
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control LPS+IFNy LPS+IFNy+L-NIL
B: 36 h
LPS+IFNy LPS+IFNy+L-NILcontrol
Figure 7.2. The effect o f  LPS+IFNy upon the CoQ status o f  primary cultures o f  rat 
astrocytes.
A: Rat astrocytes were incubated for 24h in 6 -well culture plates as
indicated. Data are mean ± SEM values of between seven and twelve independent 
culture preparations.
B: Rat astrocytes were incubated for 36h in 6 -well culture plates as
indicated. Data are mean ± SEM values of five or six independent culture preparations 
(* signifies p = 0.05).
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Figure 7.3. The effect o f DETA-NO upon CoQ status o f  rat primary astrocyte cultures
Rat astrocytes were incubated for 24h (A) or 36h (B) in 6 -well culture plates as 
indicated. DETA-NO (500 pM) was added as a source of exogenous NO; degraded 
DETA-NO was used as a control. Data are mean ± SEM values of between three and 
five independent culture preparations. (* signifies p = 0.05).
210
greater levels of NOx in culture media (DETA-NO: 189.2 ± 2 1 .7  nmol NOx/ mg 
protein; Fig 7 .IB), resulted in C0 Q9 and C0 Q 10 levels which were unchanged compared 
to control levels (control: C0 Q9 = 184.4 ± 20.7 pmol/ mg protein; C0 Q 10 = 50.5 ± 9.2 
pmol/ mg protein; DETA-NO: C0 Q9 = 172.9 ± 12.4 pmol/ mg protein; C0 Q 10 = 48.7 ± 
2.55 pmol/ mg protein; Fig 7.3B).
7.5,3, Mitochondrial ETC enzyme activities o f  astrocytes exposed to NO
Exposure o f LPS+IFNy for up to 36h did not affect mitochondrial enrichment of 
these cultures as reported in Table 7.1. Following 24h exposure to LPS+IFNy, no 
statistically significant changes ETC enzyme activities were observed when expressed 
against a protein baseline (Table 7.1). Following 36h exposure a 60% decrease in 
complex IV activity was recorded ip < 0.05; Table 7.1). Expression against CS activity 
resulted in significant decreases in the activities of complex II+III (by 36%) and 
complex IV (by 47%) after 24h ip < 0.05; Table 7.2). Inclusion of L-NIL in the culture 
media resulted in an almost complete restoration of complex IV activity. Although 
complex II+III activity was measured as being lower than control values, with the 
inclusion of L-NIL, result was no longer statistically significant. Extension of exposure 
to 36h resulted in an amelioration o f the loss o f complex II+III activity; however under 
these conditions complex IV activity was reduced by 60% ip < 0.001; Table 7.2). 
Again, L-NIL abolished this effect.
DETA-NO was used to generate exogenous NO in the culture medium, and this 
did not affect CS activity in these samples (Table 7.3). However, complex IV activity 
after 24h exposure was decreased by 57% ip < 0.001) and 43% lower after 36h ip < 
0.05), following expression against a protein baseline (Table 7.3).
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24 h 36 h
control LPS + IFNy
LPS+IFNy
+L-NIL control
LPS + 
IFNy
LPS+IFNy
+L-NIL
C xi
(nmol/min/mg) 25.0 + 4.15 29.2 ±2.2 27.3+ 6.1 17.5 + 3.3 24.4+1.8 28.8 ± 5.0
Cx II+III
(nmol/min/mg) 15.9+1.6 13.0 + 3.5 20 .6+ 1.7 9.0+  1.3 9.1 ±2.6 12.3+1.4
Cx IV
(k/min/mg) 1.78 + 0.34
1.03 + 
0.063
1.54 + 
0.141 1.03 + 0.17 0.41+0.11 1.16 + 0.16
CS
(nmol/min/mg) 111.5 + 3.5 120.9+ 6.2 103.5 + 2.2 95.3+17.3
105.8 + 
19.9 100.2 + 5.6
Table 7.1. The effect o f LPS+IFNy exposure upon the mitochondrial complex 
activities o f  primary' cultures o f rat astrocytes.
Rat astrocytes cells were incubated for 24h or 36h in 6 -well culture plates in the 
presence of absence (control) or presence of LPS+IFNy (1 pg/ ml and 100 U/ml 
respectively). The inhibitor of iNOS L-NIL was also included in some experiments. 
Mitochondrial complex activity was determined as described. Data are mean ± SEM 
values of three to four independent culture preparations, expressed against a protein 
baseline. Yellow highlighting represents a statistically significant difference compared to 
control values (p < 0.05).
24 h 36 h
control LPS + IFNy
LPS+IFNy
+L-NIL control
LPS + 
IFNy
LPS+IFNy
+L-NIL
C x i 0.23 + 0.04
0.26 ± 
0.02
0.27 ± 
0.05
0.19 + 
0.04
0.24 ± 
0.03
0.26 ± 
0.05
Cx II+III 0.14 + 0.02
0.09 ± 
0.01
0.11 ± 
0.01
0.11 ± 
0.03
0.08 ± 
0.01
0.11 + 
0.01
Cx IV
(k/nmol)
0.016 + 
0.004
0.009 + 
0.001
0.015 + 
0.002
0.011 ± 
0.001
0.004 ± 
0.001
0.011 ± 
0.001
Table 7.2. The effect o f  LPS+IFNy exposure upon the mitochondrial complex 
activities ofprimary cultures o f rat astrocytes.
Complex activities were determined as described in the table above, and 
expressed as a ratio of citrate synthase activity. Highlighting represents a statistically 
significant difference compared to control values (yellow =p  < 0.05; green =p < 0.001).
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24 h 36 h
control DETA-NO control DETA-NO
C'x I
(nmol/min/mg) 21.9 ± 2.9 21.0 + 2.9 24.3 ± 3.9 28.8 + 3.6
Cx II+III
(nmol/min/mg) 8.6 ± 1.5 7.5 ± 0.6 7.2+1.1 7.3+ 1.3
Cx IV
(k/min/mg) 1.27 ± 0.08 0.55 ± 0.07 0.87 + 0.17 0.50 + 0.09
CS
(nmol/min/mg) 99.5 ± 14.4 100.2 + 5.6 95.9+ 12.9 110.3 + 2.0
Table 7.3. The effect o f NO exposure upon the mitochondrial complex activities o f 
primary cultures o f rat astrocytes.
Rat astrocytes cells were incubated for 24h or 36h in 6 -well culture plates in the presence 
of DETA-NO (500|iM). Degraded DETA-NO was added at the same concentration as a 
control. Mitochondrial complex activity was determined as described. Data are mean ± 
SEM values of three to five independent culture preparations, expressed against a protein 
baseline. Highlighting represents a statistically significant difference compared to control 
values (yellow =p  < 0.05; green =p<  0.001).
24 h 36 h
control DETA-NO control DETA-NO
C x i 0.27 ± 0.09 0.24 ± 0.04 0.27 + 0.06 0.26 + 0.03
Cx II+III 0.09 + 0.01 0.09 + 0.01 0.07 + 0.01 0.06 + 0.01
Cx IV (k/nmol) 0.011+0.001 0.006 + 0.001 0.012 + 0.005 0.005 + 0.001
Table 7.4. The effect o f NO exposure upon the mitochondrial complex activities o f 
primary cultures o f rat astrocytes.
Complex activities were determined as described in the table above, and 
expressed as a ratio of citrate synthase activity. Yellow highlighting represents a 
statistically significant difference compared to control values (p < 0.05).
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Against CS activity, decreases in complex IV activity were also evident: 42% after 24h 
and 62% after 36h (p < 0.05; Table 7.4). None of the other respiratory complex 
activities were significantly altered following exposure to DETA-NO.
7.5.4. The effect o f  LPS+IFNy and DETA-NO on lactate dehydrogenase 
levels from  primary astrocyte cultures
LDH release from those astrocyte cultures treated with LPS/IFNy for 36h was 
not significantly increased compared to untreated controls (control: 3.6 ± 0.6%; LPS + 
IFNy: 6.5 ± 1.9%). DETA-NO treatment for the same time did not significantly alter 
media LDH activity compared to cultures treated with the degraded NO donor (control: 
4.3 ± 1.4%; DETA-NO: 7.8 ± 1.7%).
7.5.5. CoQ status o f  untreated astrocyte and neuron-enriched cultures
The C0 Q9 and CoQ 10 levels in untreated astrocytes are compared to that of 
neuron-enriched cultures under identical conditions as shown in figure 7.4A. Neuron- 
enriched cultures contained similar amounts o f C0 Q9 but significantly more C0 Q 10 than 
astrocytes (astrocyte: C0 Q9 = 174.2 ± 1 0 . 8  pmol/ mg protein; C0 Q 10 = 37.9 ± 1 .6  pmol/ 
mg protein; neuron: C0 Q9 = 183.7 ± 13.6 pmol/ mg protein; C0 Q 10 = 67.9 ± 3.9 pmol/ 
mg protein; Fig 7.4A).
7.5.6. Q status o f  neuron-enriched cultures following exposure to DETA-NO
Following exposure o f neuron-enriched cultures for 24h, DETA-NO 
(500 pM) did not significantly alter C0 Q9 or C0 Q 10 levels in these cultures (control: 
C0 Q9 = 202.7 ±31.7  pmol/ mg protein; C0 Q 10 = 70.6 ± 5.9 pmol/ mg protein; DETA-
A:
Astrocyte C0 Q9
■  Astrocyte C0 Q10
■  Neuronal C0 Q9
■  Neuronal CoQ 10
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Astrocyte Neuron
B:
degraded  DETA-NO DETA-NO
Figure 7.4. CoQ status o f  rat astrocyte and neuron-enriched rat primary cultures and 
the effect o f  DETA-NO.
A: Rat astrocyte and neuron-enriched cultures were incubated for 24h in 6 -well 
culture plates. These are compared to data obtained from identically treated astrocytes. 
Data are mean ± SEM values of between eight and twelve independent culture 
preparations.
(* signifies p < 0.05 following analysis by unpaired /-test)
B: Rat neuron-enriched cultures were similarly incubated for 24h with DETA- 
NO (500 pM); degraded DETA-NO was added as a control. Data are mean ± SEM 
values of between three and six independent culture preparations.
215
NO: C0 Q9 = 209.7 ± 23.7 pmol/ mg protein; C0 Q 10 = 81.5 ± 8 . 8  pmol/ mg protein; Fig 
7.4B).
7.6. Discussion
Following incubation with LPS+IFNy, astrocyte cultures generated significant 
levels o f NO as regulated by iNOS, which did not occur in the presence of the iNOS 
inhibitor L-NIL. However, maintenance o f these conditions for 24h did not 
significantly alter C0 Q9 or C0 Q 10 levels. Determination of ETC enzyme activities 
expressed against a protein baseline did not uncover significantly different activities 
(Table 7.1). However, against CS activity significant decreases were observed in 
complex II+III and complex IV activity. Inclusion o f L-NIL abolished the inhibition; in 
the case o f complex IV, this increase was almost to the level of the untreated controls 
(Table 7.2).
Extension o f the period o f exposure to this endogenously-generated NO resulted 
in significantly decreased C0 Q9 while apparently sparing C0 Q 10 (Fig. 7.2B). However 
under these conditions o f decreased C0 Q9 levels, no decreases were observed in 
complex II+III activity. The possibility exists (given that no more NO generation was 
evident at 36h compared to 24h), that O2 ' generation (and the resultant ONOO*) may be 
responsible for the decreases observed in C0 Q9 .
After 36h, iNOS-mediated decreases in complex IV activity were observed 
against both protein and CS baselines (Tables 7.1 and 7.2). In agreement with previous 
works (Bolafios et al., 1994, 1995; Stewart et al., 2000) complex I in astrocytes appears 
relatively resistant to inhibition by RNS. However, Complex IV was significantly 
inhibited by these conditions.
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Inclusion of DETA-NO in the culture media for 24h resulted in slightly higher 
NOx levels than those obtained with LPS+IFNy. Under these conditions, a decrease 
was observed in C0 Q9 and C0 Q 10 levels concomitantly (Fig 7.3A). While complex IV 
activity was similarly decreased with LPS+IFNy and DETA-NO (Tables 7.3 and 7.4), 
exogenous NO thus generated did not significantly affect any other ETC enzymes. 
Other studies (such as those of Gegg et al., 2003) have demonstrated significant 
inhibition of complex II+III with DETA-NO; it is unclear as to why the data from 
current study did not achieve a significant decrease with the same concentration of NO 
donor. However, it is possible that the lack of serum in the culture medium of the 
current study resulted in slightly lower control values than those previous studies.
The nature of this method o f NO generation resulted in higher levels of NOx at 
36h than at 24h incubation. NO generation from DETA-NO was approximately linear 
up to 36h: after 24h, 128.6 nmol NOx/ mg were present in the media. Compared to a 
basal rate of 26.8 nmolNOx/ mg protein, this would imply that approximately 4.25 nmol 
NOx/ mg were generated per hour. After 36h, 189.2 nmolNOx/ mg protein were 
present in the media. Thus in the 12h interim period, approximately 60 nmol NOx/ mg 
were generated: 5 nmol NOx / mg protein/ h.
iNOS generated NO at a slightly lower rate: approximately 3 nmol/ mg protein/ 
h up to 24h. However, after a further 12h, there was apparently no further generation of 
NO. This gives rise to the possibility of enzymatic recovery of complex II+III activity 
after 36h incubation with LPS+IFNy (Table 7.2), and may explain why complex II+III 
activity did not decrease after 36h as described by Bolafios et al., (1994). Stewart et al. 
(2 0 0 0 ) have previously demonstrated (using cocultured neurons) that recovery of 
complex II+III is possible upon withdrawal of iNOS generating astrocytes.
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Subsequently this data shows that recovery may be possible in astrocytes when iNOS 
activation does not generate NO continuously for prolonged periods of time.
Interestingly, the decreases in C0 Q9 and CoQ 10 after 24h exposure to DETA-NO 
did not occur at the 36h timepoint. Following 36h exposure, greater inhibition of 
complex IV was evident, although cellular levels of C0 Q9 and CoQ 10 were unchanged 
compared to controls (Fig 7.3B and tables 7.3 and 7.4). While the reasons for this 
apparent restoration of C0 Q9 and CoQ 10 levels is not clear, it may be of note that 
endogenous NO (i.e. iNOS-derived) did not alter C0 Q9 or C0 Q 10 status until 36h, 
whereas exogenous (donor-derived) NO caused an initial decrease, but after 36h levels 
were unchanged when compared to control. While the mechanisms involved in this are 
unclear, hypothetically it is possible that NO from the extracellular environment caused 
an initial decrease, followed by an restoration of C0 Q9 and C0 Q 10 status, while NO 
generated from by the cell in question after initial maintenance of C0 Q9 and CoQ 10 
levels eventually elicited a decrease in these molecules.
With regard to untreated neurons, while similar levels of C0 Q9 were observed in 
comparison with primary cultures o f rat astrocytes, a significantly higher concentration 
o f C0 Q 10 was found (Fig 7.4A). This may reflect the neuron’s greater reliance upon 
OXPHOS for ATP generation. While astrocytes can upregulate the glycolytic 
regulatory enzyme enzyme phosphofructo-1-kinase (PFK-1), neurons do not seem to be 
capable of this (Almeida et al., 2004). These authors found that inhibition o f the ETC 
by NO resulted in increased glycolytic flux in astrocytes but not in neurons (Bolafios et 
al., 1994; Almeida et al, 2004). Thus the lower levels of C0 Q 10 in astrocytes may be as 
a result o f these cells’ ability to generate ATP anaerobically. Conversely, neurons may 
contain higher levels of CoQ 10 as it is possible that the higher molecular mass isoform is 
more intimately involved in OXPHOS. This has been proposed by a number o f groups:
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Matsura et a l (1991), using rabbit hepatocytes found C0 Q9 to be primarily an 
extramitochondrial antioxidant, and proposed CoQ 10 to be a mitochondrial antioxidant 
and electron carrier. Lass et a l (1997) found O2 ' generation of sub-mitochondrial 
particles derived from a number of mammalian species correlated with C0 Q9 levels, and 
inversely with C0 Q 10 content. The findings of Battino et a l  (2001) using rat brain 
mitochondria also supported a bioenergetic role for C0 Q 10 and antioxidant role for 
C0 Q9 from mitochondria which may have been older, and thus subjected to greater 
oxidative stress.
The neuronal response to exogenous NO was different to that of the astrocyte: 
following 24h exposure, astrocytic C0 Q9 and C0 Q 10 were both decreased. However 
neurons maintained under the same conditions did not alter their CoQ status. The 
neurobiological significance o f this finding is not yet clear. However in the context of 
antioxidant availability o f astrocytes and neurons, when cultured alone, astrocytes have 
approximately double the amount of neuronal GSH (Bolafios et al, 1995), this work 
shows that C0 Q 10 levels in neurons are almost double that of astrocytes. While NO 
exposure increases astrocytic GSH content (Gegg et a l, 2003), C0 Q9 and CoQ 10 status 
appears to be compromised. Neuronal GSH decreases in response to NO, while 
neuronal C0 Q9 and CoQ 10 is maintained.
The data referring to the astrocytic ETC would suggest that C0 Q9 status may not 
be the most NO-susceptible factor in dictating complex II+III activity; electron transport 
between these complexes was not diminished as measured by the linked enzyme assay.
NO-mediated decreases in C0 Q9 or CoQ 10 did not correlate with decreased 
complex II+III activity; thus in vitro activity of this linked system may be sufficiently 
robust to be maintained despite lower availability of the major CoQ homologue.
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7.7. Conclusion
Two systems were used to generate NO in cultures of rat astrocytes: LPS+IFNy 
induced iNOS expression while DETA-NO liberated similar levels of NO as measured 
by NOx levels in culture media. Following 36h exposure to LPS+IFNy, astrocyte levels 
o f C0 Q9 (but not C0 Q 10) were significantly lower; this effect was abolished by the use 
o f L-NIL Thus activation of iNOS was seen to decrease the CoQ status of astrocytes. 
Following 24h exposure to DETA-NO, both C0 Q9 and C0 Q 10 were decreased. 
However, this decrease appears transient as after 36h both C0 Q9 and C0 Q 10 status had 
returned close to control levels, possibly reflecting an upregulation in response to 
prolonged NO generation.
The decreases observed in CoQ status did not correlate with inhibition of the 
activity of complex II+III o f the ETC. In one case, a significant decrease was observed 
in complex II+III activity; however under these conditions no changes in cellular CoQ 
status were recorded. NO derived from both endogenous and exogenous sources 
appeared to inhibit only complex IV against both protein and CS baselines.
Neuron-enriched cultures were also examined and exposed to DETA-NO. 
Determination o f the CoQ status of these untreated cultures showed substantially greater 
amounts of CoQ 10 in neurons compared to astrocytes. Whether this reflects the reliance 
of neurons upon OXPHOS to maintain ATP or a possible antioxidant defence is 
unclear. Whereas astrocytic C0 Q9 and CoQ 10 status was compromised following 24h 
exposure to DETA-NO, neuronal levels of C0 Q9 and CoQ 10 under these conditions were 
maintained.
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8. THE USE OF SHORT INTERFERING RNA TO 
ALTER UBIQUINONE BIOSYNTHESIS IN 
RAT AND HUMAN CELLS
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8. THE USE OF SHORT INTERFERING RNA (siRNA) TO ALTER 
UBIQUINONE BIOSYNTHESIS IN RAT AND HUMAN CELLS
8.1. Introduction
RNA interference (RNAi) is a relatively recently described technique with the 
potential to downregulate specific gene products. It was first recognised by Fire et al. 
(1998) using C. elegans, that microinjection of these nematodes with double-stranded RNA 
(dsRNA) (but not sense or antisense injections separately) caused potent and specific 
knockdown of gene products. This inhibition was also carried over to the Fi progeny. 
Other organisms have also been used to demonstrate effective gene silencing using ds-RNA 
including plants (Waterhouse et al., 1998), trypanosomes (Ngo et al., 1998), drosophila 
(Kennerdell & Carthew, 2000), fish (Wargelius et al., 1999) and mice (Wianny & 
Zemicka-Goetz, 2000). In addition, subsequent modification of the technique now means 
that mammalian cell culture models are also amenable to RNA-mediated interference; this 
has been shown in a number of cell types including human MCF-7 cells (Brummelkamp et 
al., 2002), human embryonic kidney and HeLa cells (Elbashir et al., 2001), and recently in 
primary cultures such as rat astrocytes (Nicchia et al., 2003).
RNA interference (RNAi) uses dsRNA homologous to the sequence of a specific 
gene to downregulate production of mRNA and thus the final gene product (Fire, et a l 
1998; Elbashir et al. 2001). Fire et al (1998) microinjected ds-RNA of length 299 to 1033 
nucleotides (nt), to down-regulate a number of gene products. However, in mammalian 
cells, it had been noted that the introduction of ds-RNA of size greater than approximately 
30-nt evoked a strong cytotoxic response and induction of interferon synthesis (Hunter et
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al. 1975, Stark et al. 1998). This apparent stumbling block was eliminated by the finding 
by Elbashir et al (2001), using 21-22-nt sequences in mammalian cells, that the cytotoxic 
response could be circumvented with shorter sections of RNA. Although this "short 
interfering RNA" (siRNA) successfully mediated strong and specific gene suppression, the 
effects were relatively short-lived: clearance and/ or degradation of siRNAs meant that 
inhibition of the endogenous mRNA was transient. However, the discovery of a number of 
novel vector systems around the same time has allowed stable transfection of siRNAs into 
mammalian cells (Paul et al., 2002; Brummelkamp et al., 2002; Sui et al., 2002; Lee et al., 
2002; Miyagishi & Taira, 2002). Of these, the pSUPER vector system can show loss-of- 
function phenotypes up to 2 months post-transfection (Brummelkamp et al., 2002). 
pSUPER is a mammalian expression vector able to direct siRNA synthesis in viable cells 
(Fig 8.1). An inserted sequence is specific for the target gene of interest and is preceded by 
the HI-RNA gene promoter and terminated by a following sequence of five thymidines 
(5T). The polymerase III HI-RNA promoter produces an RNA transcript without a 
polyadenosine tail, and with a 2 uridine (2U) 3' overhang (Brummelkamp et al., 2002).
The ds insert is of 64-nt (Fig 8.2A), such that the predicted 49-nt transcript of RNA 
folds back on itself in a hairpin-like loop: a 19nt section (derived from the target transcript) 
is followed by a 9-nt "spacer" which is followed in turn by the antiparallel compliment of 
the same sequence (Fig 8.2B). This "hairpin" structure is then believed to be rapidly 
cleaved by the Dicer enzyme (an RNase III) to form functional siRNAs (Fig 8.2C). This 
latter finding comes from the fact that Dicer-suppressed cells do not undergo hairpin- 
mediated silencing (Paddison et al., 2002).
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Figure 8.1. Schematic diagram of the pSUPER.gfp/neo vector.
Bgl II and Hind III site are marked with asterisks, and are used for the cloning of 
64-nt inserts as described in the text. This diagram was adapted form the manufacturer's 
instructions for the vector, available at
http://www.oligoengine.com/pSUPER_New/pSUPERdocs/Maps/Maps_PDF/pSUPERneo
GFP_Map.pdf
Sacll
Not!
Xbai
BamHi
Smal
Xmal
pSUPER. 
gfp/neo
target
m RNA
64-nt primers 
(forward and 
reverse)
49-nt hairpin 
transcript
A G G C U G U U C tJU G C U G G A G A  
U U l c ( C. V( \AC. \  \ (  (.  \C C l  ( I
\ ( . \U U
association with RISC and 
endogenous mRNA cleavage
Hairpin cleavage by 
DICER
''V 7 functional 
siRNA
ACCCUGl I Cl I GO e c  u ; \UU 
UUCCCGACAAGAACGACCHCl
DOW NREGULATION OF GENE PRODUCT  
Figure 8.2. Schematic diagram of siRNA mechanism with pSUPER.gfp/neo
A) dsDNA primers generate B) ssRNA with UU at one end. DICER (an RNase III) cleaves the hairpin section forming C) 19-nt dsRNA with UU 
overhangs. D) This associates with the RNA-induced silencing complex (RISC). The antisense strand of the siRNA may be important in mRNA target 
selection by RISC. Subsequently, mRNA is cleaved by the putative "SLICER" enzyme, leading to downregulation of the mRNA-encoded product. ^
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While the exact mechanism of action of siRNA has not been completely elucidated, 
it is likely that the siRNAs assemble with a putatively identified RNA-induced silencing 
complex (RISC; Fig. 8.2D). It has been shown that the 2-nt 3' overhangs are important in 
for the incorporation into RISC (Elbashir et al, 2001b). In addition, it has been proposed 
that RISC becomes activated by unwinding the duplex, then uses the antisense strand to 
guide an endonuclease to specifically cleave the complementary target mRNA (Jones et al, 
2004), thus suppressing generation of the final protein product (Tuschl, 2002; Kurrek et al., 
2003). It has been proposed that the actual mRNA cleavage occurs by the "Sheer" enzyme 
(Song et al, 2004).
Both HEK 293 cells (Elbashir et al, 2001) and rat primary astrocytes (Nicchia et 
al, 2003). have been previously used for siRNA studies. In addition, the Bolanos group 
have had success with both HEK 293 cells and primary astrocytes with the pSUPER (and 
following its subsequent modification to pSUPER/neo) vector system (Almeida et a l , 
2004; Cidad et al, 2004).
The ubiquinone biosynthetic pathway (as discussed in section 1.4.2) relies upon a 
number of enzymatic steps to generate functional ubiquinone molecules. The enzyme 
transprenyl transferase (TPTF) catalyses the conversion of famesyl pyrophosphate to 
decaprenyl and nonaprenyl pyrophosphate. These are key precursors for ubiquinone 
synthesis, necessary for the formation of the polyisoprenyl tail which is subsequently 
attachmed to the 6 -membered carbon ring (Olson and Rudney, 1983; Turunen et al, 2002; 
van Hellemond et al, 2003). In addition, Levavasseur et a l (2001) demonstrated that in 
mouse embryos and embryonic stem cells, when CoQ synthesis is knocked out at the level 
of 3-methoxy-6-methyl-5-nonaprenyl-benzoquinone-hydroxylase (elk-1; the penultimate
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biosynthetic enzyme) cells instead accumulate the intermediate demethoxyubiquinone 
(DMQ). This latter study targeted the CLK-1 gene, which encodes a highly conserved 
mitochondrial protein required for CoQ synthesis, possibly a hydrolase converting DMQ 
into 5-hydroxy-ubiquinone (Stenmark et al., 2001). However, although it was noted that 
these cells accumulated DMQ in the same quantities as CoQ and are deficient in CoQ, the 
activities of complex II+III were only modestly lower. Thus, it was concluded that 
although DMQ is not as efficient as CoQ as an electron carrier in the ETC, the 
mitochondria of such cells could still function (Levavasseur et al, 2001). Thus when 
considering an enzyme suitable for siRNA downregulation, TPTF would exclude the 
possibility of "ubiquinone precursors" acting as substitute electron carriers, as was noted by 
Levavasseur et al., (2001).
8.2. Aims
• To attempt transfection of both the HEK293T Human Embryonic Kidney cell line 
(Graham, et al., 1977; DuBridge et al., 1987) and astrocyte primary cultures with 
the pSUPER.gfp/neo vector with a 64-nt insert predicted to inhibit synthesis of 
TPTF.
• To probe any decrease in cellular levels of TPTF mRNA.
• To measure CoQ levels in such cultures directly by HPLC
• To measure the activity of mitochondrial ETC enzymes in these cultures.
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All work except that described in sections 8.3.9 and 8.3.10 was carried out in the
laboratory of Dr. Juan Bolanos, Universidad de Salamanca, Spain
8.3.1. Tissue Culture
Rat primary cortical astrocyte cultures were prepared as described previously in section
2.2.3. In addition, a Human Embroyonic Kidney cell line (HEK293T; DuBridge et al., 
1987) was used in some experiments. This well characterised cell line has been used 
previously for siRNA studies (Elbashir et al., 2001; Williams et al., 2004) and is well 
known to accept transfection using lipophilic cations (Sandor et al, 2002). These cells 
were grown in Dulbecco's Modified Eagle Media (DMEM; 4500mg glucose/1) 
supplemented with 10% (v/v) FBS, 2mM L-Glutamine and 1% (v/v) antibiotic/antimycotic.
Both the rat primary cultures and the human cell line were plated onto large (60cm ) 
Petri dishes, previously coated with poly-D-lysine as described in section 2.2.3. The 
seeding density in the plate was calculated as 1.5x10s cells/cm2 (primary astrocytes) or 
1x10s cells/cm2 (HEK 293T).
8.3.2. Small interfering RNA oligonucleotide design
In order to effect efficient gene silencing, it is necessary to determine first the 
mRNA sequence of the gene-product of interest, and then design a pair of 64 nucleotide (- 
nt) "forward" and "reverse" oligonucleotide "primers" each containing a unique and 
complementary 19-nt sequence which will form double stranded (ds) RNA. The primers 
are derived from a sequence of the target transcript. Currently, the mRNA sequence of the 
biosynthetic enzyme TPTF is known in the human and the mouse. These sequences are
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available on the National Center for Biotechnology Information (NCBI) BLAST search 
engine and databases (http://www.ncbi.nlm.nih.gov/BLAST/), and have been assigned the 
NCBI gene identifier (gi) numbers: gi31980944 and gil 1863164 for the mouse and human 
sequences respectively. The "NCBI Blast 2 sequences" facility is available at 
http://www.ncbi.nlm.nih.gov/blast/bl2 seq/bl2 .html and allows the user to align locally 2  
given sequences (Tatusova, & Madden 1999); in this case mouse and human TPTF. A 
truncated screenshot from the Blast 2 website showing sequence homology of 8 8 % 
between the mouse and human TPTF variants is shown in figure 8.3. The major 
homological sequence of the mouse and human mRNA for the gene product is shown in 
figure 8.4. As conservation of the sequence is high between mouse and human, it is likely 
also to be very similar to the TPTF sequence in the rat.
Selection of target sequences will be most likely to give strong knockdown of the 
gene product if a number of guidelines are followed:
1) The 19nt target sequence should be flanked with AA at the 5' end preferably with 
TT at the 3’.
2) The 19nt sequence should be at least lOObp from either the start or the 
termination of translation.
3) The bases guanine and cytosine (G and C respectively) should account for a 
minimum of 30% to 50% of the targeting sequence. This determines the annealing 
temperature of the 2 primers. Ideally, the annealing temperature of both primers should be 
similar.
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Blast 2 Sequences results
BLAST 2 SEQUENCES RESULTS VERSION BLASTN 2.2.9 [May-01-2004]
Sequence gi Mus musculus trans-prenyltransferase (Tprt), f
1 31980944 mRNA ' Lengt
Sequence gi Homo sapiens trans-prenyltransferase (TPRT),
2 11863164 mRNA Lengtl!
l IIHI
JL
2
1
8 8 % homology
Identities = 1158/1313 (8 8 %), Gaps = 27/1313 (2%)
Figure 8.3. A truncated screenshot o f the NCBI "Blast 2 sequences" local alignment 
tool
This screen shows 8 8 % homology between the mouse (termed sequence "1") 
and human (sequence "2M) transprenyl transferase mRNA. This sequence was used to 
design 19-nt sections of the forward and reverse 64-nt pSUPER primers used for the 
siRNA experiments, and additionally to determine the sequence of primers used later in 
RT-PCR.
*
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4) When using the pSUPER vector system, it is vital that the 19-nt selection does 
not contain four or more adenines (AAAA) or thymines (TTTT) as this will give premature 
termination of the transcript.
As highlighted in orange in figure 8.4, a section of the sequence corresponding to 
bases 601-619 of the mouse and 661-679 of the human sequence was selected as the target 
by Dr. Juan Bolafios using "Oligo 4.0" (National Biosciences, Plymouth, MN) and 
Oligoengine "Workstation" software (available from www.oligoengine.com). The selected 
siRNA sequence was then subjected to a further BLAST search to avoid the targeting of 
other homologous genes.
Within the pair of 64-nt primers, the 19-nt target sequence appears in both the sense 
and antisense orientations, with flanking regions at the 5 - and 3'- ends. A 9-nt "spacer" 
sequence must also be included between the sense and antisense 19-nt specific target 
regions which forms the hairpin loop of the pre-siRNA molecule. When using pSUPER, 
the ends of the primer and the spacer section must have the sequence as follows:
forward primer:
5' 3'
GATCCCC-[sense target sequence]-TTCAAG AG A-[antisense target sequence]-TTTTTGGAAA
reverse primer:
3' 5’
GGG-[antisense target sequence]-AAGTTCTCT-[sense target sequence]-AAAACCTTTTCGA
Having chosen a target sequence, flanking regions and the spacer were added (Fig 
8.5), and the primers synthesised by Isogen Life Science (Maarssen, The Netherlands).
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I I I I I I I II I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I III 
4 87 c c c g a g c a t g c a a t a t t c a t c a t a a c a a c t c c c g a c a t g t g c a a g c c a g c c a g c g c g c c a  54 6 
106 A R A C N  I H H N N S R H V Q A S Q R A
4 87 t a g c c t t a g t t g c a g a a a t g a t c c a c a c t g c t a c t c t g g t t c a t g a t g a c g t t a t t g a t g  54 6 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
547 t a g c c t t a a t t g c a g a a a t g a t c c a c a c t g c t a g t c t g g t t c a c g a t g a c g t t a t t g a c g  606 
126 I A L I A E M I H T A S L V H D D V I D *
547 a t g c a a g t t c t c g a a g a g g a a a a c a t a c a g t t a a t a a a a tc t g g g g tg a g a a a a a g g c t g  606 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I
607 a tg c a a g t tc tc g a a g a g g a a a a c a c a c a g t ta a t a a g a tc t g g g g tg a a a a g a a g g c t g  666 
146 D A S S R R G K H T V N K I W G E K K  A
6Q7t t c t t g c t g g a g a t t t a a t t c t t t c t g c a g c g t c t g t a g c t c t g g c a c g g a t t g g a a a c a  666 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I  I I I I I I I I I I I I I I I I I I I I I I 
667t t c t t g c t g g a g a t t t a a t t c t t t c t g c a g c a t c t a t a g c t c t g g c a c g a a t t g g a a a t a  726 
166V L A G D L I L S A A S I A L A R I G N
667 c a g c t g t t g t a t c t a t g t t a g c c c a a g t t a t t g a a g a t t t g g t g c g t g g t g a a t t t c t t c  726 
II I I I I I I I I I I I I III I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
727 c a a c t g t t a t a t c t a t t t t a a c c c a a g t t a t t g a a g a t t t g g t g c g t g g t g a a t t t c t t c  786 
186 T T V I S  I L T Q V I E D L V R G E F L
727 a g c t a g g g t c a a a a g a a a a tg a g a a t g a a a g g t t t g c c c a c ta c c t tg a g a a g a c c t t c a  786
I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I It  I
787 a g c tc g g g t c a a a a g a a a a tg a g a a t g a a a g a t t t g c a c a c ta c c t tg a g a a g a c a t tc a  84 6 
206 Q L G S K E N E N E R F A H Y L E K T F
787 a g a a g a c a g c c a g c c t g a t a g c c a a c a g t t g t a a a g c a g t c t c t g t c c t g g g t t g c c c t g  84 6 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II II II II I 
84 7 a g a a g a c c g c c a g c c t g a t a g c c a a c a g t t g t a a a g c a g t c t c t g t t c t a g g a t g t c c c g  906 
226 K K T A S L I A N S C K A V S V L G C P
847 a c c c a g t g g t g c a t g a g a ta g c c t a tc a g t a tg g g a a a a a t g t t g g a a t a g c t t t t c a g c  906 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I 
907 a c c c a g t g g t g c a t g a g a tc g c c ta t c a g ta c g g a a a a a a t g ta g g a a t a g c t t t t c a g c  966 
246 D P V V H E I A Y Q Y G K N V G I A F Q
907 t c a t a g a t g a t g t a t t g g a t t t c a c c t c a t g t t c t g a c c a g a t g g g c a a g c c a a c a t c t g  966 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
967 t a a t a g a t g a t g t a t t g g a c t t c a c c t c g t g t t c t g a c c a g a t g g g c a a a c c a a c a t c a g  1026 
266 L I D D V L D F T S C S D Q M G K P T S
967 c a g a c c t g a a g c t a g g c a t a g c c a c t g g c c c t g t c t t g t t t g c t t g c c a g c a g t t c c c a g  102 6 
I II I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I 
1027 c t g a t c t g a a g c t c g g g t t a g c c a c t g g t c c t g t c c t g t t t g c c t g t c a g c a g t t c c c a g  1086 
286 A D L K L G L A T G P V L F A C Q Q F P
1027 a a a tg a a tg c ta tg a ta a tg a g a c g g t tc a g t t tg c c a g g a g a tg tg g a c a g a g c a c g a c  1086 
I I I I I I I I I I I I I I I I III I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
1087 a a a tg a a tg c ta tg a t c a tg c g a c g g t t c a g t t tg c c t g g a g a tg t a g a c a g a g c t c g a c  114 6 
306 E M N A M I M R R F S L P G D V D R A R
1087 a g t a t g t a t t a c a g a g tg a t g g c g tg c a g c a a a c a a c c t a c c t c g c c c a g c a g ta c t g c c  114 6 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
1147 a g t a t g t a c ta c a g a g t g a tg g t g tg c a a c a a a c a a c c t a c c t c g c c c a g c a g ta c t g c c  1206 
326 Q Y V L Q S D G V Q Q T T Y L A Q Q Y C
1147 a c a a a g c tg tg a g a g a g a tc a g g a a g c t ta g a c c a tc ta c a g a a a g g g a c g c c c tc a t tc  1206 
I I I I I I I I I I I II I I I I II III I I I I I I I I I I I I I I II I I I I I I I I I I 
1207 a tg a a g c a a ta a g a g a g a tc a g ta a a c t t c g a c c a tc c c c a g a a a g a g a tg c c c tc a t tc  1266 
4 6 H E A I R E I S K L R P S P E R D A L I
1207 a g c t t t c a g a a a g t g t g c t c a c c a g a g a t a a a t g a c a a t t c c t c c t c t t c t t t c t g g c a g  1266 
I I I I I I I I I II I I I I  I II I I II I I I II II I I I I I I II I II I I I I I I I II I II I 
1267 a g c t t t c a g a a a t t g t a c t c a c a a g a g a t a a a t g a c a a c t c t t t c t g t t c t t t c t g g c a g  1326 
366 Q L S E I V L T R D K  AAA
1267 c t a t t t t a c c a g a c t g t g c c t a a t g a - t t t t g t g a a a c a c ------ t a t t t g c t t c a t g t g c  1321
I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I II II I I I I I I I I I I I I I I I
1327 c t a t c t t a c c a g a c t g t g c c t a a a g a a t t t t g t g g a a t a c a c t t t g t t t g c t t c a t g t g c  1386
1322 a g a a a a c c a a a a a t c a t t t t a a g a a a t a a t t t c a a c c t t a t t g a t g g g c a a t t t ----------  1375
III I I I I I 1 I I I I I I I I I I I I I III I I I I I I I I I I I I I I I I I I I I I I 
1387 a g a t a a c c a a a a a t c a t t t t a a a a g a t a  t c a a a c t t a t t g a t g g g c a a t t t a t t t t t  14 4 3
1376 — t t a t t g g c a a a g - t t t t t c g g a a a a c t t t t t a a a t g t a a t t  aaaccag------------  1422
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
14 4 4 t t t t a t t g c a a a a g g t t t t t c a g a a a a c t t t t t a a a t g t a a t t a a t a a a c c a c c t g a a t c  1503
1423 t g t c a t t a t a g t c c t a t a a a t t c t a a t c g a g g t a t c c t g a t g g t t a t a t g t g g t a t t g t t  14 82 
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I 
1504 t g t c a t t c t a g t c c t a t a a a t t a t a a t c a a g g t a t c t t g a t g g t t a t a t g t g g t a t t g t t  1563
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1483 t a c a c t g t t a a t g c c c a c a t g t a a a g c c a t t a c a c a a a t a a a t a a t c a a c g t t  1535 
I I I  I I I I I I I I I I I I I I I I I I I I I I I  I I I I  I I  I I I  I I I I I  I I I I I  I I I  
1564 t a c a c t g t t a a t a t c c a c a t g t a a g g c c a t t a c a c a a a t a a a t a a c c a a t g t t  1616
Figure 8.4. The major homological sequence between mouse and human 
transprenyl transferase mRNA
The mouse sequence is shown in blue, the human sequence in green, 
and the amino acid sequence in black. The 19-nt sequence used to design the 
pSUPER primers is shown in orange between 601-619 (mouse) and 661-679 
(human)
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Forward primer sequence:
(sense orientation) (antisense orientation)
5-GATCCCCAGGCTGTTCTTGCTGGAGATTCAAGAGATCTCCAGCAAGAAC 
AGCCTTTTTTGGAAA -3'
Reverse primer sequence:
(sense orientation) (antisense orientation)
5-AGCTTTTCCAAAAAAGGCTGTTCTTGCTGGAGATCTCTTGAATCTCCAGC 
AAGAACAGCCTGGG -3'
Annealed and phosphorylated oligonucleotide primers ready for insertion into pSUPER
End of
► forward primer ^  transcription
GATCCCCAGGCTGTTCTTGCTGGAGATTCAAGAGATCTCCAGCAAGAACAGCCTTTTTTGGAAA
GGGTC C GA( AAGAACGA( (  TCTAAGTTCTCTAGAGGTCGTTCTTGTCGG AAAAAACCTTTTCGA
I
1 Start of <4 reverse primertranscription
Figure 8.5. The forward and reverse sequence o f  the 64-nt primers inserted into the 
pSUPER.gfp/neo vector system.
The primers were annealed and phosphorylated prior to insertion, to form 
dsDNA as shown.
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8.3.3. Ligation o f oligonucleotides into pSuper.gfp/neo, and transformation in 
bacteria 
8.3.3.1 .Annealing o f  primers
Unless otherwise stated, all water used is nucleotide and nuclease free. This was 
accomplished by the addition of the histidine-specific alkylating agent diethyl 
pyrocarbonate (DEPC; 0.1%, v/v) followed by autoclaving. The two 64-nt primers were 
supplied separately in a lyophilised and dephosphorylated state to ensure the single 
stranded DNA was linear. Before insertion of the primer into pSUPER.gfp/neo, the 64-nt 
primers were first annealed to form double-stranded (ds)DNA and then phosphorylated to 
aid entry to the dephosphorylated vector.
1 pg of each primer was added to 48pl of annealing buffer (lOx; lOOmM NaCl, 50 
mM HEPES; pH 7.4). To anneal the 2 single strands, it was necessary to rapidly bring the 
mixture up to 100°C for 4 minutes, and then reduce it in a controlled, step-wise manner as 
follows:
70°C for 10 minutes
50°C for 10 minutes
37°C for 10 minutes
20°C for 5 minutes, then cool in ice, and the dsDNA can be stored at -20°C.
8.3.3.2. Phosphorylation o f  primers
Phosphorylation of the dsDNA used the polynucleotide kinase (PNK; Promega, 
Charbonnieres, France):
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2pl of the ds primers were added to lpl T4 PNK buffer (lOx; 0.5M Tris-HCl; 
lOOmM MgCh, lOOmM 2-mercaptoethanol, pH 7.4; Promega, Charbonnieres, France), 1 pi 
PNK (10 u/ml; Promega, Charbonnieres, France), ATP (ImM) is necessary as a cofactor. 
The total volume was made up to 1 Opl with water.
This mixture was incubated at 37°C for 30mins, to allow the reaction to proceed. It was 
then heated to 70°C for 10 mins to inactivate PNK.
8.3.3.3. Linearisation o f  pSUPER.gfp/neo, and purification in agarose gel
Linearisation of the pSUPER.gfp/neo vector was achieved using with Hind III and 
Bgl II restriction enzymes and CIP (Calf Interstinal Alkaline Phosphatase; Promega, 
Charbonnieres, France). 2.2 pg of pSUPER.gfp/neo was added to lpl Hind III (Promega, 
Charbonnieres, France), 3pl buffer B (lOx; lOOmM Tris-HCl, lOOmM MgCb, 1 mg/ ml 
BSA, pH 7.5; Promega, Charbonnieres, France) and 23pl of water. After incubation for lh 
at 37°C, lpl Bgl II was added, and the reaction allowed to proceed for a further 2h at 37°C. 
The restriction enzymes were then inactivated by incubation at 70°C for 20 min. 
Dephosphorylation of the vector used CIP to remove the phosphate groups from both 5' 
ends of the DNA, hence preventing recircularisation.
To this end, 30 pi of digestion product was added to 4 pi alkaline phosphatase 
reaction buffer (lOx; 500 mM Tris-HCl; 10 mM MgCb, 1 mM ZnCb, 10 mM spermidine; 
Promega, Charbonnieres, France), 4pl CIP (O.lu/ pi) and 2pl water. The reaction was 
incubated at 37°C for 15mins, and CIP inactivated by incubation at 70°C for lOmins.
The plasmid was then run in a 1% agarose gel to check the size of the fragment size 
(5429bp), remove the fragment between Bgl II and Hind III, and to separate any undigested
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circular plasmid. The band was cut from the gel, and purified using the Matrix Gel 
Extraction System (Marligen, Ijamsville, USA) according to the manufacturer's 
instructions. 350 mg of gel was dissolved in 30 pi Gel Solubilisation Buffer (a proprietary 
solution containing concentrated sodium perchlorate, sodium acetate and solubiliser). 35 pi 
silica resin was added, and the mixture incubated at 50°C for 20 min and vortexed regularly 
to ensure gel dissolution. DNA bound to the Silica resin was isolated by centrifugation at 
12,000 x g for 30s. Supernatant was discarded, and the resin pellet washed with 100 pi of 
Gel Solubilisation Buffer before the mixture was centrifuged at 12,000 x g and the 
supernatant discarded. The resin pellet was then twice resuspended in Wash Buffer (a 
proprietary solution containing NaCl, EDTA and Tris-HCl in ethanol), centrifuged and the 
supernatant discarded. The resin was then dried and DNA eluted from the resin by 
resuspension in 20 pi TE buffer (10 mM Tris-HCl, 0.1 mM EDTA, pH 8.0). This was 
incubated at 50°C for 5 min and centrifuged at 12,000 x g for 30s. The pSUPER.gfp/neo 
DNA-containing supernatant was transferred to a fresh tube and stored at -20°C.
8.3.3.4. Ligation o f  the primers into pSUPER.gfp/neo, transformation in 
bacteria and plasmid extraction
Ligation of the phosphorylated dsDNA into the pSUPER.gfp/neo vector required 
DNA ligase (MBI Fermentas GmBH, St. Leon-Rot, Germany). 2pl of the annealed 
phosphorylated primers were added to lpl T4 DNA ligase (1 Weiss unit/ pi; 200 cohesive 
end ligation units/ pi; MBI Fermentas, St Leon-Rot, Germany) and 1 pi of ligase buffer 
(lOx; 660 mM Tris, 50 mM magnesium chloride, 10 mM dithiothreitol, 10 mM ATP; pH
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7.5; MBI Fermentas, St Leon-Rot, Germany), lpl of pSUPER.gfp/neo (digested with Bgl 
II and Hind III, and CIP-treated) was added, and the mixture incubated overnight at 16°C.
The pSUPER.gfp/neo both with and without the TPTF primer insert was then 
transformed in E.Coli DH5a bacteria. 10 pi of each plasmid (pSUPER.gfp/neo and 
pSUPER.gfp/neo+TPTF; between 1 and 10 ng/ pi) were incubated separately with 100 pi 
competent bacteria. This was done on ice, and mixed gently for 30mins, whereupon the 
tubes were transferred to a 42°C waterbath for exactly 45s. They were then returned to ice 
for at least 2 mins.
100 pi SOB media (20g/L Bactotryptone, 5g/L yeast extract, lOmM NaCl, 2.5 mM KC1, 
lOmM MgCh, lOmM MgS0 4  20mM glucose) was added to each tube, and the mixture 
incubated while shaking for lh at 37°C. Between 50 and 100 pi was added to each LB agar 
plate and colonies grown overnight in LB agar plates (lOg/L bactotryptone, 5g/L yeast 
extract, 250 mM NaCl; 15g/L agar; pH 7.5). Ampicillin was added at 0.05g/L; resistance 
was conferred only to the transfected bacteria. The transformation of the bacteria was 
confirmed by re-seeding the colonies with 2XYT media overnight.
The GenElute Plasmid Miniprep kit (Sigma-Aldrich Quimica SA, Madrid, Spain) was used 
to isolate the plasmid DNA from the bacterial cultures. Bacterial cells were harvested via 
centrifugation (5000 x g), and then alkaline lysed . When loaded onto the supplied column, 
the DNA becomes bound to silica. The column was washed to remove contaminants and 
the purified DNA was eluted in water. Digestion with Eco RI and Hind III was used to 
confirm insertion of the primers into the vector (the Bgl II site of pSUPER.gfp/neo is lost 
following insertion of the 64-nt insert) prior to electrophoresis in an agarose gel (1%). This
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effectively allowed visualisation of the insert: following digestion the empty vector has a 
size of around 240 bp. With the insert, this is increased to approximately 300 bp.
Plasmid extraction was effected using the Promega "Wizard Plus Midipreps" Kit 
(Promega, Charbonnieres, France) in accordance with the manufacturer's instructions. In 
summary, the following steps were followed. Initially, the vector-contraining bacteria were 
centrifuged to form a pellet. Then, following resuspension in 3ml "Cell Resuspension 
Solution", 3ml "Cell Lysis Solution" is used in alkaline lysis of the cells. A further 3ml of 
"Neutralisation Solution" was added, the mixture centrifuged and the supernatant decanted. 
In order to purify the plasmid DNA, it was necessary to mix 10ml of the proprietary DNA 
Purification Resin to the lysate and transfer to the Midicolumn. A vacuum was applied to 
pull the mixture into the column until all had passed through. The DNA was left on the 
resin, which subsequently needed washing twice with 15ml of column wash solution and 
the column dried by pulling air through for 30s. The Midicolumn was then spun at 10,000 
x g for 2 minutes to remove any residual Column Wash Solution. Following transfer of the 
column to new tube, 300pl of nuclease-free water preheated to 65°C was added to the 
column. DNA was eluted from the column by a spin at 10,000 x g for 20s. In order to 
remove fine particulate matter from the eluate, the sample is spun a final time at 1 0 , 0 0 0  x g 
to pellet the fines. The DNA-containing supernatant was carefully removed and transferred 
to a clean microcentrifuge tube. The extracted pSUPER vector DNA both with the inserted 
64-mer (pSUPER.gfp/neo+TPTF) and the control without (pSUPER.glp/neo) were stored 
in water at -20°C.
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8.3.4. Transfection o f cells with pSuper.gfp/neo and transprenyl transferase 
knockdown siRNA
Cells were transfected using Lipofectamine 2000 (Invitrogen S.A., Barcelona, 
Spain). For transfection of a single 60cm2 plate, 30pg of pSUPER.gfp/neo vector was 
dissolved in 1.5ml Opti-MEM transfection medium without antibiotic (Invitrogen S.A., 
Barcelona, Spain). 30pl of Lipofectamine 2000 was dissolved, again in 1.5ml Opti-MEM 
in another tube. After 5 minutes at room temperature, the 2 tubes were combined, gently 
mixed and incubated at room temperature for 20 mins to allow the siRNA:Lipofectamine 
2000 complexes to form. The 3ml total was then added to the plate. Cells were transfected 
with both control vector (pSUPER.gfp/neo) and the proposed TPTF knockdown 
(pSUPER.gfp/neo+TPTF) in parallel experiments.
8.3.5. Imaging o f  cell cultures fo r  transfection efficiency
Expression of the vector (and thus the siRNA hairpin) was confirmed by checking 
the presence of the GFP tag when viewing the cultures using fluorescence microscopy. 
Blue light (Amax=488) was directed at the cultures from a Leica DM IRB microscope 
causing GFP emission at Amax=507 and the images captured using a Leica DC 100 digital 
camera.
8.3.6. RNA extraction and isolation from cultures followed by 
spectrophotometric determination and agarose gel electrophoresis
Following transfection with control pSUPER.gfp/neo and pSUPER.gfp/neo+TPTF, 
RNA was extracted from the cells in order to perform RT-PCR to visualise the amount of
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TPTF mRNA in cultures as a result of pSUPER.gfp/neo+TPTF-mediated siRNA 
production. In order to extract total RNA, the GenElute Mammalian Total RNA Kit 
(Sigma-Aldrich Quimica SA, Madrid, Spain) was used, and the manufacturer’s protocol 
followed. Briefly, all RNases were inactivated with 2-mercaptoethanol, cells are lysed and 
homogenised. Following addition of lysate to the filtration column, RNA was bound to the 
silica membrane, and following washing was eluted for RT-PCR.
Culture medium was removed and the cells were rapidly and thoroughly disrupted 
with 500 pi Lysis Solution (a proprietary formulation containing guanidine thiocyanate) 
supplemented with 2-mercaptoethanol (1% v/v), to inactivate RNase enzymes. A cell 
scraper was used to thoroughly ensure disruption. Lysed cells were transferred to the 
GenElute Filtration Column, spun at 16,000 x g to remove cellular debris and shear DNA. 
The column was discarded, and 500 pi ethanol (70% (v/v)) added to the filtrate before 
being thoroughly vortexed and loaded into the GenElute Binding Column. This was spun 
in a microcentrifuge at 16,000 x g for 15s. The flow-through was discarded, and 500 pi 
Wash Solution 1 (proprietary) added to the column before another 16,000 x g 15s spin. 500 
pi of Wash Solution 2 (a proprietary solution containing ethanol) was loaded onto the 
column and centrifuged at 16,000 x g for 15s. Filtrate was again discarded, before a second 
500 pi addition of Wash Solution 2 was added and the spin extended to 2 mins to dry the 
column. In order to elute the isolated RNA, the GenElute Binding Column insert was 
transferred to a fresh tube, 50 pi of the proprietary Elution Solution added, and spun at 
16,000 x g for 1 minute. Purified RNA was contained in the eluate. Purity and 
concentration of RNA was determined by spectrophotometric analysis. A 1% (w/v) 
agarose denaturing gel stained with ethidium bromide (EtBr) was prepared and
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electrophoresis conducted to ensure the amount of DNA in the sample was low and the 
RNA harvested was not degraded (Srivastava and Schlessinger, 1991). This is shown in 
Figure 8 .6 . Storage was at -70°C.
8.3.7. Reverse Transcription and Polymerase Chain Reaction
In order to visualise the amount of TPTF mRNA in these cells, it was necessary to 
employ Reverse Transcriptase (RT) to convert the RNA to DNA, and then amplify this 
with the Polymerase Chain Reaction (PCR; Mullis et al, 1986). The Reverse Transcription 
System Kit (Promega, Charbonnieres, France) contains avian myeloblastis virus (AMV) 
RT which was used to perform the RT reaction. DNA Polymerase and PCR buffers were 
supplied by Biotools.
8.3.7.1.Reverse Transcription
1 pg of total RNA was added to 1 pg of the 3' primer, and the final volume made up 
to lOpl with nuclease-free water. This was allowed to incubate at 70°C for 10 min to allow 
the primer to bind to the straight, denatured RNA. Rapid cooling in ice ensured the 
structure of the RNA remained straight. Then 9 pi of the cooled RNA+3' primer was added 
to 4pl of MgCl2 (25mM), 2 pi of RT buffer (lOx; 100 mM Tris-HCl, 500 mM KC1, 1% 
(v/v) Triton X-100; pH 9.0), 2 pi of deoxynucleotide mix (dNTP mix) (lOmM), 25 units 
RNasin Ribonuclease Inhibitor, 15 units AMV RT. The volume was made up to 20 pi with 
the nuclease-free water supplied, and the reaction incubated at 42°C for 60 min, 95°C for 5 
minutes, followed by rapid cooling on ice. The last two temperature steps inactivate AMV 
RT and prevent it binding cDNA.
24h 24h
control siRNA
48h
siRNA
28S subunit 
18S subunit
Figure 8.6 Total RNA as extracted from  rat astrocytes transfected with pSUPER. 
gfp/neo and pSUPER.gfp/neo +TPTF.
Following transfection, RNA was extracted as described in the text. 
Electrophoresis was conducted in a EtBr-stained 1% agarose gel. The 28S and the 18S 
ribosomal subunits are evident and 28S:18S intensity is approximately = 2 confirming 
isolation of intact RNA.
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8.3.7.2. The Polymerase Chain Reaction
PCR primers were designed by Dr. Juan Bolanos, Universidad de Salamanca, 
corresponding to the mouse TPTF sequence nt's 705 to 725 and the antiparallel of nt’s 825 
to 801 for the forward (5') and reverse (3') respectively (shown in upper case in Fig. 8.7).
Forward: 5'-TTG GTG CGT GGT GAA TTT CTT-3’
Reverse: 5'-CTG CTT TAC AAC TGT TGG CTA TCA G-3’
These primers would predict a PCR product of size 121 -nt as shown in black in Fig 
8.7 and were synthesised by Isogen Bioscience (Maarsen, Netherlands)
9pl of RT product was added to 5 pi DNA Polymerase buffer (lOx; 750 mMTris 
HC1, 20mM MgCh, 500mM KC1, 200mM (N H ^SO ^ pH 9; Biotools), 1 pi 3' primer (50 
pM), 1 pi 5' primer (50pM), 1 pi of dNTP mix (lOmM, Promega), 0.5 pi DNA Polymerase 
(1 unit/ pi; Biotools). Thermocycling was as follows:
94°C for 5 mins initial denaturing cycle 
—► 94°C for 15 secs denaturing 
56°C for 30 secs annealing 
—  72°C for 60 secs synthesis 
72°C for 5 mins final extension 
The PCR product was stored at 4°C.
A number of different cycles were used in an attempt to visualise knockdown of the 
PCR product. At first, 35 cycles was used as this is likely to be saturating (i.e. no more 
product generated with an increasing number of cycles), but this was later reduced in order
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Figure 8.7 Selection ofprimers fo r  the amplification o f  TPTF cDNA by RT-PCR
Shown in black is the section of the cDNA sequence of TPTF predicted to be 
amplified by the forward (mouse; blue; 705-725; human; green; 765-785) and reverse 
(mouse; blue; 801-825; human; green; 861-885) primers as shown in black in upper 
case.
The sequence used to design the primers for pSUPER is shown in orange.
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to reduce the amount to product formed. This form of semi-quantitative RT was used in 
conjunction with Northern blotting for the TPTF mRNA directly.
8.3.8. Northern Blotting
Northern blotting allows visualisation of RNA for a protein of interest. RNA was 
first separated by electrophoresis, then transferred to a nitrocellulose membrane. After 
transfer, the membrane was hybridised with a complementary radiolabeled 32P probe 
specific for the RNA of interest. The radiolabeled probe bound to the RNA on the 
membrane could thus be visualised following exposure of the photographic film whereupon 
relative size and abundance were observed.
8.3.8.1. Radiolabeling the probe
The RT-PCR product of 2pg RNA was electrophoresed in an agarose gel. When 
pouring the gel, 5 wells were taped together to make a single large well. This dsDNA was 
used to make the radiolabeled probe, the gel is shown in Fig 8 .8 . The band was excised, 
and the DNA extracted as previously with the Marligen Gel Extraction kit (Marligen, 
Ijamsville, USA) as in section 8.3.3.3. 20ng of 5' DNA was denatured by boiling for 10 
mins, and rapidly cooled to uncoil the DNA. To the sides of the tube were added lpl of 
each dATP, dGTP, and dTTP (all lOmM), 2 pi of "Hexanucleotide Reaction Mix" (lOx, a 
mixture of random hexanucleotides in reaction buffer, Roche Farma, Madrid, Spain). In a 
designated radioactive area, 2 pi 32P-dCTP (3000 Ci/mmol) and 1 pi Klenow enzyme 
(2units/ pi, Roche Farma, Madrid, Spain) were added. The latter is responsible for the 
synthesis of the probe as it catalyses the addition of mononucleotides (including
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Figure 8.8 Large scale R T-PCR and gel electrophoresis to make a probe fo r  
Northern blotting
5 wells of the comb were taped together before pouring the gel and a large 
amount of DNA purified by excising the band, and the radioactive probe synthesised 
using 32P labelled cytosine.
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radiolabeled dCPT) complementary the PCR product (i.e. TPTF). This was then mixed and 
incubated at 37°C for 30 mins. The Klenow enzyme was inactivated by the addition of 
60pl TE buffer, giving a final volume of 80 pi.
Purification of the probe was with a sepharose column, made with an eppendorf 
tube with a pinhole in the bottom, packed with glass wool. Sepharose (previously mixed) 
was added to the glass wool in the tube, and spun briefly at 5000 x g. 1 ml of TE buffer 
was added and the column spun again at 5000 x g. A third spin eliminated all TE from the 
column. The column was placed inside a fresh eppendorf tube and 80pl of impure probe 
was added to the column and centrifuged at 5000 x g for 1 min. When checking with a 
Geiger counter, the radioactive count of the eluted pure probe was approximately equal to 
that remaining in the column. The probe was stored at -20°C.
8.3.8.2.RNA electrophoresis
A 2% agarose gel was prepared using nuclease-free water with 2.2% formaldehyde 
and MOPS: in 100 ml, 6 ml folmaldehyde (37%) and 10 ml 3-(N-
Morpholino)propanesulfonic acid (MOPS lOx: 20.9g MOPS, 8,3ml 3M sodium acetate and 
10ml 0.5M EDTA made up to 500 ml; pH 7, autoclaved; Sigma-Aldrich Quimica SA, 
Madrid, Spain). The running buffer in this case was MOPS lx made up with nuclease-free 
water.
8,3.8,3.Sample preparation
15pg RNA was added to autoclaved eppendorf tubes and freeze-dried for 
approximately 30 mins. 40pl of the following "loading mixture" was added to each sample:
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80 |il MOPS lOx, 400 pi formamide, 120pl formaldehyde, 120pl water, 80pl RNA loading 
buffer (lOx; comprising glycerol (50%, v/v), bromphenol blue (0.4%, v/v) xylene cyanol 
(0.4%, v/v). The reaction mixture was incubated at 65°C for 10 mins, and cooled rapidly 
on ice. After a final spin, 35pl was loaded onto the gel. Electrophoresis was conducted at 
approximately 40v for 6 h.
8.3.8.4. Transfer o f RNA to the membrane
Following electrophoresis, the RNA was transferred to the "GeneScreen Plus" 
membrane (NEN Life Sciences, New England, USA) by capillary action, assisted by the 
fact that the membrane was placed into firm contact with the gel. A bath of SSC (lOx; 
1.5M NaCl, 0.15M sodium citrate) was used as the blotting solution, and the transfer 
allowed to run overnight. The set up is shown in the schematic diagram in figure 8.9. 
Upon removal of the newly transferred membrane, the RNA was immediately cross-linked 
using a Hoefer UVC500 Crosslinker set to 254 nm. The membrane was dried at room 
temperature overnight.
8.3.8.5.Hybridisation o f the membrane and exposure o f the film
The membrane was wetted first with water then 2x SSC for 10 min. It was then 
carefully placed in a hybridisation tube, with the RNA-coated side innermost. 10ml 
prehybridisation solution (1% SDS, 1M NaCl, 10% dextran sulphate) was added and the 
tube placed in a hybridisation oven set to 65°C and 4 rpm. After lOminutes, the 
radiolabeled probe was added, and the hybridisation allowed to proceed overnight.
A number of washes were then conducted in the hybridisation oven to remove any 
non-bound probe which would otherwise cloud the photographic plate:
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weight tissue
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"GeneScreen Plus” 
hybridisation membrane
Filter paper 
"wick"
lx SSC 
solution
Figure 8.9. A schematic diagram o f the apparatus used to transfer RNA from  the gel 
to the hybridisation membrane
Details of the method used to generate the Northern Blot are given in the text. 
Capillary action draws NaCl/sodium citrate solution (SSC) from the reservoir. Image 
reproduced and adapted from the Dept, of Biochemistry, University of Arizona website 
(http://www.biochem.arizona.edu/ classes/bioc471/pages/Lecture2/AMGl. 14-North, gif)
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One wash with 2x SSC with 1% SDS at 65°C for 5 min
2 washes with 2x SSC with 1% SDS at 65°C for 30 min each
One wash with O.lx SSC at room temperature. The background count of the 
membrane was at this point low. The membrane was wrapped in cling film to prevent it 
drying out. In a darkroom, it was placed in an exposure box with a sheet of film and 
allowed to expose the film for 48h at -80°C.
8.3.9. Measurement o f ubiquinone levels in transfected cultures
Cellular lipids were extracted from primary astrocyte and HEK 293T cultures which 
had been transfected with the pSUPER.gfp/neo vector as described in section 3.2.5. CoQ 
levels in were measured by reverse-phase UV-HPLC as described in section 3.2.3.
8.3.10. Determination o f ETC activity in transfected cultures
Following transfection, with both pSUPER.gfp/neo and pSUPER.gfp/neo+TPTF, 
respiratory chain enzyme activities were determined in both cell types as described in 
section 2.3.
8.4.Experimental Protocols
Rat primary astrocyte cultures and immortalised human embryonic kidney 
(HEK293T) cultures were plated as described in section 8.3.1. Both cell types were 
transfected with the pSUPER.gfp/neo vector and following media replacement, allowed 
to remain in the plate for up to 48h (HEK 293T) or 72h (astrocytes) post-transfection. 
In some cases the vector was "empty” (i.e. control experiments), while other cultures
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received the vector with an additional ds 64-nt insert. Intracellular generation of siRNA 
molecules could potentially interfere with ubiquinone biosynthesis. This was examined 
in a number of ways:
Visualising any downregulation of TPTF mRNA as a product of RT-PCR 
Northern Blotting for TPTF mRNA 
Measurement of CoQ directly in transfected cultures 
Determination of the activity of complex II+III in such cultures
8,5. Results
8.5.1. Visualising Green Fluorescent Protein as a marker o f cellular transfection
Following transfection, with pSUPER.gfp/neo and pSUPER.gfp/neo+TPTF, the 
same visual field of the cultures were photographed in both phase contrast, and under violet 
(visible) light. Figure 8.10A shows a control culture of HEK 293T 48h post-transfection. 
Figure 8.1 OB shows acceptable transfection of the same cell line and time point with the 
siRNA insert. Having obtained favourable results with the cell line model, Figure 8.11 
shows rat primary astrocytes 72h after transfection with pSUPER.gfp/neo+TPTF.
8.5.2. Confirmation o f  RT-PCR product as TPTF
Following transfection, RNA was extracted from primary astrocyte cultures as 
described in section 8.3.6 after 24h and 48h. The reverse transcriptase reaction was 
performed in both the presence and absence of the reverse transcriptase enzyme to ensure 
any subsequent amplification during PCR was not due to DNA contamination, and the 
product was RT- dependant. In this case, 35 PCR cycles used was likely to be saturating as
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Figure 8.10. HEK 293 T cells photographed 48h after transfection with 
pS UPER.gfp/neo
Cultures were transfected with the empty pSUPER.gfp/neo vector, and the 
culture maintained for 48h. The same visual field was photographed A) in phase 
contrast with a light microscope and B) under UV exposure to show GFP-expressing 
cells.
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Figure 8.11. Rat primary astrocytes photographed 72h after transfection with 
pSUPER.gfp/neo +TPTF
Cultures were transfected with pSUPER.gfp/neo +TPTF, and the culture 
maintained for 72h. The same visual field was photographed A) in phase contrast with 
a light microscope and B) under UV exposure to show GFP-expressing cells.
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is shown in figure 8.12. Extension of the time post-transfection to 72h, as well as a 
reduction in the number of PCR cycles to 28 (as shown in figure 8.13) appeared to show 
little difference when compared to a 48h incubation with 35 PCR cycles.
Subsequently, in order to visualise any TPTF knockdown, the semi-quantitative 
PCR performed is shown in Figure 8.14. Rat primary astrocytes were transfected with both 
the empty control vector and the vector + TPT-specific insert. 72h later, RNA was 
harvested, and a number of separate PCRs with differing numbers of cycles from (5 to 25 
cycles) performed. Only at 25 cycles is the TPTF band just visible, and it is not clear if 
there is substantially less TPTF DNA in the siRNA-treated cells.
8.5.3. Northern Blotting fo r  TPTF mRNA
mRNA for TPTF was visualised by a Northern blot. Astrocytes were treated for up
to 72h, and HEK 293T cells for up to 48h. Following hybridisation of the membrane with
‘>‘7
the ^P-labelled probe and exposure of the photographic film to the radioactive 
nitrocellulose membrane, the results were as shown in figure 8.15. Again in both astrocytes 
and HEK 293T cultures, there would appear to be little effect upon TPTF mRNA levels.
8.5.4. Measurement o f CoQ in siRNA transfected cultures
CoQ levels were measured as in previous chapters, by lipid extraction from the harvested 
culture (section 3.2.5) followed by reverse-phase HPLC coupled to a UV detector (section 
3.2.3).
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Figure 8.12. Electrophoresis o f  the astrocyte RT-PCR product.
The cDNA product of the RT-PCR performed as described in the text was 
shown to be RT dependant and to give a band of the predicted size at 121 bp. RNA was 
extracted from astrocytes following maintenance for 24h after transfection with the 
control vector and 24h and 48h after transfection with pSUPER.gfp/neo+TPTF. 
RT-PCR was performed using 35 cycles to ensure maximum possible amplification.
50 bp 24h 72h
ladder Ctrl tptf Ctrl tptf
Figure 8.13. Astrocyte RT-PCR product following 28 PCR cycles
Astrocytes were transfected with both control and TPTF siRNA vectors. RNA 
was extracted after being maintained in culture for 24h and 72h, and RT-PCR 
performed. Following 28 PCR cycles, the cDNA was visualised in a EtBr agarose gel.
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Figure 8.14. Semiquantitative RT-PCR using an increasing number o f  cycles to aid 
visualisation o f  possible TPTF knockdown
Astrocytes were transfected with both control (upper image) and TPTF siRNA 
(lower image) vectors. RNA was extracted after being maintained in culture for 72h, 
and RT-PCR performed. The number of PCR cycles employed is as indicated and 
cDNA was visualised in a EtBr agarose gel. Only after 25 cycles is there sufficient 
product to be visualised.
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Figure 8.15. Northern Blot fo r  TPTF mRNA in primary astrocyte and HEK 293T 
cultures.
Following the procedure as detailed in the text, after being maintained post­
transfection with either the control or the siRNA vector for a maximum of 72h 
(astrocytes) or 48h (HEK 293T), RNA was isolated from the cultures. Equal amounts 
were loaded into a 2 % agarose gel prior to electrolysis, transfer, probe hybridisation and 
subsequent exposure of the photographic film.
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8.5.4.1.HEK 293T cultures
Cultures of HEK 293T cells were transfected as described in section 8.3.4. 
Following incubation in the transfection media for 6 h, the media was completely replaced 
and the cells cultured for a further 24h or 48h. Figure 8.16 shows the amounts of C0 Q9 and 
CoQ 10 extracted from cultures treated in single transfection experiments. Values of C0 Q9 
and CoQ 10 did not appear to change substantially, except perhaps in the case of the 48h 
treatment group which showed an increase in the amount of both C0 Q9 and C0 Q 10. (24h 
C0 Q9 : control = 3.93 pmol/ mg, siRNA = 4.71pmol/ mg; 48h control = 4.50 pmol/ mg, 
siRNA = 8.31pmol/ mg. 24h C0 Q 10: control = 57.92 pmol/ mg, siRNA = 60.68 pmol/ mg; 
48h control = 60.03 pmol/ mg, siRNA = 80.41 pmol/ mg [data represent single 
transfections]).
8.5.4.2.Primary astrocyte cultures
Identical experimental methods were used to treat rat primary astrocyte cultures. In 
addition, the post-transfection time-point was extended to 72h. These data are shown in 
figure 8.17. In each case, C0 Q9 are lower in the siRNA-transfected cells; the most 
profound decrease was observed after 72h. After 24h and 48h, these decreases were 
moderate (6 % and 8 % respectively). However, 72h post-transfection, a 25% decrease was 
abserved in C0 Q9 levels compared to control values. C0 Q10 levels decreased 5% after 24h, 
and 8 % following 48h transfection. In the case of 72h post-transfection, C0 Q10 levels 
appeared to increase by 7%. (24h C0 Q9 : control = 222.71 pmol/ mg, siRNA = 205.95 
pmol/ mg; 48h control = 259.82 pmol/ mg, siRNA = 244.63 pmol/ mg; 72h control = 
317.45 pmol/ mg, siRNA = 236.6 pmol/ mg. 24h C0 Q 10: control = 67.52 pmol/ mg, siRNA
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Figure 8.16. Ubiquinone levels in HEK 293T cultures following transfection
Cultures were transfected with either control (empty) vector, or the same vector 
containing the TPTF-knockdown primers. Following maintenance in culture for either 
24h or 48h, lipid extraction was performed on these cells and C0 Q9 and C0 Q 10 levels 
measured by UV-HPLC. Data are the product of single culture preparations expressed 
against a protein baseline.
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Figure 8.17. Ubiquinone levels in primary astrocyte cultures following transfection.
Cultures were transfected with either control (empty) vector, or the same vector 
containing the TPTF-knockdown primers. Following maintenance in culture for 24h, 
48h, or 72h lipid extraction was performed on these cells and C0 Q9 and C0 Q10 levels 
measured by UV-HPLC. Data are the product of single culture preparations expressed 
against a protein baseline.
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= 63.93 pmol/ mg; 48h control = 99.90 pmol/ mg, siRNA = 91.82 pmol/ mg; 72h control 
= 65.73 pmol/ mg, siRNA = 70.24 pmol/ mg [data represent single transfections]).
8.5.5. Determination o f ETC enzyme activities in siRNA transfected cultures
8.5.5.LHEK 293T cells
In the same samples, the activities of NADH-CoQi reductase, succinate-cytochrome 
c reductase and cytochrome c oxidase (complex I, complex II+III and complex 4 
respectively) were determined spectrophotometrically and expressed both against a protein 
baseline (Table 8.1 A) and as ratio of citrate synthase activity (Table 8 . IB).
8.5.5.2.Primaiy astrocytes
The same assays were also conducted using the primary astrocyte cultures the 
treatment of which as been described previously. These are shown in Table 8.2A 
expressed against a protein baseline, and in Table 8.2B as a ratio of citrate synthase 
activity.
Given that these data are derived for single transfections, it would be premature to 
draw strong conclusions from them. However, the control data would appear to be within 
approximately similar ranges to previous findings (Bolanos et al., 1994, Stewart et al., 
1997; Orth et al., 2003). Astrocyte complex I and II+III activity when expressed against a 
protein baseline, seem higher than previous findings. However, when expressed as a ratio 
of citrate synthase activity, these data do not appear to be outwith previous finding from 
this and other laboratories (Bolanos et al, 1994, Vasquez et al, 2001).
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A
HEK 293T complex I
(nmol/min/mg)
complex II+III
(nmol/min/mg)
complex IV
(Mnin/mg)
24h control 17.7 11.9 0.62siRNA 13.7 1 2 .1 0.61
48h Control 28.8 7.6 0.48siRNA 56.6 5.8 0.56
B
HEK 293T complex I complex II+III complex IV
24h control 0.14 0.09 0.0049siRNA 0 . 1 2 0 . 1 0 0.0052
48h Control 0 .2 1 0.06 0.0035siRNA 0.42 0.04 0.0041
Table 8.1. Mitochondrial complex activities in HRK 293T cultures following 
transfection.
Cultures were transfected with either control (empty) vector, or the same vector 
containing the TPTF-knockdown primers. Following maintenance in culture for 24h or 
48h, cells were trypsinised and harvested as described previously. Data are expressed 
A) against a protein baseline and B) as a ratio to citrate synthase activity. Data are the 
product of single culture preparations expressed against a protein baseline.
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A
Primary astrocytes complex I
(nmol/min/mg)
complex II+III
(nmol/min/mg)
complex IV
(klmmJmg)
24h control 55.3 36.4 2.14siRNA 61.3 28.96 2.43
48h control 1 2 2 . 2 49.54 3.72siRNA 47.7 44.8 4.04
72h control 289.7 32.3 2.58siRNA 192.6 34.1 1.14
B
Primary astrocytes complex I complex II+III complex IV
24h control 0.27 0.18 0 . 0 1 0siRNA 0.32 0.15 0.013
48h control 0.49 0 . 2 0 0.015
siRNA 0.19 0.18 0.016
72h control 0.79 0.16 0.013siRNA 0.65 0.16 0.006
Table 8.2. Mitochondrial complex activities in primary astrocyte cultures following 
transfection.
Cultures were transfected with either control (empty) vector, or the same vector 
containing the TPTF-knockdown primers. Following maintenance in culture for 24h, 
48h or 72h, cells were trypsinised and harvested as described previously. Data are 
expressed A) against a protein baseline and B) as a ratio to citrate synthase activity. 
Data are the product of single culture preparations expressed against a protein baseline.
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8.6. Discussion
During the course of this investigation, a number of techniques were applied to cells 
previously transfected with a vector for the expression of siRNA molecules in mammalian 
cells. A primary aim of this work was to decrease in CoQ synthesis as the result of siRNAs 
targeted against mRNA encoding the biosynthetic enzyme transprenyl transferase (TPTF).
Successful transfection with control (pSUPER.gfp/neo) and siRNA 
(pSUPER.gfp/neo+TPTF) vectors was achieved using the human HEK 293T cell line. This 
was confirmed by expression of GFP in at least 50% of these cells (Fig 8.10). In primary 
cultures of rat astrocytes, the number of cells expressing GFP was approximately 20%, and 
GFP was visually less abundant in such cells (fig. 8.11). However GFP visualisation was 
still possible in every culture so treated. The problems associated with transfecting primary 
cultures has been previously observed (Spankuch-Schmitt et al., 2002) and it is known that 
transfection of primary cultures results in a much lower efficiency of transfection than with 
cell lines (Almeida et al., 2004). However, in neither cell line did the presence of the TPTF 
insert in the vector did not appear to strongly influence GFP expression.
Having confirmed entry and expression of the vector into the host cells (albeit at a 
lower level in the primary cultures), RT-PCR was performed upon RNA isolated from 
primary cultures. The predicted product (121 bp) was obtained (Fig, 8.12), and basic semi- 
quantitative PCR (between 5 and 35 cycles) used to visualise any possible knockdown of 
TPTF. In control cells, the band intensity showed dependence upon the number of cycles; 
it was just possible to visualise a faint band at 25 cycles, but not below. The band was 
stronger at 28 and stronger still at 35 cycles. Knockdown of a gene product would be 
supported under these conditions by the presence of the control band at a lower cycle
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number than that at which the siRNA-transfected cultures appears. This did not happen 
when semi-quantitative RT-PCR was performed using RNA extracted from these cultures.
In order to visualise the mRNA levels directly, a Northern blot was performed. A 
radiolabelled probe was synthesised from the RT-PCR product to hybridise TPTF mRNA 
following electrophoresis. The relative abundance of TPTF mRNA in both the rat primary 
and the human cell line cultures is shown in figure 8.15. Post-transfection time prior to 
RNA isolation was up to 48h in HEK 293T cells and up to 72h in primary cultures. 
However, no evidence (either from RT-PCR or from the Northern blot) was found to 
support strong knockdown of TPTF.
Analysis of CoQ status and ETC complex activity was performed in cells harvested 
from single experiments. While 24h incuabtion did not markedly alter C0 Q9 or C0 Q10 
status, 48h siRNA treatment of HEK 293T cultures showed an increase in both C0 Q9 and 
C0 Q10. Under these conditions, complex II+III activity in these cells did not change 
substantially. Although it is not possible to draw strong conclusions from data derived 
from single observations, C0 Q9 levels in astrocyte cultures appeared to decrease following 
transfection; this was greatest following 72h culture post-transfection, whereupon decrease 
in the region of 25% was observed. As previously observed, basal levels of C0 Q9 in 
control cultures show an increasing trend with time in culture. This increase may be 
inhibited by the presence of siRNA in these cells. In addition, as the half life for CoQ 
turnover is estimated to be 90h in rat brain (Andersson et al., 1990), it is possible that 
decreases in cellular levels of C0 Q9 (or C0 Q 10) may not become evident until later time- 
points. While profoundly decreased mRNA levels were not evident, it is unknown as to the 
degree of inhibition of TPTF expression necessary to invoke CoQ downregulation.
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However, as in previous chapters, the activity of complex II+III did not reflect 
alterations observed in C0 Q9 status.
siRNA is a relatively novel technique, the mechanisms of which are not yet 
completely understood. However, there are an abundance of studies within the literature 
demonstrating that it can be extremely specific and efficacious with regard to gene 
silencing and with a number of applications (Hannon, 2002; Kurreck, 2003; Jones et al, 
2004). A number of reasons can be proposed for a lack of effect with regard to gene 
product knock-down. However, some possibilities can be ruled out. The 64-nt 
pSUPER.gfp/neo primers are likely to be specific for TPTF, given the extensive electronic 
database comparisons. Although the Blast 2 sequences search compared mouse and 
human, TPTF sequences, the study examined rat primary cultures, and transformed human 
cultures. In addition, primer efficacy is by no means guaranteed, and it is likely that most 
siRNA studies use a number of possible primer sequences with differing results 
(Brummelkamp et al, 2002; Devroe and Silver 2003; Davies et al 2004). Ideally, rather 
than rely on a single proposed sequence, this study could have used a number of similar 
primers, with slight discrete alterations of the sequence. Unfortunately this was outside the 
scope of the current study. Since this work was undertaken, more has appeared within the 
literature on the subject of siRNA sequence design; Reynolds et a l (2004) have described 
novel "rules" for optimal sequence design. In this work, they suggest that a low C/G 
content, and some sense-strand base preferences may allow for more efficacious sequence 
selection. Perhaps alternative and better sequences could have been could have been 
selected if this information were available at the time.
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Transfection efficiency was relatively low in the astrocyte study; however abundant 
expression of GFP in the HEK 293T cell line would suggest that low transfection is not 
responsible for the lack of knockdown in these cultures. However, it is likely that in both 
cell types transfection efficiency could be optimised with regard to exposure time to the 
vector-containing liposomal media and cell density.
Finally, if TPTF protein turnover were shown to be extremely low then it is possible 
that longer time between transfection and RNA isolation may be necessary before any 
down-regulation becomes evident. A similar study (Nicchia et al, 2003) was able to show 
protein knockdown after 2 days, but levels were much lower after 4 days. The 25% 
decrease in cellular CoQg observed in rat primary cultures 72h post-transfection may thus 
further decrease with increasing incubation time.
8 .7. Conclusion
Rat primary astrocytes and HEK 293T cells were transfected with the 
pSUPER.gfp/neo vector containing inserts which may be specific for the knockdown of 
TPTF. Vector expression in both cell types was confirmed by the visualisation of the GFP 
tag associated with the vector. However, abundant expression of GFP in the HEK 293T 
cells would suggest higher transfection efficiency than in the primary cultures. Semi 
quantitative PCR for TPTF cDNA did not reveal any noticeable difference in the amount of 
TPTF mRNA between the control and siRNA cultures. Northern blotting for mRNA 
encoding TPTF confirmed this finding. In addition, as in previous chapters, determination 
of the activities of mitochondrial respiratory chain enzymes (in particular complex II+III) 
did not indicate that ETC function had been compromised over the time frame of this study.
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Measurement of CoQ levels in the HEK 293T cultures up to 48h post-transfection did not 
show lower abundance of C0 Q9 or CoQ 10. In rat primary astrocyte cultures, lower levels of 
C0 Q9 may have been evident at 72h post-transfection; under these conditions C0 Q 10 levels 
showed a small increase. It is possible that the decrease in C0 Q9 levels would become 
greater with further increasing the time in culture post-transfection.
271
9. GENERAL DISCUSSION AND 
SUGGESTED FURTHER WORK
272
9. GENERAL DISCUSSION AND SUGGESTED FURTHER WORK
This thesis described the establishment of an HPLC method, employing an 
internal standard, to detect C0 Q9 and C0 Q 10 in a number of cell culture systems. 
Subsequently, aims included characterisation of the CoQ status of these cultures, 
assessing the effects of NO exposure, and investigation of potential pharmacological 
and molecular biological mechanisms for inhibition of the CoQ biosynthetic 
pathway.
9.1. HPLC Method
The conjugated nature of the 6 -membered ring with oxygen atoms at 
positions 1 and 4 gives ubiquinone distinct redox properties, and allows detection 
due to a A™ax of absorption at 275 nm. This is exploited in the HPLC method 
described in this thesis. Similarly the length of the hydrophobic tail determines the 
elution time from the column. With regard to an internal standard, previous studies 
have used CoQ homologues which do not predominate in the species being 
examined; i.e. C0 Q9 as an internal standard for bacterial (Santos Ocana et al., 2002) 
and human (Okamoto et al, 1985; Ogashara et al., 1989) studies, and C0 Q6 in 
rodent studies (Thelin et al, 1992; Tang et al, 2004). However the presence of 
small quantities of such analogues as a result of dietary intake or synthesis by gut 
flora may affect quantification of the internal standard. The synthesis of a non- 
physiological analogue of CoQ 10 (diethoxy-CoQio) allowed accurate determination 
of losses occurring due to the lipid extraction process. Based on a modification of
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the methods of Edlund (1988) and subsequently Eaton et al. (2000), this has been 
used for the successful determination of both rodent and human CoQ status. The 
method displayed good recovery and acceptable inter and intra assay variability 
(Table 9.1).
Recovery 107 ± 2 %
Variability
inter-assay 6.5 %
intra-assay 4.8 %
Table 9.1 Recovery and variability o f  HPLC method
These were determined as described in sections 3.3.2 and 3.4.3
9.2. Human and rodent cell line responses to lovastatin and iNOS activation
Human and rat brain cell line cultures responded differently to exposure to 
10 pM lovastatin. While the human astrocytoma required the prodrug’s conversion 
to the active form to decrease C0 Q9 levels (Fig. 4.6), rat glioma cells (which have 
higher basal total ubiquinone levels than the human astrocytoma cell line) decreased 
C0 Q9 status with both the prodrug and activated form by approximately 33% (Fig. 
4.8). This may suggest that whereas the rat glioma cell line has a paraoxonase 
isoform (lactonase) to hydrolyse the lactone ring of lovastatin, the human 
astrocytoma cells did not.
Additionally human astrocytoma cultures also appeared relatively resistant 
to the effects of LPS+IFNy; in contrast, rat glioma cells significantly increased C0 Q9 
levels by 55% under the same conditions (Fig. 4.2). This was likely to be due to
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iNOS activation (but not NO as the increase was not accompanied by an increase in 
NOx in the culture media; Fig. 4.3) and was abolished by L-NIL. However, it is 
necessary to consider that basal levels of NOx generated by these systems were 
approaching the limit of detection of the Greiss assay. Thus it is possible that NO 
was being generated in such small quantities that it could not be detected by this 
assay. Nonetheless, iNOS has been described as a system capable of O2' generation 
under certain conditions (Heinzel et al., 1992; Consentino et al., 2001); thus these 
cultures may increase C0 Q9 status in response to CV. The simultaneous presence of 
NO in the rat glioma media (generated from DETA-NO) abolished this increase; this 
may be attributed to the clearance of O2' due to its reaction with NO (Fig. 4.14). 
DETA-NO itself did not alter the status of C0 Q9 or C0 Q 10 in these cells.
9.3. CoQ status o f primary astrocytes and neurons
Differing roles of C0 Q9 and C0 Q 10 with regard to electron transport, 
antioxidant function and superoxide generation have been previously suggested in a 
number of studies (Kagan et al., 1990; Matsura 1991, 1992; Lass et al, 1997; 
Battino et al., 2001).
Kagan et al. (1990) and Matsura et al. (1992) proposed C0 Q9 to be a more 
potent inhibitor of lipid peroxidation than C0 Q 10, an action possibly attributed to 
relative partitioning of the two molecules in biological membranes. In hepatocytes, 
different roles for the two isoforms were considered by Matsura et al. (1991): C0 Q9, 
found to be largely extra-mitochondrial, was suggested to function as an antioxidant,
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while C0 Q10 which was mainly localised in mitochondria was ascribed roles as both 
an antioxidant and as a carrier within the electron transport system.
In this study primary cultures enriched with neurons contain the same 
amount of C0 Q9 as primary cultures of astrocytes. However, the neuron-enriched 
cultures contained almost twice as much C0 Q 10 as the astrocytes (Fig 7.4, Table 
9.2). This may be a reflection of the greater dependence of the neuron for 
mitochondrial OXPHOS. When compared to astrocytes, neurons appear unable to 
upregulate glycolysis in the face of inhibition of the mitochondrial ETC (Bolanos et 
al., 1994; Almeida et al, 2004), suggesting a particular reliance by neurons for 
OXPHOS. This dependence may be reflected in the greater C0 Q10 level of neurons 
and possibly suggests that C0 Q9 and C0 Q10 perform distinct metabolic roles.
9.4. Cellular dependence on OXPHOS and differences in C 0 Q 9 and C 0 Q 10 
levels
It is of note that both the C0 Q9 and C0 Q 10 status in the transformed glial cell 
lines was lower than that of the primary astrocyte cultures examined. This may be a 
result of the “Warburg effect”, a shift in cancer cells’ primary energy production 
from OXPHOS to glycolysis (Warburg 1930, 1956; reviewed in Gatenby and 
Gillies, 2004). Thus the lower dependance of transformed cells for mitochondrial 
OXPHOS may manifest as a relative lower abundance of cellular ubiquinone. As 
described, and shown subsequently in table 9.2, neurons are almost entirely 
dependant upon OXPHOS for ATP generation; these cells display higher levels of 
both C0 Q9 and C0 Q 10 than either the transformed cell lines or the primary cultures.
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Thus as OXPHOS dependancy increases, not only does the total C0 Q9 + C0 Q10 
increase, but the percentage of C0 Q 10 in total C0 Q9 + C0 Q10 also increases. This 
may again reflect a role C0 Q10 over C0 Q9 in mitochondrial electron transport.
C0 Q9 C0 Q 10 % C0 Q10
Rat C6  glioma 114.3 ± 15.7 17.8 ±3.3 13%
Primary astrocytes 174.2 ± 10.8 37.9 ± 1.6 18%
Primary neurons 183.7 ± 13.6 67.9 ±3.9 27%
Table 9.2 C0 Q9 and C0 Q10 status o f different rat cell types
As the cell types’ dependence upon OXPHOS increases, note that not 
only does total cellular CoQ increase, C0 Q10 increases disproportionately
9.5. Influence o f serum-withdrawal on astrocyte CoQ availability
Withdrawal of serum from cell cultures has been reported to increase 
oxidative stress (Barroso, 1997; Palazzotti et ah, 1999), possibly via the direct or 
indirect promotion of cellular O2' generation (Menzies et al., 2002; Maestre et al,
2003). The resultant oxidative stress has also been reported to increase CoQ levels, 
possibly as a protective antioxidant response in cultures of human promyelocytic 
HL-60 cells (Barroso et al., 1997; Gomez-Diaz et al. 2003).
The current work has shown that serum withdrawal from astrocyte cultures 
for 36h resulted in significant increases by approximately 2 0 % in both C0 Q9 and
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CoQio (Fig. 5.1). While this may be due to increased biosynthesis in response to 
removal of exogenous C0 Q9 or CoQ 10 from culture media, oxidative stress may also 
be implicated (Huertas et al, 1991). Mataix, et al. (1997) suggested that increased 
oxidative stress in rats elevated C0 Q9 levels in the mitochondrial membrane. 
Additionally, increased antioxidant defence at the level of manganese superoxide 
dismutase (MnSOD) was described by Palazzotti et al. (1999) following serum 
deprivation. Primary glial cultures also increase synthesis of the mitochondrial 
antioxidant GSH in response to oxidative or nitrosative stress (Iwata-Ichikawa et al., 
1999; Gegg et al, 2003). Thus serum-withdrawal-mediated ROS generation in the 
primary cultures described in this thesis may have resulted in elevated CoQ status.
9.6. Influence o f lovastatin on CoQ availability ofprimary astrocyte cultures 
In contrast to the rat glial cell lines discussed earlier, the CoQ status of 
primary cultures of rat astrocytes was unchanged following exposure to 10 pM 
lovastatin; however, 100 pM lovastatin elicited a decrease of up to 50% in C0 Q9 
following 24h exposure. Again C0 Q 10 levels were unaffected (Fig. 6.2).
In the primary astrocyte cultures, it was not necessary to hydrolyse lovastatin 
to the p-hydroxy acid to affect CoQ status; however, the effects were abolished in 
the absence of FBS. As serum withdrawal alone increased CoQ levels; this could 
otherwise mask the direct effects of lovastatin. Alternatively, albumin in the serum 
may be necessary to transport lovastatin into the cell (Peters, 1985; Nagasawa et al.,
2004). Thirdly, lactonase activity due to PON isoenzymes has been reported in the 
sera of a number of species including rat, rabbit and human; if present in FBS, this
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may be shown to result in more effective conversion of the prodrug to the active 
isoform (Roth et al., 1967; Billecke, et al., 2000; Teiber et al, 2003).
9.7. Influence o f iNOS and NO on CoQ availability
In primary astrocytes, following 24h activation of iNOS, no alteration in
CoQ status was observed. Extension of incubation to 36h demonstrated a
statistically significant decrease in C0Q9 with no change in C0 Q10 levels (Fig 7.2).
Bolanos et a l (1994) showed using cultured astrocytes that maintenance of
iNOS activation for 36h resulted in an inhibition of complex II+III which did not 
occur after 18h (Bolanos et al, 1994). ONOO' has also been demonstrated to 
directly oxidise short-chain ubiquinol to the semiquinone form (Schopfer et al, 
2000). The possibility therefore exists that the deleterious effects of RNS upon CoQ 
may be responsible for the inhibition of this linked enzyme system. While it is 
possible that the findings of Bolanos et al. (1994) could be attributed to decreased 
CoQ availability, under the conditions described here, no significant decreases in 
complex II+III were detected. It is possible that the absence of serum from the cell 
culture media of the current study resulted in the absence of complex II+III 
inhibition. This work has shown that serum withdrawal for 36h increased cellular 
CoQ status. Subsequently, this may either confer additional antioxidant protection 
against the RNS-mediated inhibition of complex II+III activity, or allow 
maintenance of electron transport at the levels of complex II+III in the face of 
inhibition of the ETC. In keeping with the findings of Bolanos et al, (1994), 
complex IV was the particularly susceptible to RNS-mediated inhibition.
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Exposure of similar astrocyte cultures to NO from an exogenous source (i.e. 
DETA-NO) resulted in an initial decrease in both C0 Q9 and C0 Q10; however, 
extended exposure resulted in an apparent restoration of CoQ levels. Given the 
greater levels of NOx generated by DETA-NO compared to LPS + IFNy after 36h, 
this may represent a mechanism whereby cellular antioxidant status can be 
upregulated in times of prolonged or severe oxidative / nitrosative stress. Such 
mechanisms have previously been described for CoQ (Huertas et al, 1991; Barroso 
et al., 1997; Gomez-Diaz et al. 2003), GSH (Gegg et al, 2003), MnSOD (Palazzotti 
et al., 1999), catalase (Treichel et a l, 2004) and ascorbate (reviewed in Rice et al, 
2002).
9.8. Differential effects o f  DETA-NO on astrocytes and neurons
As previously discussed, basal levels of C0Q9 between astrocyte and neuron- 
enriched cultures are the same, but neuron-enriched cultures contain 1 .8 -fold more 
CoQ 10, possibly as a result of their higher dependence on OXPHOS. However, the 
astrocytic and neuronal response to DETA-NO was also different. While astrocyte 
cultures decrease C0Q9 and C0Q10 by approximately 32% and 44% respectively 
after 24h exposure to DETA-NO; neuronal levels of C0Q9 and C0Q10 were 
unchanged. The full implications of this finding have not yet been elucidated; 
however it is possible that while the astrocyte can utilise glycolysis to generate ATP 
following ETC inhibition, the preservation of C0Q9 and CoQ 10 by the neuron 
represents a response to maintain sufficient electron transport in the face of RNS- 
mediated inhibition.
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In addition, these findings may become clearer in light of existing knowledge 
of another cellular and mitochondrial antioxidant, GSH. Monocultures of astrocytes 
have approximately double the amount of GSH than that of neurons (Bolanos et al, 
1995). The present study shows almost double the amount of C0Q10 in neurons 
compared to astrocytes. Furthermore, Gegg et al. (2003) have shown that exposure 
of astrocytes to DETA-NO causes an increase in GSH content; both C0Q9 and 
CoQ 10 decrease under these conditions. It would appear however that neuronal loss 
of GSH in response to NO (Gegg et al, 2003) may be counteracted by the 
maintenance of C0Q9 and C0Q10 in these cells. This gives rise to the possibility of a 
compensatory effect, i.e. the upregulation of one antioxidant in response to the 
decrease of another.
9.9. CoQ status and ETC activity
The complex II+III assay requires endogenous CoQ, and it has been 
proposed that CoQ availability may be limiting for this assay (Clark et al, 1994; 
Rahman et al, 2001). Thus to gain insight into the effects of CoQ depletion upon 
the ETC, the respiratory chain enzyme activities of the primary cultures of rat 
astrocytes were determined.
Although C0 Q9 levels decreased by up to 50% following treatment with 
lovastatin (100 pM), no decrease in the activity of the linked II+III assay was 
observed (Tables 6.10 and 6.11). Similarly, neither NO generated from iNOS nor 
DETA-NO were seen to inhibit complex II+III activity even though C0 Q9 levels had 
decreased by 22% with LPS+IFNy and 32% with DETA-NO (Table 7.6). It is
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possible that these overall findings of complex II+III activity which appears not to 
be limited by CoQ status may suggest that a threshold of depletion necessary for 
C0 Q9 to inhibit complex II+III activity was not reached. These data would suggest 
that such a threshold would have to represent depletion of C0 Q9 of at least 32% in 
rat primary astrocyte cultures. Alternatively, a decrease in cellular CoQ may not 
necessarily reflect a decrease in CoQ in the inner mitochondrial membrane. Given 
the maintenance of C0 Q10 levels under these conditions, it is also possible that 
complex II+III activity in these cells relies more heavily upon the availability of 
CoQ 10 than C0 Q9 for electron transport. In support of this last hypothesis, 
consideration of the complex II+III activity of the human astrocytoma cell line and 
the rat primary astrocyte cultures may be important. Although the present study did 
not measure the ETC activities of the cell lines, this has previously been done by 
Stewart et al. (1998). These authors describe very similar values for complex II+II 
activity (11.7 ± 1.2 and 13.9 ± 2.4 nmol/min/mg protein for primary rat astrocytes 
and human astrocytoma cultures respectively). The current work has shown that 
while C0 Q9 status of these cultures differs by > 50-fold, C0 Q10 levels are almost 
identical (35.4 ± 2.7 and 33.8 ± 7.6 pmol/mg protein for primary rat astrocytes and 
human astrocytoma cultures respectively). Thus availability of C0 Q10 rather than 
C0 Q9 may be particularly important in determining activity of complex II+III.
9.10. siRNA study
The use of siRNA directed against transprenyl transferase a key biosynthetic 
enzyme was examined (Fire, et a l 1998; Elbashir et al. 2001). Following
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confirmation of efficient siRNA transfection with immortalised HEK 293T cultures, 
rat primary astrocytes notably expressed lower levels of the GFP tag associated with 
the pSUPER.gfp/neo vector (noted in Spankuch-Schmitt et al, 2002). Thus it is 
possible that siRNA transfection efficiency could be improved in primary astrocytes 
(as achieved by Nicchia et al., 2003 and Almeida et al., 2004) and to lesser degree 
HEK 293T cells.
Semiquantitative RT-PCR for the transprenyl transferase mRNA did not 
show decreased levels (Fig. 8.14); similarly Northern blotting did not display 
markedly lower values of mRNA (Fig 8.15). However, while the HEK 293T cells 
did not show decreases in cellular C0 Q9 or C0 Q 10, levels of particularly C0 Q9 were 
decreased by 25% 72h post-transfection. Given that the half life in turnover of CoQ 
in rat brain has been postulated as being in the region of 90h, it is possible that a 
longer period in culture post-transfection would have mediated a more profound 
decrease in C0 Q9 levels. As described in previous chapters, measurement of ETC 
complex activities did not indicate inhibition complex II+III activity under these 
conditions. While it is possible that more effective gene silencing could have been 
effected with alternative primers, and a number of protocols and observations have 
allowed more accurate and efficient design, it is still unknown as to why some 
primers give better gene product downregulation than others (Reynolds et al., 2004). 
For this reason, siRNA studies generally trial a number of primers in parallel before 
the selection of one as the most effective at mediating knockdown of the gene 
product of interest (Brummelkamp et al., 2002; Devroe and Silver, 2003).
283
9.11. Conclusions and potential implications o f research
The effects observed in the models described were predominantly upon C0 Q9 
with an apparent sparing of CoQ 10. It has been proposed that an interconversion 
between C0 Q9 and C0 Q10 can occur: studies administering dietary C0 Q10 to rodents, 
have reported increased levels of both C0 Q9 and CoQ 10 in a number of tissues 
(Lonnrot et al., 1998; Kwong et al., 2002) and in mitochondrial membranes (Lass et 
al., 1999). Thus in vivo, C0 Q9 may be synthesised from C0 Q10 and vice versa. 
Indeed it has been suggested that the addition of a final isopentenyl pyrophosphate 
to nonaprenyl pyrophosphate is a rate limiting step in C0 Q10 biosynthesis 
(Yamamoto et al., 1989).
Transformation of cells involves a lowered reliance on OXPHOS; this may 
account for the lower C0 Q9 and CoQ 10 levels in the rat glioma than the 
corresponding primary astrocyte cultures. Similarly, the higher C0 Q10 levels in 
primary rat neurons compared to astrocytes may be a reflection of their relative 
reliance on functional mitochondria. Given that complex II+III activity did not 
decrease under conditions where C0 Q9 availability was compromised (and C0 Q10 
levels were maintained), a body of evidence is accumulating which may support the 
role of CoQ 10 as the primary electron carrier in the mitochondrial ETC. The 
similarity in the documented complex II+III activities of human astrocytoma cells 
and rat primary astrocytes (Stewart et al., 1998), and the current finding of near­
identical C0 Q 10 levels (although vastly different C0 Q9 status) may provide 
circumstantial evidence to support this.
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Exposure to DETA-NO for 24h caused a lowering of both C0Q9 and C0Q10 
in astrocytes. However, following 36h exposure, these levels had returned almost to 
control values. These findings could have implications for oxidative / nitrosative 
stress studies in that C0Q9 and C0Q10 levels in astrocytes may increase following 
prolonged oxidative insult (i.e. 36h withdrawal of serum) or recover after an initial 
decrease following prolonged nitrosative stress (36h DETA-NO exposure).
While 36h exposure to LPS + IFNy caused a significant decrease in C0Q9 but 
not C0Q10, in contrast to previous works (such as that of Bolanos et al, 1994) 
complex II+III activity did not decrease. However, it is possible that the lack of 
serum in the cell culture medium of the current study may have prompted cellular 
upregulation of C0Q9 and or CoQ 10 leading to the maintenance of complex II+III 
activity.
Expression of siRNA in primary astrocytes for 72h has shown a 25% 
decrease in C0 Q9 levels compared to control values. As the predicted half life of 
turnover of CoQ in rat brain (Andersson et al., 1990), this initial finding may 
represent a method to decrease cellular levels of C0 Q9 in rat tissue.
Finally, the apparently higher sensitivity of the CoQ biosynthetic pathway to 
lovastatin in rat glioma and human astrocytoma cells when compared to rat primary 
astrocyte cultures may support the proposed anti-tumourogenic properties of the 
statin drugs. Lovastatin and other HMG-CoA reductase inhibitors have been shown 
to have the potential to trigger apoptosis in some tumour-derived cells both in vitro 
(Dimitroulakos and Yeger, 1996; Dimitroulakos et al, 1999; Wong et al., 2001) and 
in vivo (Minden et al, 2001). An epidemiological study has also reported a
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decreased risk of cancer in statin users (Blais et al., 2000). Specifically, the 
potential for statin drugs in the treatment of CNS malignancies has been investigated 
in vitro (Soma et al., 1992; Prasanna et al, 1996; Dimitroulakos and Yeger, 1996) 
and using animal models (Soma et al., 1995; Kikuchi et al., 1997). Thus the statin 
class of drugs may have antiproliferative, proapoptotic, anti-invasive and 
radiosensitising properties and have been proposed as potential chemotherapeutic 
agents (reviewed in Chan et al., 2003).
SUGGESTED FUTURE WORK
• As this work has found little evidence that disruption of cellular C0 Q9 
status affects mitochondrial electron transport, it is recommended that future studies 
address mitochondrial C0 Q 10 status. This could be achieved by subcellular 
fractionation using the method of Almeida and Medina (1998) prior to C0 Q10 
determination. Subsequently this could be dissected into the response of C0 Q10 in 
mitochondria extracted from primary astrocytic and neuronal cultures. Preliminary 
data has been obtained describing the C0 Q9 and CoQ 10 content of rat brain non- 
synaptic mitochondria isolated using the method of Lai and Clark (1979), shown in 
Table 9.3.
(pmol/ mg protein)
C0 Q9 32.3
C0 Q10 14.2
Table 9.3 Preliminary findings examining C0 Q9 and CoQw content o f non- 
synaptic mitochondria from rat brain (n=2)
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• It has been observed that C0 Q9 levels in primary cultures can
decrease by 50% following incubation with lovastatin. Thus it would be of interest 
to administer lovastatin to animals in order to assess whether such a situation may 
exist in the brain or other tissues following lovastatin treatment.
• CoQ-deficient states resulting from inborn errors of metabolism have
been identified in human patients. Oral administration of C0 Q10 or idebenone (the 
CoQ analogue which crosses the blood-brain barrier) has been beneficial in the 
treatment of such conditions. If lovastatin-mediated cellular CoQ depletion were 
observed in vivo in experimental animals, the potential for oral CoQ and / or 
idebenone administration in the therapeutic intervention of such a state would also 
be of clinical interest.
• With regard to the siRNA study, although it was not possible to
conclusively demonstrate “knock-down” of TPTF mRNA or protein, C0 Q9 levels 
appeared to decrease by 25% in primary rat astrocyte cultures. Extension of time in 
culture post transfection may show further decreases in cellular C0 Q9 or C0 Q10. As 
proof of principle with regard to transfection, RT-PCR and Northern blot probes has 
been achieved, further investigation is warranted. Initially, such a study could 
continue to investigate the HEK 293T cell line and primary cultures of rat astrocytes 
(and subsequently neurons) at extended time points. Additional work with a number 
of different primers for the same enzyme may produce an siRNA sequence more 
effective in lowering TPTF mRNA and protein levels.
• The apparent sensitivity to lovastatin of rat glioma cells compared to 
primary astrocytes may merit the treatment of experimental glioma-type tumours in
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animals with this drug. The inhibitor of GSH biosynthesis L-BSO has been shown 
to increase the sensitivity of human cancer cells to radiation possibly as a result of 
the decreased antioxidant capacity of the tumour cells (Lippitz et al, 1990; Kato et 
al, 2000); radiosensitisation has also been hypothesised following lovastatin 
treatment (Chan et al, 2003), an effect which may also represent a targeted decrease 
in the antioxidant capacity of such cells. Given that increased susceptibility of 
tumour cells over healthy tissue is a major goal of current cancer therapy, the 
findings of this current work merit further study with regard to the therapeutic 
potential of the statin drugs as anticancer agents.
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APPENDIX I: AN INVESTIGATION INTO A POSSIBLE CASE OF HUMAN 
UBIQUINONE DEFICIENCY
A .l Introduction
As described in the main introduction, human ubiquinone deficiency can give rise to 
mitochondrial encephelomyopathies. Usually these occur as a result of an inborn error of 
metabolism. The Neurometabolic Unit of the National Hospital for Neurology and 
Neurosurgery, Queen Square, London, UK routinely assesses the mitochondrial function of 
patients suspected to be suffering from mitochondrial encephelomyopathies.
A muscle biopsy was received from a patient for analysis of mitochondrial function. 
The boy was the second child of unrelated parents of Norwegian origin. He presented at 4 
months with severe hypotonia, feeding difficulties, and had developed apnoeic spells. 
After an initial muscle biopsy was taken at 6 months, the patient was given carnitine, 
riboflavin and oral CoQio, until his death at 10 months, possibly due to pneumonia 
complicating his primary condition. Permission was obtained for a post-mortem muscle 
biopsy.
Prior to death, the patient underwent various clinical metabolic investigations, and 
on several occasions displayed increased lactate in blood and CSF. While both muscle 
samples appeared to be histologically normal, analysis of the initial biopsy revealed 
complex I+III activity was decreased, and complex II+III activity was almost abolished. 
The post-mortem sample however, showed that (possibly due to CoQio supplementation)
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these enzyme activities had increased. Consequently, in order to clarify this, CoQio levels 
in both biopies were determined.
A.2 Methods
The biopsy was homogenised on ice using a pre-chilled teflon: glass hand held 
homogeniser. Tissue was homogenised to 10% (w/v) in ice-cold muscle isolation buffer 
(320 mM sucrose; 10 mM Tris; 1 mM EDTA dipotassium salt; pH 7.4). CoQio content of 
these homogenates was determined by HPLC, as described in Chapter 3. DiethoxyCoQio 
was employed as an internal standard. CoQio in the pre-supplementation and the post­
mortem muscle samples was determined, and the findings expressed against a protein 
baseline as shown in table A.I.
Pre-CoQio
supplementation
Post-CoQio
supplementation
Reference
Range*
CoQio levels 
(pmol/mg 
protein)
414 300 140 - 580
Table A .l. Patient muscle ubiquinone concentration and the paediatric reference 
range (* from Rahman et al., 2001)
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A. 3 Results
From these data, there was no evidence of a CoQio deficiency, with levels in both 
the pre- and post-mortem samples falling clearly inside the paediatric reference range (from 
Rahman et al., 2001). It can also be seen that oral supplementation did not increase CoQio 
concentration in muscle homogenate.
A.4 Conclusions
The fact that in this case CoQio appeared to decrease, following supplementation 
would suggest that CoQ was not taken up to any part of the cellular fraction, possibly due 
to lipid membrane saturation. This may support the proposal outlined by Turunen et al., 
(1999) that appropriate tissue uptake of dietary CoQ probably only occurs in deficient 
states.
However evidence for this is equivocal and it remains a topic of debate within the 
literature (Matthews et ah, 1998; Dallner & Sindelar, 2000; Beal & Mathews, 1997; Kwong 
et al., 2002). As yet, it is also unresolved how mitochondrial levels are affected by oral 
ubiquinone therapy, if at all.
Thus it is unclear as to why in this case the activities of complex I+III and complex 
II+III linked assays appear to be sub-normal. The possibility exists that impairment of the 
membrane-bound complexes may be responsible for the clinical symptoms. If the activity 
of complex III were found to be diminished, this may explain the observed inhibition of the 
I+III and II+III assays. However, as ubiquinone levels in this patient were normal, the
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increased activities of the complex I+III and complex II+III assays following CoQ 
supplementation introduce the possibility of a more subtle complex III mutation. A Km 
mutant of the ubiquinol : cytochrome c reductase complex may have a reduced affinity for 
ubiquinol (i.e. an increased Km). Although the post-mortem sample would suggest that 
CoQio status did not increase in skeletal muscle homogenate, as the amount of ubiquinone 
in the mitochondrial inner membrane has not been determined, the possibility of this patient 
expressing a Km mutant complex III cannot be excluded. Alternatively it is also possible 
increased ETC enzyme activity may have occurred as a result of an antioxidant effect of 
CoQio administration.
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